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Abstract 
The kisspeptin receptor (KISS1R), functioning as a metastasis suppressor and gate-
keeper of GnRH neurons, is a potent activator of intracellular Ca
2+
. The surge in 
cytoplasmic Ca
2+
 mediates the exocytosis of GnRH from GnRH neurons. However, 





 excitotoxicity via a signalling off-switch mechanism remain unclear. 
This thesis provides evidence for the interaction between KISS1R and the Ca
2+
 
regulated proteins of calmodulin (CaM), and αCa
2+
/CaM-dependent-protein kinase II 
(α-CaMKII). Binding of CaM to KISS1R was shown with three independent 
approaches. Firstly, cell-free spectrofluorimeter assays showed that CaM selectively 
binds to intracellular loop (IL) 2 and IL3 of the KISS1R. Secondly, KISS1R co-
immunoprecipitation experiments identified ligand/Ca
2+
-dependent binding of 
KISS1R to HEK-293 endogenous CaM. Thirdly, confocal experiments showed CFP-
CaM co-localises with YFP-KISS1R. The functional relevance of CaM binding was 
examined with alanine substitution of critical residues of the CaM binding motifs in 
IL2 and IL3 of KISS1R. This approach revealed that the receptor activity (relative 
maximum responsiveness) was increased in the mutated residues of the 
juxtamembrane regions of IL3 and the N-terminus of IL2 relative to wild-type 
KISS1R. The Ca
2+
/CaM regulated CaMKII was also found to interact with KISS1R 
by selectively phosphorylating T77 of IL1. Phosphomimetic mutations of T77
 
into E 
or D created a receptor that was unable to elicit inositol phosphate production upon 
ligand stimulation. Finally, in vivo studies using ovariectomised rats that were 
intracerebroventricularly administered with a cell-permeable CaMKII inhibitor 
augmented the effects of kisspeptin ligand stimulation of plasma luteinizing hormone 
levels. Taken together, this thesis demonstrates that the KISS1R-G protein coupling 
is regulated by Ca
2+
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1. Introduction  
1.1. Overview 
The introduction is divided into four parts; in the first part I give an overview 
of GPCR structure and function that is most conserved. The second part is an 
introduction to the biochemistry and physiology of kisspeptin receptor and its 
cognate ligands. In the final two parts I introduce calmodulin and αCaMKII structure 
and function.  
1.2. G protein coupled receptors  
G protein coupled receptors (GPCRs) are 7-transmembrane cell-surface 
proteins that are partly exposed to the extracellular milieu and recognise a multitude 
of signals such as photons, ions, nucleotides, lipids and biogenic amines, to peptides 
and larger proteins (Schlyer and Horuk, 2006). This makes GPCRs indispensable cell 
surface proteins that transduce a vast array of intracellular signals, and have provided 
pharmacologists a reservoir of drug targets. In fact, 30 % of pharmacological drugs 
on the market target GPCRs (Jacoby et al., 2006, Schlyer and Horuk, 2006, 
Overington et al., 2006). This section will provide an overview of GPCR trafficking, 
their structural & functional properties, and interacting proteins.  
1.2.1. Trafficking to the cell surface 
The process of GPCR maturation requires nascent receptors to fold correctly, 
ready for export from the endoplasmic reticulum (ER) to their place of residence on 
the cell surface (Figure 1.1) (Duvernay et al., 2005, Radford and Dobson, 1999, 
Sanders and Nagy, 2000, Trombetta and Parodi, 2003). The ER quality control 
system (QCS) determines the fate of nascent GPCRs by controlling their trafficking 
and routing within the cell (Ellgaard and Helenius, 2001, Cahill et al., 2002). 
Therefore, ER QCS must utilise a variety of complex systems such as folding 
proteins, retention factors, enzymes, escort proteins, and chaperones in order to sort 
receptors depending on their maturation status. Molecular chaperones are accessory 
components of the ER QCs, and serve to target misfolded proteins (Hartl and Hayer-
Hartl, 2002, Sitia and Braakman, 2003). The important regions in chaperone-protein 
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interactions include unpaired cysteines, immature glycans, or exposed motifs in the 
hydrophobic domains of misfolded proteins (Ellgaard and Helenius, 2001, Tan et al., 
2004, Dong et al., 2007). To this end molecular chaperones aim to stabilise 
structurally unstable nascent polypeptides in order to rescue correct folding and 
prevent aggregation (Hartl and Hayer-Hartl, 2002). In the event that the nascent 
polypeptides fail to fold correctly then they are targeted to the proteasomes for 
destruction (Werner et al., 1996; Schubert et al., 2000).  
Several GPCR-interacting chaperones have been identified; e.g. the 
mammalian RanBP2 is thought to bind to the red/green opsins and promote their 
proper folding and trafficking to the cell surface (Ferreira et al., 1996). The ODR4 
assists olfactory receptors in their proper folding and ER exit (Dwyer et al., 1998). 
Calreticulin and calnexin bind several GPCRs including gonadotropin-releasing 
hormone receptor (GnRHR), luteinizing hormone receptor (LHR), follicle-
stimulating hormone receptor (FSHR), vasopressin receptor (V2R), and thyrotropin 
receptor (TSHR) (Schrag et al., 2003, Helenius et al., 1997, Vassilakos et al., 1998, 
Rozell et al., 1998, Brothers et al., 2006, Morello et al., 2001). Calreticulin and 
calnexin bind oligosaccharides containing terminal glucose residues of proteins, 
which aid in degradation. During protein processing, glucose residues are removed 
from the core oligosaccharide, which is added during N-linked glycosylation. In the 
event of misfolded proteins, "overseer" enzymes will re-add glucose residues in the 
rough ER for the purpose of calreticulin/calnexin to bind and prevent proteins to 
proceed to the Golgi (Helenius et al., 1997, Schrag et al., 2003). One example of this 
is V2R R337X mutant, which results in the increased interaction between the mutant 
receptor calnexin and increase ER retention and inhibition of cell surface expression 
(Morello et al., 2001).  
The receptor activity modifying proteins (RAMPs) are another class of 
molecular chaperones that aid GPCR trafficking. RAMPs are known to interact with 
receptors like the vasoactive intestinal polypeptide (VIP), the pituitary adenylate 
cyclase-activating peptide receptor (PACAP), the calcitonin receptor-like receptor 
(CALCRL), the glucagon receptor, the parathyroid hormone receptor (PTH1R and 
PTH2R) (Christopoulos et al., 2003).  
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The unfolded protein response (UPR) pathway is a cellular stress response 
that is activated when misfolded proteins accumulate in the lumen of the ER. Several 
proteins are involved in the UPR pathway such as the transmembrane kinase 
endoribonuclease IRE1, activating transcription factor 6, BiP/Grp78, and the 
pancreatic ER kinase (Yang et al., 1998). Misfolded proteins induce a cascade of 
interactions starting with BiP dissociating from its three proximal sensors and binds 
to the misfolded proteins in an attempt to refold them, BiP dissociation releases the 
sensors from a negative inhibition which then transduces the UPR-inducible genes 
and decreases protein expression (Forman et al., 2003). Normal functioning of the 
UPR pathway will reduce new protein translocation and increase protein refolding or 
degradation (Harding et al., 2002; Kaufman, 2002). However, overwhelming the 
UPR pathway may lead to apoptosis (Forman et al., 2003).  
 
 
Figure 1.1 GPCR trafficking. GPCRs are transcribed in the nucleus, then translated 
and simultaneously incorporated into the lumen of the ER where they are correctly 
folded. In the event of misfolding GPCRs will be assisted or degraded in the ER. 
Subject to correct folding GPCRs are trafficked to the Golgi and then further 
transported to the plasma membrane [as reviewed in (Conn et al., 2007)] 
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1.2.2. Overview of GPCR structure and function 
Signal transduction is the fundamental process that orchestrates cellular 
physiology. Membrane proteins are upstream signalling units, and one of the most 
diverse membrane protein families is GPCRs. These 7-transmembrane proteins 
respond to a variety signals from the extracellular milieu, ranging from hormones, 
neurotransmitters, lipids, and to photons and converting them into cellular responses 
via heterotrimeric G-proteins and other GPCR interacting proteins [as reviewed in 
(Katritch et al., 2012)]. Pharmacological drugs that alter GPCR activity are already 
used in the treatment of asthma, migraines, and cardiac malfunction. Therefore, 
determining the structure of GPCRs is critical for advancing our understanding of 
fundamental biology, but also for disease modulation. In the last 15 years the 
structure of 18 different Class A (rhodopsin-like) GPCRs have been solved (Figure 
1.2). GPCRs are grouped into five major classes and numerous subclasses (Figurer 
1.3). These structures validate the common 7-transmembrane (7-TM) architecture, as 
well as show a structural diversity among GPCR, which are fundamental to their 
specialised functions. The solved structures are composed of closely related GPCR 
subtypes (β1AR and β2AR) with sequence identity of 65 %, different subfamilies 
(D3R, β2AR, and H1R) with sequence similarity of ~35 %, and from different sub-
branches of the same α-branch (β2AR and A2AAR) with ~30 % identity. Furthermore, 
there are solved structures from different branches i.e. α- and γ- branches of class A 
GPCRs (β2AR and CXCR4) with 25% identity (Figure 1.3) [as reviewed in (Katritch 
et al., 2012).  
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Figure 1.2 Time-line of solved GPCR structures. Time-line of GPCR structures by 
year of publication. A representative set of GPCRs are shown. The active GPCR 
structures are marked with black asterisks and the intermediate-active conformation 
is represented in grey asterisks. The Protein Data Bank accession numbers are 
presented below the structures. Obtained with permission from Nature Publishing 
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Figure 1.3 Sequence homology tree of human GPCRs. The solved GPCR 
structures are superimposed onto their respective locations on the tree dependent on 
the sequence similarly between the TM domains (>35 % homology). The highlighted 
areas represent close homology with the solved structures. GPR54, also known as the 
kisspeptin receptor (KISS1R), is emphasised (red circle) because of its importance in 
this thesis (see later sections). Obtained with permission from Elseveir B.V. (license 




Chapter 1: Introduction 
 
   7 
GPCRs are composed of seven transmembrane α-helical domains which are 
connected by three extracellular loops (ECL1–3) and three intracellular loops (ICL1–
3) (Figure 1.4). The EC region in conjunction with the N-terminus is responsible for 
ligand recognition (Lagerstrom and Schioth, 2008). The IC region interacts with 
intracellular proteins such as G proteins, arrestins and other GPCR interacting 
proteins. Furthermore, the IC region of GPCRs is usually composed of helix VIII and 
a C-terminus palmitoylation site that functions to anchor the receptor to the plasma 
membrane (Maeda et al., 2010a, Tobin et al., 2008). The most conserved GPCR 
region is the 7TM helical bundle, which contain signature motifs such as the ‘ionic 
lock’ (composed of D[E]RY) in helix III, the NPxxY motif in helix VII, and the WxP 
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Figure 1.4 The modularity of GPCRs. The major regions and features of GPCRs 
are shown using as example the solved structure of Dopamine receptor (D3R) (PDB 
3PBL). The extracellular region (EC) is formed of 3 extracellular loops (ECL) and an 
N-terminus. The 7-transmembrane helical bundle contain strategically positioned 
flexible proline residues that make ‘kinks’ and divide the receptor into two modules; 
the EC (extracellular) and IC (intracellular) modules. The EC module is also 
composed of TM-EC and is highly diverse in its structure and ligand binding 
properties. The IC module (also composed of TM-IC region) is more conserved, but 
undergoes greater structural change upon GPCR activation. The IC module is 
responsible for interfacing with downstream effectors such as G proteins and 
arrestins. The blue ribbon denotes highly conserved motifs that are also functionally 
important in class A GPCRs. Helix VIII in many GPCRs is responsible for anchoring 
the receptor to the membrane via a palmitoylation site. Obtained with permission 
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The 7-TM helical bundle serves to transduce ligand binding signals into G-
protein regulation. GPCRs are sufficiently similar in their sequence to constitute a 
family and different enough to have divergent functions. A structure based-sequence 
alignment study of the different GPCR structures, which includes both active and 
inactive conformations, revealed a shared network of 24 inter-TM contacts that are 
mediated by 36 topologically equivalent residues as represented by the Ballesteros–
Weinstein numbering scheme (Figure 1.5) [as reviewed in (Venkatakrishnan et al., 
2013)]. Some of the topologically equivalent amino acids have been reported to be 
functionally important and include highly conserved residues (Madabushi et al., 
2004): For instance, Asn 1.50, Asp 2.50, Trp 4.50 and Pro 7.50. Furthermore, they 
can tolerate amino acid substitutions. For instance, the non-covalent contact between 
2.42 and 3.46 is observed in all structures, but the amino acids are different in 
different structures. For example, the bovine rhodopsin corresponding residues are 
Ile 75 contacting Leu 131 and for the human k-OR it is Tyr 97 contacting Met 152. 
Therefore, the consensus network may provide a rigid structural scaffold that 
maintains the GPCR fold irrespective of conformational change or evolution driven 
sequence change. The spatial location of the consensus network within the receptor is 
largely in the middle and cytoplasmic side of the TM bundle and predominately 
located between TM1-TM2, TM3-TM4, TM4-TM5, and TM3-TM6-TM7. An 
important region is TM3, which is thought to be a ‘structural hub’, because of its 
extensive interfacing with other TM regions (Figure 1.5) [as reviewed in 
(Venkatakrishnan et al., 2013)].  
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Figure 1.5 Conserved GPCR inter-helical non-covalent contacts. The structure 
based sequence alignments of 17 solved structures were used to determine the 
consensus network that is common among all GPCR structures irrespective of their 
conformational state. A network of 24 inter-TM contacts between 36 topological 
equivalent residues (represented as Ballesteros-Weinstein numbering scheme) is 
presented (a) with a representative structure of inactive β1-AR. (b), Left, schematic 
representation of the conserved inter-helical contacts, the TM domains are presented 
as grey circles and the green line denotes the contacts with the thickness of the line 
being proportional to the number of contacts.  (b), Right, Ballesteros-Weinstein 
numbering of the 36 topological equivalents with their respective contacts (the line 
here is uniform). Obtained with permission from Nature Publishing Group (license 
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Upon receptor activation, G proteins interact with the cytoplasmic end of 
TM3 and intracellular loop 2 (Arg 3.50 of the DRY motif) (Rasmussen et al., 2011b). 
A case in point is rhodopsin; a salt bridge between Arg 3.50 and Glu 6.30 is broken 
upon receptor activation. This observation is commonly referred to as an ‘ionic lock’ 
and is thought to exist in the inactive state of some receptors (Lebon et al., 2012). A 
study of the active-state structures of rhodopsin (metarphodopsin II) bound a peptide 
mimicking the C-terminal tail of Gt and of β2-AR bound to the G protein (Gs) gives 
insights into the consensus structure that forms the interface between TM and G-
proteins. The interface is formed of ~8 residues in TM3, TM5, and TM6 (Figure 1.6) 
[as reviewed in (Venkatakrishnan et al., 2013)]. Upon receptor activation, the TM-G 
protein interface is created with a considerable movement of TM5 and TM6 (Figure 
1.6). An interesting and emerging observation is that G-protein coupling to receptor 
brings bidirectional regulation between the ligand-binding site and the G-protein 
binding site (Hino et al., 2012). Furthermore, G-protein coupling has been shown to 
induce a receptor conformation that is more sensitive to agonist (100- fold higher 
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Figure 1.6 The receptor–G protein interface. (a), Comparison of β2-AR TM 
movements between the active (cyan) and inactive (grey) conformations. The TMs 
that interface Gs protein and Gt peptides are presented in parentheses. The 
Ballesteros-Weinstein numbering is used to depict equivalent residues and the black 
dots represent residues that interact with the Gs and Gt peptides in both β2-AR (cyan) 
and rhodopsin (orange). (b), Intracellular view of β2-AR and rhodopsin with the 
highlighted residues that compose the interface between G-proteins. (c) A 
representation of the GPCR TM domains and G-protein (grey circles) interactions 
(green lines). The thickness of the green lines is proportional to the number of 
consensus contacts. Obtained with permission from Nature Publishing Group 








Chapter 1: Introduction 
 
   13 
1.2.2.1. The ternary complex model  
A molecule that binds to a GPCR and initiates a positive physiological 
response is referred to as an agonist. The power of an agonist to produce a response 
is referred to as efficacy. The concentration of agonist required to produce an effect 
of given intensity is termed as potency. Conversely, a molecule that binds to a 
receptor and induces a depression in basal physiological function is referred to as 
inverse-agonist. Furthermore, a molecule that binds a receptor but does not induce a 
physiological response is termed as an antagonist. One way to express this is the 
ternary complex (Figure 1.7). There exists equilibrium between agonist, GPCR and 
G-proteins, and the changing concentrations can make the equilibria shift. For 
example, an increase in agonist will shift the equilibria left of Figure1.7 creating an 
agonist-active receptor complex. An increase of receptors will increase the potency 
and efficacy of available agonists if not otherwise saturating (Kenakin, 2002b).  
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Figure 1.7 Commonly used models for GPCR equilibria. (a) In the classical 
receptor activation model, agonist (A) binding to an inactive receptor (Ri) forms a 
complex (ARi) which in turns creates an active agonist-receptor complex (ARa). In 
the case of antagonists, the ligand binds the receptor but does not create an active 
complex, and an inverse agonist reverses the equilibria from the active complex to an 
inactive complex. (b) A deeper understanding GPCR pharmacology incorporates G-
proteins in a ternary ARaG complex model. (c) The expanded ternary complex model 
captures the spontaneous formation of the active-state receptor (Ra) independent of 
agonist binding. The activation of the receptor from Ri to Ra modifies the affinity of 
the receptor for G-proteins (α, β and γ) and determines the efficacy. (d) The cubic 
ternary complex model allows for the formation of Ri complexed with G protein and 
the affinity is modified by the factors δ, β and γ. Obtained with permission from 
Nature Publishing Group (license number 3460351409397) [as reviewed in 
(Kenakin, 2002b) 
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1.2.3. Desensitization and endocytosis  
Cell signalling is fine-tuned to convey cellular physiology and therefore the 
receptors that initiate signalling must be turned off by a mechanism known as 
desensitization. Receptor desensitization is the process whereby overstimulation 
leads to reduced receptor response to the extracellular milieu. The level of 
desensitization is dependent on the amount and duration of the overstimulation, as 
well as the intracellular interacting proteins [as reviewed in (Ferguson, 2001, Kelly et 
al., 2008). The classical model of GPCR desensitization starts with inhibitory 
phosphorylation of the receptor intracellular loops and/or tail, which leads to G 
protein uncoupling (Figure1.7). The inhibitory phosphorylation is carried out by 
protein kinases such as cAMP-dependent protein kinase (PKA), G protein-coupled 
receptor kinases (GRKs), and protein kinase C (PKC) (Benovic et al., 1986, Benovic 
et al., 1985). Receptor desensitization by internalisation is initiated when β-arrestins 
associate with the phosphorylated receptors, recruiting β2-adaptin and clathrin, and 
therefore promoting endocytosis by clathrin-coated pits (Figure 1.8)(Ferguson et al., 
1996, Lohse et al., 1992, Zhang et al., 1996). The internalised receptors can be 
dephosphorylated by phosphatases and recycled back to the plasma membrane. 
However, sustained receptor down-regulation involves proteolytic degradation by 
proteasomes and reduced protein expression (Ferguson, 2001, Ritter and Hall, 2009, 





Chapter 1: Introduction 
 
   16 
 
 
Figure 1.8 Cartoon illustration of GPCR desensitization by endocytosis. The 
process of GPCR desensitization begins with the inhibitory phosphorylation (P) of 
hormone (H) stimulate GPCRs by protein kinases such as G-protein-coupled 
receptor kinase (GRK). Thereafter, β-arrestins (βarr) bind and inhibit G-protein (G) 
coupling. βarr also recruit β2-adaptin and clathrin, promoting endocytosis by clathrin 
coated pits. Recycling of GPCRs are then dephosphorylated by G protein-coupled 
receptor phosphatase (GRP) and reintegrated back into the plasma 
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1.2.4. The Receptosome: GPCR interacting proteins (GIPs) 
The classical understanding of G protein-coupled receptor (GPCR) signaling 
is that an agonist binds to the extracellular region of the receptor which promotes a 
conformational change that favours the interaction of heterotrimeric G proteins. 
GPCRs are commonly referred to as ‘guanine nucleotide exchange factors’, because 
GPCRs catalyses the exchange of GDP for GTP on the Gα subunit. This nucleotide 
exchange induces the dissociation of Gα and Gβγ subunits (Figure 1.9). There are 
four main subtypes of Gα, including Gαs, Gαi, Gα12/13 and Gαq. Upon activation 
the Gα•GTP complex regulates the activity of effectors such as adenylyl cyclase, 
RhoGEF and phospholipase Cβ (PLCβ). These molecules generate second 
messengers such as cyclic AMP, DAG and IP3 that further modulate downstream 
effectors, such as protein kinase A (PKA) and protein kinase C (PKC). The βγ 
subunits also have their unique cellular function of regulating ion channel 
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Figure 1.9 The classical GPCR signalling pathway. Agonist binding to the 
receptor EC region induces conformational changes to the IC region and promotes 
heterotrimeric G-proteins (α, β, and γ) to bind to the receptor. Upon formation of the 
receptor G-protein complex, the α subunit exchanges guanosine diphosphate (GDP) 
for guanosine triphosphate (GTP), resulting in the dissociation of the α and βγ 
subunits from the receptor. The activated subunits regulate their respective 
downstream effector proteins. The heterotrimeric G-proteins reassemble after the 
hydrolysis of GTP to GDP. Adapted and obtained with permission from Nature 
Publishing Group. Top panel obtained from [as reviewed in (Rasmussen et al., 
2011b)(license number 3342240463377)]. Bottom panel adapted from [as reviewed 
in (Ritter and Hall, 2009)(license  3343410290024)]. 
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The process of evolutionary adaptation of proteins to new environmental cues has 
generated more than 1000 GPCRs that are dedicated to cell-cell communication and 
the recognition of light, taste, and smell (Mansuy et al., 2011, Zhao and Kriegsfeld, 
2009, Quaynor et al., 2007). Before the turn of the century, the up-stream GPCR 
signal transduction pathways were believed to be simple. It was thought of in the 
following terms. Specific ligands activate GPCRs, which in turn cause the 
rearrangement of the transmembrane regions and intracellular domains. This 
conformational change enables a limited number of heterotrimeric G proteins to 
undergo structural changes. An exchange between GDP-GTP takes place within the 
G protein, leading to the separation of G-GTP and Gβγ subunits. Subsequently, 
both subunits bind and regulate various molecular effectors (Jacobi et al., 2007).  
However, GPCRs are now understood to interact with an increasing repertoire of 
GPCR interacting proteins (GIPs).  
GIPs took centre stage with the discovery of ‘receptosomes’ composed of 
inactivation-no-afterpotential D (INAD) (Tobet and Schwarting, 2006, Barrow and 
Trowsdale, 2006), Ste5 (Kirby et al., 2010, Aydin et al., 2010), and arrestins (Makri 
et al., 2008). Subsequently, an increasing number of GIPs have been discovered [as 
reviewed in (Duvernay et al., 2005, Salvi et al., 2006)]. GIPs interact with different 
intracellular regions of GPCRs and are responsible for targeting GPCRs to particular 
regions of the cell. In addition, GIPs are responsible for ‘fine tuning’ GPCR activity. 
Although complex there are lessons to be learnt in order to appreciate common 
interacting proteins.  
The concept of ‘receptosomes’, which describes the GPCR signaling 
complexes, was first described with the study of the phototransduction cascade in 
Drosophila. The GPCR that was implicated in this cascade was rhodopsin, eliciting 
the classical pathway that results in the regulation of ion channels and thus enabling 
a photon of light to excite a photoreceptor cell. The rhodopsin signaling complex, 
composed of direct and indirect protein associations is responsible for the efficacy of 
the cascade. The signaling complex is composed of the scaffolding protein INAD 
and Gq, PLCβ, store-operated Ca
2+
 entry channels [TRP], nonspecific cationic 
conductance channels [TRPL], εPKC and Ca
2+
/calmodulin. INAD acts as a 
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scaffolding protein because it contains 5 PDZ domains (Clarkson et al., 2008). PDZ 
domains are the most common protein interaction, responsible for signaling units 
(Clarkson et al., 2008).  
Another example is the GPCR - -factor pheromone receptor in the budding 
yeast Saccharomyces cerevisiae. In this example, the receptor upon activation 
enables the release of the Gβγ subunit, which then interacts with the scaffolding 
protein Ste5, causing it to translocate to the membrane. Afterwards, Ste5 via Ste20 
recruits MAPKKK (Ste11), the MAPKK (Ste7), and the MAPK (Fus3) (Kirby et al., 
2010). The two examples given above are interactions that are, on the whole, not 
physically associated with GPCRs. 
The visual arrestin was one of the first proteins shown to physically bind to 
GRK phosphorylated rhodopsin (Ang et al., 2000). Arrestin proteins and G-protein 
coupled receptor kinases (GRKs) have historically been the most common GIPs and 
are now understood to be critical in the GPCR desensitisation, internalization, 
trafficking, and signalling. The GRK family is composed of seven member genes. 
The expression of GRK1 and 7 is found in the retinal rods and cones, respectively. 
GRK4 expression is limited to the cerebellum, kidney and testis. The expression of 
GRK3, 5 and 6 are expressed widely in mammalian tissues. Arrestins consist of four-
members in the family. The expression of arrestin 1 and 4 are found in retinal rods 
and cones, respectively Arrestin 2 and 3 (they are also known as β-arrestin 1 and β-
arrestin 2) are ubiquitously expressed [as reviewed in (Reiter and Lefkowitz, 2006)].  
Increasing evidence is now emerging that the function of GRKs and arrestins 
are not only restricted to desensitisation and internalization, but extend to inducing 
downstream signaling via interacting proteins (Figure 10). GRKs and arrestin have 
the ability to scaffold signaling proteins and translocate them to receptors. Initial 
experiments that determined β-arrestin dependent signaling revealed the recruitment 
of the proto-oncogene Src (c-Src) to the receptor and thereafter resulting in the 
activation of the extra-cellular signal-regulated kinase (ERK1 or 2). The c-Src family 
proteins of Hck, Yes and Fgr, which are non-receptor tyrosine kinases are also 
recruited to the receptor via β-arrestins. β-Arrestins are able to scaffold JNK, ERK1 
and 2, MAPK, MAPKKK and MAPKK with the receptor. Furthermore, GRK 5 and 
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6 is required for β-arrestin dependent ERK activation by V2R, β2AR and AT1AR 
receptors, GRK2 and 3 appear to attenuate the β-arrestin dependent ERK activation. 
This would suggest that the GRKs are competing are competing with each other in 
order to provide a balance between signaling and desensitization and to coordinate 
the different pathways dependent on extracellular stimuli. Because GRK2 and 3 
require G-protein activation and GRK5 and 6 actually reside at the plasma membrane 
their unique locations will further facilitate divergent signaling by receptors [as 




Figure 1.10 The downstream signaling cascade of GRK and arrestin signaling.  
Ligand binding to the GPCR promotes the recruitment and activation of GRKs and 
arrestins. They either activate (green line) or inhibit (red line) downstream pathways. 
β-arrestin 1 can translocate into the nucleus and regulate gene expression.  Obtained 
with permission (license number - 3463340582990) from Elservier (Reiter and 
Lefkowitz, 2006), 
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Upon direct GPCR binding, arrestins 2 and 3 stoichiometerically bind clathrin of the 
clathrin-based endocytic vesicles [as reviewed in (Duvernay et al., 2005, Salvi et al., 
2006)]. GPCR endocytosis and trafficking is initiated by arrestins recuiting 
intracellular trafficking proteins, such as the N-ethylmaleimide-sensitive factor 
(NSF), the endocytic protein AP2, phosphoinositides, and the ADP-ribosylation 
factor ARF6,  along with its exchange factor ARNO. ARF6 recuits COP1 coatomers 
to regulate vesicle budding. Some GPCRs undergo internalisation through a non-
arrestin dependent manner (Tung and Lee, 2012, Cavallaro and Christofori, 2004). 
Furthermore, Arrestin 3 is ubiquitinylated upon binding to E3 ubiquitin ligase 
Mdm2 (Evans et al., 2008). This is necessary for β2-adrenergic receptor (β2-AR) 
internalization, as well as for β2-AR ubiquitinylation and degradation (Evans et al., 
2008, Cavallaro and Christofori, 2004, Tung and Lee, 2012). Arrestin 3 is also 
important for agonist-dependent internalization and degradation of the yeast 
pheromone receptor Ste2p and Ste3p and the vasopressin V2 receptor (Dalkyz et al., 
2000, Yaphe et al., 2000).  
GPCRs can interact with multiple proteins that enhance the efficiency and 
diversity of G-protein-mediated signaling. One prominent example includes the 
Homer proteins, which can interact with mGluR1, mGluR5 and the InsP3 receptors, 
thereby linking these receptors to increase the efficiency of mGluR-stimulated Ca
2+
 
signaling (Brakeman et al., 1997, Xiao et al., 1998, Tu et al., 1998). Other enhancers 
of GPCR signaling are members of the A-Kinase anchoring protein (AKAP) family, 
which interact with β-adrenergic receptors (β2AR) to tether protein kinase A (PKA) 
in the vicinity of the receptor and increase the efficiency of PKA-mediated 
phosphorylation of various substrates, including the receptor itself. The increased 
interaction with β2AR enhances receptor resensitization resulting in a more robust 
β2AR-mediated ERK signaling (Shih et al., 1999, Fraser et al., 2000, Tao et al., 2003, 
Gardner et al., 2006). 
The most extensively studied example of GIPs that can regulate receptor 
pharmacology are the receptor activity modifying proteins; RAMP 1, RAMP2 and 
RAMP3. The discovery of RAMP proteins is a classic example of research through 
serendipity. They were identified in experiments that attempted to search for the 
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receptor that was activated by calcitonin gene-related peptide (CGRP). In order to 
express functional CGRP receptor it required the co-expression of calcitonin 
receptor-like receptor (CAlCRl; also known as CRlR), with RAMP1. Furthermore, 
when RAMP2 and CAlCRl were co-expressed it resulted in formation of receptors 
activated not by CGRP, but a related peptide termed as adrenomedullin. 
Additionally, CAlCRl and RAMP3 can interact to form adrenomedullin receptor 
subtypes. Surprisingly, the co-expression of RAMP and a distinct receptor known as 
the calcitonin receptor (CAlCR) creates the formation of receptors with unique 
pharmacological properties. Moreover, the preferential activation of some RAMP–
CAlCR combinations are brought about by a distinct peptide known as amylin. It is 
now evident that the pharmacological properties of CAlCR and CAlCRl are 
dependent by cell type, depending on RAMP expression. Furthermore, RAMPs can 
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Table 1.1 GIPs that regulate G-protein mediated signalling. Adapted from Nature 











β2AR and β1AR CT Thethers PKA near to the receptor  
Calmodulin 5-HT1A IL3 Competes with PKC for GPCR 
phosphorylation 
 5-HT2A IL2 and CT Impairs G protein coupling 
 5-HT2c CT  Promotes arrestin-dependent ERK 
activation  
 D2R IL3 Modulates G protein signalling 
 mGluR7 CT Regulates GPCR phosphorylation  
 PTH1R CT Inhibits GPCR activity  




 μOPR IL3 Inhibits G protein coupling  
Homer mGluR1 and 
mGluR5 
CT Regulates GPCR signalling and 
localisation  
INAD Rhodopsin CT Enhances speed and efficiency of 
GPCR signalling 
JAK2 AGTR1 and 
PTAFR 
CT Promotes Jak-STAT signalling 
LARG (ARHGEF12) LPAR2 CT Facilitates GPCR-mediated activation 
of Rho 
MAGI3 Frizzled 4 and 
LPAR2 
CT Enhances GPCR-mediated activation 
of the MAPK ERK 
MUPP1 (MPDZ) GABAB and 
MT1 
CT Enhances GPCR-mediated Gαi 
signalling 





CT Enhances Gαq-mediated receptor 
signalling 






NHERF2 (SLC9A3R2) LPAR2 CT Enhances Gαq-mediated receptor 
signalling  
 mGluR5 and 
P2RY1 




 PTH1R CT Enhances Gαq-mediated receptor 
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signalling  




LPAR2 CT Facilitates GPCR-mediated activation 
of Rho 
Periplakin MCHR1 and 
μOPR 
CT Impairs G protein-mediated signalling  
Spinophilin D2R IL3 Reduces G protein and arrestin-
mediated signalling 
 α2AR and 
mAChR 
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1.3. The kisspeptin system  
1.3.1. RFamides and their cognate receptors 
RFamides are neuropeptides that share at their C-terminus an arginine-
phenylalanine-amide (RF-NH2) motif. Mammalian genomes contain five RFamide 
genes that are expressed to create precursor polyproteins that are later proteolytically 
cleaved to make physiologically active ligands (Figure 1.11). Although the grouping 
of these ligands is based on their C-terminus homology, the N-terminus is where the 
greatest diversity exists and confers onto the peptides their unique binding and 
signalling characteristics. One sure way of differentiating between these ligands is 
through a method of structure-activity relationship (SAR), in where the 3D structure 
and amino acid sequence of the peptides is related to its biological activity. SAR 
enables researchers to group RFamides in order to determine the chemical groups 
that evoke a target biological response in an organism of interest. This becomes of 
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NPFF 5.2 ± 2.4 
(1DMe)Y8Fa 5.3 ± 1.0 
NPFF-OH 4200 ± 800 
rNPSF 37 ± 12 
hNPY 4000 ± 1200 
hNPY18-36 1200 ± 200 
hPrRP20 23 ± 5 
hPrRP31 19 ± 4 
hRFRP-1 15 ± 2 
hRFRP-3 55 ± 4 




Figure 1.11 The RFamide family of peptides and their cognate receptors. Top, 
The genes that encode PrRP (prolactin releasing peptide), NPFF (Neuropeptide FF), 
RFRP (RFamide related peptide), KiSS-1 (kisspeptin), and QRFP (pyroglutamylated 
RFamide peptide) bind their respective G-protein coupled receptors (GPCRs). Cross-
talk between PrRP, NPFF, and RFRP peptides and their targets is indicated by 
arrows [adapted from (Jhamandas and Goncharuk, 2013)]. Below, a table of relative 
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The physiological roles RFamides is the subject of intense research, but 
currently we know that RFamides are master regulators of endocrine function, and 
are associated with the regulation of important pituitary hormones. These hormones 
include luteinising hormone (LH), follicle stimulating hormone (FSH), prolactin, 
growth hormone, adrenocorticotrophic hormone (ACTH), arginine vasopressin 
(AVP), and oxytocin. The downstream endocrine effects of RFamides are the 
regulation of mammalian growth, reproduction, maternal physiology, stress 
responses, blood pressure, and diuresis (Bechtold and Luckman, 2007, Osugi et al., 
2006).  
Some RFamides show an affinity for more than one GPCR, for example 
NPFF is known to bind NPFF1 and NPFF2 (Engström et al., 2003) (Figure 1.11). 
Additionally, both these receptors are also known to exhibit affinity for neuropeptide 
Y (an RYamide), as well as orexin and cholecystokinin peptides. This promiscuity 
may function to complement RFamide function in a yet unknown cross-talk 
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Table 1.2 Amino acid sequence comparison between human RFamide peptides. 
[adapted from (Findeisen et al., 2011)]. 








(Kotani et al., 2001, 
Ohtaki et al., 2001) 
 
KP13 LPNYNWNSFGLRF-NH2   
KP10 
 
YNWNSFGLRF-NH2   
NPFF SQAFLFQPQRF-NH2 






(Ubuka et al., 2009, 









(Bruzzone et al., 






(Hinuma et al., 
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The first RFamide to be discovered was neuropeptide FF (NPFF- 
FLFQPQRFa). The amino acid sequence of NPFF is conserved amongst mammalian 
species. NPFF expression is highest in the hypothalamus and to a lesser extent in the 
peripheral tissue (Hinuma et al., 2000). The precursor mRNA also encodes for NPSF 
(SLAAPQRFa), and NPVF (VPNLPQRFa) peptides (Bonini et al., 2000, Liu et al., 
2001). NPFF is known to control the neuronal processing of noxious stimuli by 
opioids (Chen et al., 2006, Mouledous et al., 2010). As well as playing a significant 
role in the autonomic nervous system’s control of cardiovascular response, 
neuroendocrine regulation, and feeding (Panula, 2009, Jhamandas and Goncharuk, 
2013). RFRPs have been shown to act on the pituitary and hypothalamus to facilitate 
prolactin release, inhibit GnRH release, and increase food intake (Johnson et al., 
2007, Clarke et al., 2008, Hinuma et al., 2000). RFRP1 acts in the hypothalamus to 
inhibit dopaminergic neuronal activity (Samson et al., 2003). RFRP3 has emerged as 
important regulator of reproductive function (Murakami et al., 2008).  
1.3.2. Kisspeptins and KISS1R 
The kisspeptin ligands (KPs) are products of the KiSS1 gene. The initial 
discovery of the KiSS1 gene occurred in Hershey, Pennsylvania, USA, where it 
gained its name after the famous Hershey’s chocolates kisses (Lee et al., 1996a). The 
KiSS1 gene encodes for a 145 amino acid (aa) propeptide that is cleaved to form C-
terminally amidated 54 aa peptide (KP54). Further cleavage creates peptide 
fragments called KP14, KP13, and KP10 (denoting the number of amino acids) 
(Figure 1.12). KPs are cognate ligands for the once orphaned GPCR called GPR54 
(also known as, KISS1R, AXOR12; HH8; HOT7T175; and KISS-1R). However, for 
this purpose of this thesis it will be referred to as KISS1R. All of the KP ligands have 
similar binding and signalling properties on KISS1R. Although the biochemical 
properties of the KP ligands are similar, the in vivo bioactivity of KP10 is greater 
than the other ligands. The termination of biological activity of KP ligands is brought 
about by the matrix-metalloproteases 2 and 9 (MMP-2/9)[ as reviewed in (Oakley et 
al., 2009)]. 
The KiSS1 mRNA expression profile by in situ hybridisation determined that 
levels are high in the pancreas, placenta, testis, small intestine, liver, and the 
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hypothalamus (Lee et al., 1996a, Ohtaki et al., 2001, Muir et al., 2001). Furthermore, 
KiSS1 mRNA expressing neurons have been identified in the hypothalamus (Kelly et 
al., 2013). Additionally, the expression profile of the KISS1R protein is high in the 
placenta, hypothalamus, and pituitary. The role of KISS1R expression became self-
evident in 2003 when clinical mutations of the KISS1R encoding gene showed 
individuals with hypogonadotropic hypogonadism (HH) (Seminara et al., 2003, de 
Roux et al., 2003). KP ligands and KISS1R function is now known to be critically 
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Figure 1.12 The cleavage products of Kisspeptin-145. The KiSS1 gene upon 
transcription and translation produces kispeptin 145 prepropeptide that is cleaved to 
make the kisspeptin 54 and then further cleaved to create the kisspeptin 14, 13, and 
10 peptides. Note the RF (denoting Arginine and Phenylalanine)  at the C-terminus 
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The KISS1R shares 45 % sequence homology with the galanin receptor 
(GAL1), this is a high sequence homology between two GPCRs. This would suggest 
that KISS1R and GAL1 share a common ancestor, however, the KP ligands do not 
bind nor activate GAL1 and vice versa (Lee et al., 1999). The KISS1R amino acid 
sequence is conserved amongst mammals, for example the sequence similarity 
between rat KISS1R and human KISS1R is 85%, and the transmembrane domains 
comprise 98% identity. Furthermore, the sequence similarity between mouse and 
human KISS1R is 82%. Thus, the KISS1R has structurally and functionally 
diversified from its closely related GPCR, but remains conserved among primate and 
rodent species (Kotani et al., 2001, Ohtaki et al., 2001, Muir et al., 2001). 
The principle signal transduction mechanism of KISS1R is through 
heterotrimeric G proteins (Figure 1.13). The G-protein q/11 enables phospholipase 
Cβ (PLCβ) to hydrolyse phosphatidylinositol 4, 5-bisphosphate (PIP2) to form diacyl 
glycerol (DAG) and inositol 1, 4, 5-trisphosphate (IP3). DAG activates protein kinase 
C (PKC) and IP3 binds its cognate receptors on the endoplasmic reticulum (ER), 
causing calcium puffs (Constantin et al., 2009, Liu et al., 2008, Muir et al., 2001, 
Stafford et al., 2002, Kotani et al., 2001). The surge in cytoplasmic Ca
2+
 results in the 
stimulation of extracellular signal–regulated kinase (ERK) 1 and ERK2 kinase 
(Kotani et al., 2001). DAG function is important in the depolarization of 
gonadotropin releasing hormone neurons (GnRH neurons), by means of activating 
nonselective cation channel (TRPC), and at the same time inhibiting inwardly 
rectifying potassium channels (Kir) (Liu et al., 2008, Pielecka-Fortuna et al., 2008).  
With the use of a GnRH promoter driven green fluorescent protein (GFP) reporter, 
researchers have been able to identify GnRH neurons in mouse brain slices, and 
carry out electrophysiological tests. Using this method, KP ligands were found to be 
potent activators of GnRH neurons by increasing their rate of action potentials (Han 
et al., 2005, Quaynor et al., 2007). One of the signalling mechanisms of action is 
through the inhibition of γ-amino-butyric acid (GABA). GABA is inhibitory 
neurotransmitter that is known inhibit GnRH secretion from GnRH neurons through 
neuronal hyperpolarisation (Clarkson and Herbison, 2006). KP ligands have been 
shown to suppress the effects of GABAB receptor in GnRH neurons (Zhang et al., 
2009). Like other GPCRs, the KISS1R is desensitised through the process of 
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internationalisation and interactions with β-arrestin and G-protein coupled receptor 







Figure 1.13 The signal transduction mechanism of KPs and KISS1R. KP ligand 
binding to KISS1R induces G protein q/11 to activate phospholipase C (PLC) and 
enable the cleavage of phosphoinositide 4, 5-bisphosphate (PIP2) to form diacyl 
glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 activates its cognate 
receptors on the endoplasmic reticulum and promotes the increase of intracellular 
Ca
2+
. This process activates protein kinase C (PKC) and a kinase phosphorylation 
cascade (RAF, MEK1/2, ERK1/2) is initiated. In the case of gonadotropin  releasing 
hormone neurons (GnRH neurons), depolarization is known to be controlled by DAG 
activating nonselective cation channel (TRPC), and at the same time inhibiting 
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Prior to the discovery of kisspeptins’ cognate GPCRs (being known), KPs 
were exclusively thought to be metastasis inhibitors, hence their early name, 
metastin. Although the KP/KISS1R pathway is appreciated for its role in the 
regulation of the reproductive axis, this pathway also has a role in modulating 
disease states. The KP/KISS1R system functions as anti-metastatic in some types of 
cancers such as pancreatic cancer, melanoma, and gastric carcinoma (Masui et al., 
2004, Shoji et al., 2009). The molecular mechanisms that underlie this anti-metastatic 
function are poorly understood and require further investigation. However, KISS1R 
is known to inhibit the action of MMP-9, increase the expression of the tissue 
inhibitor of matrix metalloprotease-1 (TIMP-1), and increase the activity of focal 
adhesion kinase (FAK). This leads to the inhibition of cell migration, development of 
focal adhesions and stress fibres (Kotani et al., 2001, Makri et al., 2008). The impact 
of the KP/KISS1R system has been shown to inhibit cell proliferation, motility, 
invasion, and chemotaxis (Kotani et al., 2001, Ohtaki et al., 2001). 
1.3.3. KISS1R Agonists 
All the natural cognate ligands for KISS1R ( KP54, 14, 13, and 10) have 
similar binding and signalling characteristics to each other (Kotani et al., 2001). The 
similarity is caused by the conserved C-terminal region of the KP ligands (Figure 
1.12 and Table 1.2). As a result, researchers used the N-terminally truncated KP10 as 
a template for structure-activity studies (Gutiérrez-Pascual et al., 2009, Ohtaki et al., 
2001). They found that the five C-terminal residues are critical for KISS1R 
activation (Niida et al., 2006). Ala scanning mutagenesis studies revealed that 
KP10’s critical residues were Phe6, Arg9, and Phe10, Ala substitution here would 
result in loss of agonistic activity (Niida et al., 2006, Gutiérrez-Pascual et al., 2009, 
Orsini et al., 2007). A nuclear magnetic resonance study using KP13 corroborated 
the importance of these three residues as they lie on the surface of a helix and are 
thought to constitute the pharmacophore site (Orsini et al., 2007).  
Several compounds that have KP10-like agonist activity have been 
developed. For example the down-sized FM052a and FM053a are equipotent to 
KP10 (Niida et al., 2006). Further optimization of these analogues created another 
agonist; H-Amb-Nal(2)-Gly-Leu-Arg-Trp-NH2 (compound 34), which is reported to 
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be 4 times more potent than KP10 (Tomita et al., 2006). Another analogue termed 
FTM145 was created to inhibit proteinase degradation and increase bioactivity by 
inserting (E)-alkene dipeptide isostere at the Gly-Leu site (Tomita et al., 2008). 
Similarly, the [D-Y]1KP10 analog, although having  a lower binding affinity for 
KISS1R is reported to have a higher in vivo bioactivity because of a resistance to 
proteolytic degradation compared to KP10 (Curtis et al., 2010).  
1.3.4. The role of kisspeptin in reproduction and puberty  
During the developmental stages of mammals, gonadotropin releasing 
hormone (GnRH) expressing neurons originate in the olfactory placode, where they 
migrate and colonise a region of the basal forebrain known as the preoptic area 
(POA) and the mediobasal hypothalamus (Wray et al., 1989b, Schwanzel-Fukuda 
and Pfaff, 1989, Wray, 2002). GnRH neurons are surrounded by terminals of KP 
expressing neurons (Irwig et al., 2004). The anatomical architecture of the 
hypothalamus, median eminence (ME), and the pituitary gland create precise control 
of the gonadotropin cells of the pituitary. GnRH neurons extend their projections 
onto the external secretory zone of the ME, where GnRH neuronal terminals interact 
with the primary capillary bed of the hypophyseal portal system (Page and Dovey-
Hartman, 1984).  
The mammalian brain expresses KP neurons in the arcuate (Arc) nucleus and 
the anteroventral periventricular nucleus (AVPV) (Navarro et al., 2009, Mayer et al., 
2010). The KP neurons of the AVPV are thought to be responsible for the onset of 
puberty (Mayer et al., 2010). In the female brain, KP neurons of the AVPV control 
preovulatory surge of LH. The male neonatal masculisation process creates an 
AVPV that expresses low numbers of KP neurons relative to females. The pulsatile 
section of GnRH is thought to be regulated by the KP neurons of the Arc 
(d'Anglemont de Tassigny and Colledge, 2010, Colledge, 2004).  
In order to insure the survival of all species, reproductive function is fine-
tuned by central and peripheral signals that coordinate the hypothalamic pituitary 
gonadal (HPG) axis (Fink, 2000). The hypothalamus is where sparsely distributed 
neurons secrete GnRH, which acts on gonadotropin cells of the anterior pituitary to 
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secrete follicle stimulating hormone (FSH) and luteinizing hormone (LH). The 
gonads generate gametes that secure for future generations a continued genome, as 
well as synthesising peptide hormones and sex steroids (Fink, 2000, Schwartz, 
2000a). 
The HPG axis is governed by feed-forward loops (Figure 1.14). In order to 
establish homeostatic regulation, other forms of feedback regulatory loops are 
present. GnRH neurons are critical units in the hypothalamic component of the HPG 
axis, because the subsequent secretion of GnRH regulates downstream processes. 
Therefore, regulating GnRH pulsatile secretion is critical for synchronising the axis 
(Santoro et al., 1986, Belchetz et al., 1978). GnRH neurons are regulated by 
hypothalamic afferent neurons (Maeda et al., 2010b). The HPG axis of males and 
females is differentiated to give unique capabilities at puberty. This sexual 
dimorphism arises from the stages of foetal and postnatal development to bring about 
differences in the timing of puberty, the reproductive brain circuits, and the sexual 
dimorphic role of the HPG axis in adulthood (Fink, 2000, Herbison, 2006, Schwartz, 
2000a). These differences give rise to female-specific roles in the ovarian cycle, 
lactation, and pregnancy (Roa et al., 2006, Schwartz, 2000b, Smith and Grove, 
2002).  
The reproductive system is important for general health, energy homeostasis, 
and immune/inflammatory state (Fernandez-Fernandez et al., 2006, Tena-Sempere, 
2007, Tomaszewska-Zaremba and Herman, 2009). Furthermore, the reproductive 
system is responsive to environmental cues, such as stress conditions and 
photoperiods (Kinsey-Jones et al., 2009, Li et al., 2010, Simonneaux et al., 2009). 
The GnRH pulse generator interacts with circulating hormones, neurotransmitters, 
and neuropeptides (Fink, 2000, Herbison, 2006, Schwartz, 2000b). Additionally, 
GnRH neurons are regulated by many interacting glial and trans-synaptic inputs 
(Herbison, 2006, Ojeda et al., 2006, Ojeda et al., 2009). Glial cells are emerging as 
important regulators of puberty onset and adult reproductive function due to their 
facilitatory role, for example glial cells are known to stimulate GnRH neurons via 
glutamate and growth factors (Ojeda et al., 2006, Ojeda et al., 2009). Afferent 
neurons that regulate the pulsatile secretion of GnRH have been partially elucidated 
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(Herbison, 2006, Ojeda et al., 2008). Neurotransmitters such as glutamate and 
norepinephrine are known to be major excitatory factors, whereas endogenous 
opioids and GABA are inhibitory signals (Ojeda et al., 2009). However, in particular 
cases GABA can excite GnRH neurons (Herbison and Moenter, 2011). Briefly, some 
other participating factors that regulate reproductive function are as follows; 
members of the RF-amide superfamily and GnIH (Clarke et al., 2009, Navarro et al., 
2006, Smith and Clarke, 2010). Tachykinins including NKB (Lehman et al., 2010), 
as well as metabolic neuropeptides like NPY and nesfatin-1(García-Galiano et al., 
2010, Pralong, 2010). 
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Figure 1.14 The hypothalamic-pituitary-gonadal (HPG) axis.  Hypothalamic 
GnRH neurons are regulated by afferent neurons. GnRH is released into the blood 
system via the hypophysial portal. GnRH levels drive the pulsatile secretion of FSH 
and LH in the pituitary, which in turn regulate gonadal function (both the testes and 
ovaries are present). The axis is regulated by feedback regulatory loops, such as 
gonadal steroids like testicular testosterone (T), which is inhibitory to 
GnRH/LH/FSH (negative feedback). However, ovarian steroids mainly progesterone 
(P) and estradiol (E2) have dual roles, they can function as positive or negative 
feedback subject to the stages of the ovarian cycle. Metabolic hormones also regulate 
the HPG axis. These include the leptin, which is produced in white adipose tissue 
(WAT). Other abbreviations include – RFR, RF-related peptides; Glu, glutamate; 
NE, norepinephrine; NKB, neurokinin-B; EOP, endogenous opioid peptides; Dyn, 
dynorphin; GABA, γ-aminobutyric acid. Obtained with permission from the 
American Physiological Society (license number 3337131130885) (Pinilla et al., 
2012).  
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1.3.5. The role of kisspeptin and KISS1R in pathology  
The first reported cases of disease causing mutations of the KISS1R gene was 
shown by de Roux and colleagues of 2003 and quickly followed by Seminara and 
colleagues in 2003, in the same year. Both groups independently reported the 
presence of deletions leading to inactivating mutations of the KISS1R gene in 
patients with sporadic or familial forms hypogonadotropic hypogonadism (IHH), a 
rare condition leading to impaired gonadotropin secretion and infertility (de Roux et 
al., 2003, Seminara et al., 2003). These observations were further corroborated with 
mice engineered to lack KISS1R function, these studies were a phenocopy of the 
affected patients (Funes et al., 2003, Seminara et al., 2003). These findings were 
needed to realise the critical role of KISS1R and KP ligands in the reproduction 
system. Later studies confirmed these observations with KiSS1 null mice 
(d'Anglemont de Tassigny et al., 2007, Lapatto et al., 2007). However, the KiSS1 KO 
mice showed a less severe reproductive phenotype than KISS1R-deficient mice 
(Colledge, 2009). This may be due to the compensatory role of other RF-amides.   
Patients suffering from clinical inactivating mutations of KISS1R responded 
to exogenous GnRH administration, partially rescuing their reproductive phenotype 
(Seminara et al., 2003). Furthermore, precocious puberty (time of vaginal opening) 
was observed with the chronic central administration of KP ligand into pre-pubertal 
female rats (Navarro et al., 2004). Conversely, a KP antagonist (p234) delayed 
puberty in female rats [as reviewed in (Pineda et al., 2010)]. Another supporting 
piece evidence for the role of KP in puberty is the observed increased expression of 
KiSS1 mRNA in the hypothalamus of pubertal monkeys of both sexes (Shahab et al., 
2005).  
Several reports have suggested that the timing of the onset of puberty in girls 
has become earlier over the last 30 years. A major contributor to this is the increasing 
levels obesity in children (Kaplowitz, 2008). However, little is known about the 
mechanistic processes that govern this. KP neurons have been found to express leptin 
receptors, suggesting that the increase in leptin from white adipose tissue may 
regulate the HPG axis via KP neurons (Smith et al., 2006). Furthermore, leptin 
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deficient mice (ob/ob mice) exhibited reduced KiSS1 mRNA levels in the arcuate 
nucleus of the hypothalamus (Smith et al., 2006).  
The first described function of KPs was an anti-metastasis factor in human 
melanoma cell-lines (Becker et al., 2005, Takino et al., 2003). KPs inhibit RhoA-
mediated tumor necrosis factor-alpha (TNFα) induced nuclear factor-kappa (NF-kB) 
pathway and thus suppresses cancer development and metastasis in breast cancer 
proliferation, migration, and invasion (Lee et al., 1996a). Furthermore, upon KP 
ligand binding, the KISS1R has been shown to inhibit cell proliferation, motility, 
chemotaxis and metastasis (Hori et al., 2001, Kotani et al., 2001, Lee and Welch, 
1997, Ohtaki et al., 2001, Yan et al., 2001). The expression level of KP is inversely 
related to the metastatic potential of many types of tumours, such as in malignant 
melanoma, bladder, ovarian, gastric, breast, esophageal, uveal melanoma, 
osteosarcoma, renal and pancreatic cancers (Sanchez-Carbayo et al., 2003a, Dhar et 
al., 2004, Hata et al., 2007, Hesling et al., 2004, Ikeguchi et al., 2004, Lee et al., 
1996b, Lee and Welch, 1997, Martins et al., 2008, Masui et al., 2004, Mitchell et al., 
2006, Nagai et al., 2009, Shirasaki et al., 2001, Yi et al., 2008, Yoshioka et al., 2008, 
Sanchez-Carbayo et al., 2003b) 
The clinical mutations of KPs and KISS1R are extremely rare (Cerrato et al., 
2006). Nevertheless, they have provided insights into the role of KPs and KISS1R in 
reproduction. For example, inactivating clinical mutations of human KISS1R have 
been reported with a 155-nt deletion between intron 4 and exon 5, the R331X and 
X399X mutations, and the homozygous L148S mutation, all of which lead to IHH 
(Seminara et al., 2003, de Roux et al., 2003). Furthermore, C223R, R297L, L102P, 
and F272S substitutions have been reported to cause IHH in patients (Semple et al., 
2005, Tenenbaum-Rakover et al., 2007, Nimri et al., 2011, Todman et al., 2005) . 
Additionally, an insertion at 1001_1002C has been reported which shifts the open-
reading frame leading to IHH (Lanfranco et al., 2005). An illustration of the clinical 
mutations of KISS1R is presented in Figure 1.15. 
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Figure 1.15 Schematic representation of human KISS1R with clinical mutations. 
The inactivating mutations are indicated in red and the activating mutation is 
indicated in blue. The insertion site is indicated in red arrow. [as reviewed in (Pinilla 
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Two clinical missense mutations in the KiSS1 gene (KPs) have been reported 
(P74S and H90D) and are reported to cause central precocious puberty. The 
mechanism of action here is the increased stability of KP54 and thus increased 
bioactivity (Silveira et al., 2010). Another clinical mutation that leads to precocious 
puberty is reported in the KISS1R R386P. This autosomal dominant mutation has 
been demonstrated in vitro to prolong KISS1R activity as a measure of IP3 
production upon KP stimulation (Teles et al., 2008). 
1.3.6. Cell-line models of GnRH neurons. 
Researchers have developed physiologically relevant in vitro assays to study 
KP and KISS1R function. The challenge was that the intracellular molecular 
pathways that modulate GnRH neuronal function have been hindered by the low 
number and sparse distribution of these neurons in the hypothalamus (King et al., 
1982, Wray et al., 1989a). Although, primary cell cultures circumvent this, the 
challenge is how to separate GnRH neurons from other cells. Thus researchers turned 
to the use of cell-lines derived from GnRH neurons. These immortalised cell-lines 
commonly referred to as ‘GnRH neurons’ bear some limitations, mainly from the 
immortalisation procedure and the unknown developmental stage at which the GnRH 
neurons were transformed.  
The GT1-7 cell-line was created by incorporating a hybrid gene encoding for 
the SV40 T-antigen driven by the GnRH promoter into the mouse genome. This 
approach targets tumorigenesis to specific hypothalamic neurons that express GnRH. 
This GT1-7 cell-line was found to express endogenous GnRH mRNA, secrete GnRH 
in response to depolarization, and display neuronal, but not glial markers.  It also 
appeared to show extended neurites (Mellon et al., 1990). However, constitutive 
expression of the immortalization agent – SV40 T-antigen may interfere with the 
normal functioning of cellular processes. Indeed, epidemiological and molecular 
evidence exists that links the expression of T-antigen to various molecular regulation 
pathways (Slack et al., 1999, Seinsoth et al., 2003, May et al., 2004, Cotsiki et al., 
2004). Thus, the expression of the T-antigen may hinder the usefulness of the GT1-7 
cell-line.  
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Alternative to GT1-7 cells, researchers created the GnV3 cell-line. This cell-line is 
derived from adult GnRH neurons of the rat hypothalamus. This was done by 
generating two lentiviral constructs: in the first construct, the GnRH promoter was 
cloned 5’ to the tetracycline transactivator sequence; in the second construct, the 
TRE was cloned 5’ to v-myc (the immortalization agent) and followed by the 
minigene encoding resistance to puromycine at the 3’ (Salvi et al., 2006). These 
constructs enabled the researchers to conditionally, with the use of doxycycline, 
induce significant increase in cell proliferation, and with puromycine select for cells 
derived from GnRH neurons. Whereas in the absence of doxycycline GnV3 cells 
stop proliferating and develop many features common to GnRH neurons, such as 
electrophysiological, morphological similarities to neurons and they have been 
reported to express and secrete GnRH (Salvi et al., 2006, Mansuy et al., 2011).  
1.4. Ca2+/calmodulin 
The chemical element calcium was created in the furnaces of stars when oxygen and 
neon bound successive α particles. Now calcium is the fifth most abundant element 
on earth and its ionised version [Ca
2+
] is a principle regulator of cell signalling. 
Binding of Ca
2+
 to cognate proteins alters their shape, charge, and interactions. 
Moreover, cells must maintain a 20,000-fold gradient between their intracellular and 
extracellular Ca
2+
 concentrations. In contrast, Mg
2+
 levels barely differs across the 
plasma membrane. Why is Ca
2+
 vigorously removed from the cytosol? One 
explanation is that Ca
2+
 precipitates phosphate. Therefore, cells have adapted 
mechanisms to sequester and utilise cytosolic Ca
2+
 for signal transduction purposes. 
Moreover, Ca
2+
 cannot be chemically altered, thus cells have to chelate, 
compartmentalise, or extrude it. To this end, hundreds of proteins have evolved 
affinities for Ca
2+
 over a million-fold range (nM to mM), that function to buffer Ca
2+
 
levels or to induce cellular processes (Clapham, 2007). The cell’s “professional” 
protein chelator of Ca
2+
 is the EF hand domain, which was first described after the E 
and F regions of parvalbumin (Nakayama and Kretsinger, 1994). The EF hand motifs 
contain negatively charged oxygen atoms that cradle Ca
2+
. The best studied EF hand 
protein is calmodulin. Below I describe calmodulin’s structural features and its 
interactions with GPCRs.  
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1.4.1 Structural features of calmodulin  
The name calmodulin is in fact an abbreviation for calcium modulator protein 
and is also represented in short form as CaM. CaM is relativity small with 148 amino 
acids and a molecular weight of 16.7 kDa (Figure 1.16) (Babu et al., 1985, da Silva 
and Reinach, 1991, Gnegy, 1993), The structure of CaM can be thought of as a 
dumbbell, in that the two globular domains are separated by a linker region 
(Persechini and Kretsinger, 1988, Kuboniwa et al., 1995). The linker region is 26 
amino acids long and connects the last alpha helix of the N-terminal domain and the 
first alpha helix of the C-terminal domain. The linker region also functions to 
distance the two globular domains (Meador et al., 1993). The two globular domains 
of CaM each have two helix-loop-helix EF-hand regions that bind Ca
2+
. The CaM N-
terminal domain has a 10-fold lower affinity for Ca
2+
 than the C-terminal globular 
(Linse et al., 1991) 
 
Figure 1.16 Calmodulin sequence 
schematic. The calmodulin protein 
contains two Ca
2+
 binding EF-hand regions 
in the N-terminal (represented as – I and 
II), and the C-terminus (shown as - III and 
IV). The alpha-helical regions are 
highlighted with bold circles. With 
permission from Elsevier (license number - 









Chapter 1: Introduction 
 
  46 
1.4.2. Calmodulin conformational states 
There are three CaM conformational states; the first is the Ca
2+
 free CaM, 
otherwise known as apocalmodulin, the second is Ca
2+
 bound CaM, which is 
represented as Ca
2+
/CaM, and third is the Ca
2+
/CaM-bound to target protein. The 
main characterising feature of the apocalmodulin conformation is the retention of 
hydrophobic residues imbedded inside the structure of the globular domains (Jurado 
et al., 1999). The retention of the hydrophobic core is maintained by strongly twisted 















Figure 1.17 The apocalmodulin structure. The Ca
2+-
free CaM is compact with 
hydrophobic residues retained inside the structure and hydrophilic amino acids 
covering the outside of the protein. Panel A- the worm rendering shows that the 





. Panel B- the space filled rendering shows blue and brown colours, which 
denote hydrophilic and hydrophobic residues, respectively. This structure was 
created using Cn3D program with PDB ID; 1CFD. The structure was previously 
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the opening of the EF-hand regions. The conformation of the Ca
2+
/CaM induces the 
hydrophobic residues to swing outwards forming a hydrophobic cup at both globular 
domains (Figure 1.18). The hydrophobic cups of Ca
2+
/CaM bind to hydrophobic 
regions of target proteins (Kuboniwa et al., 1995). The stretching of the central α-
helix observed in the crystal structure is indeed a crystallographic artefact and in 















Figure 1.18 The Ca
2+
/CaM structure. The crystal structure of Ca
2+
/CaM shows that 
the EF-hand regions swing out and expose the once hidden hydrophobic core. Panel 
A is a worm rendering and panel B is a space filled representation and shows 
hydrophilic to hydrophobic residues depicted as blue to brown colours. The 
rendering was created using Cn3D program with PDB ID; 3CLN, obtained from 
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/CaM is thought to interact with approximately ~100 proteins (Fallon and 
Quiocho, 2003). The solved structure of Ca
2+
-CaM bound αCaMKII peptide (290-
314aa) has revealed that the two globular domains compact and the hydrophobic 
cups interact with bulky hydrophobic residues of the target peptide (Meador et al., 
1993). It is therefore not surprising, that αCaMKII T305/306 autophosphorylation 
inhibits Ca
2+











Figure 1.19 The structure of Ca
2+
/CaM bound CaMKII 290-314 aa peptide. 
The Ca
2+
/CaM bound to CaMKII peptide is compacted due to the unwinding 
central helix in order to enable the hydrophobic cups to interact with the hydrophobic 
residues of the peptide. The worm rendering was created using Cn3D program with 
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1.4.3. Calmodulin binding to GPCRs 
CaM has been shown to interact with several GPCRs and modulate their 
function [as reviewed in (Ritter and Hall, 2009)] (Table 1.3). For example CaM has 
been shown to bind to the third intracellular loop of the -opioid receptor and 
attenuate G-protein coupling (Wang et al., 2000, Wang et al., 1999) Furthermore, 
single-nucleotide polymorphisms in the G-protein coupling domain of the -opioid 
receptor were found to increase the receptor basal activity by altering CaM binding 
(Wang et al., 2001). Additionally, previous reports have shown that CaM interacts 
with the 5-hydroxytryptamine receptors 1A, 2A, and 2C (5-HT). The 5-HT1A 
receptor contains two CaM binding sites in the third intracellular loop, which 
incidentally is a protein kinase C (PKC) binding site. The binding of CaM and PKC 
to the 5-HT1A receptor is antagonistic and therefore important in modulating receptor 
activity (Turner et al., 2004). The 5-HT2A contains two CaM binding sites, one in the 
second intracellular loop and the other within the C-terminal region. Binding of CaM 
to the C-terminal region of 5-HT2A antagonises PKC binding, however, CaM binding 
the second intracellular loop attenuates G-protein coupling (Denis et al., 2012). The 
5-HT2C receptor also binds CaM at the C-terminal region (Becamel et al., 2002, 
Labasque et al., 2008). Moreover, CaM binding stabilises the 5-HT2C/β-arrestin 
complex resulting in G-protein-independent ERK1/2 signalling (Teles et al., 2008).  
CaM also binds metabotropic glutamate receptor 5 (mGluR5) at the C-
terminal tail, which also overlaps a PKC phosphorylation site. CaM and PKC 
interactions with mGluR5 appear to be antagonistic with one another (Minakami et 
al., 1997). CaM binding stabilises mGluR5 surface distribution, while PKC 
phosphorylation abolishes CaM binding and promotes receptor internalisation Lee et 
al. (2008). CaM binding is also reported occur at the C-terminal tail of several Class 
B receptors, which results in the modulation of the agonist-stimulated activity of 
vasoactive intestinal peptide, calcitonin, glucagon-like peptide, parathyroid hormone, 
and pituitary adenylate cyclase activating corticotrophin releasing hormone receptors 
(Mahon and Shimada, 2005). Taken together, these observations suggest that CaM 
binding to GPCRs affect receptor trafficking, as well as G-protein-dependent and 
independent signalling.  
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Impact on GPRCR Reference 
5-HT1A IL3 Impairs PKC biding for 
receptor phosphorylation 
(Turner et al., 2004) 
5-HT2A IL2 and CT Inhibits G protein coupling (Turner and Raymond, 
2005) 
5-HT2C CT Induces arrestin-dependent 
ERK activation 
(Labasque et al., 2008) 
D2R IL3 Regulates G protein signalling (Bofill-Cardona et al., 
2000, Liu et al., 2007) 
mGluR5 CT Promotes receptor expression (Minakami et al., 1997, 
Lee et al., 2008) 
mGluR7 CT Modulates receptor 
phosphorylation 
(Nakajima et al., 1999, 
Sorensen et al., 2002) 
PTH1R CT Inhibits GPCR activity (Mahon and Shimada, 
2005) 




(Nickols et al., 2004) 
OPR IL3 Regulates GPCR signalling 
and localization 
(Wang et al., 1999) 
Chapter 1: Introduction 
 
  51 
1.5. αCaMKII 
1.5.1. Structure and regulation   
α-Ca
2+
/calmodulin dependent protein kinase II (αCaMKII) is Ser/Thr protein 
kinase that is regulating by Ca
2+
/CaM binding. This oligomeric protein kinase 
holoenzyme is composed of four domains; an N-terminal catalytic domain, 
regulatory domain, variable linker domain, and the C-terminal association domain. 
The monomeric molecular weight is ~54 kDa (Figure 1.20). The structure of 
αCaMKII is hexagonal with the association domain at the centre governing the 
oligomerisation. Extending outwards is the variable linker domain, which is 
responsible for sub-cellular localisation of the enzyme. Adjacent to the variable 
linker domain is the regulatory domain that contains the Ca
2+
/CaM binding site and 
the inhibitory autophosphorylation site of T305/306. Also present is the T286 
autophosphorylation site, which plays a role in enzyme activation and stabilises the 
active conformation [as reviewed in (Coultrap and Bayer, 2012)] 
The structure of αCaMKII is analogous to ‘petals on a flower’. The first 
structural study of αCaMKII was with electron microscopy. The derived 
images/models revealed a hexagonal structure consisting of a smaller inner and a 
larger outer ring. The smaller inner ring was calculated to be ~6 nm in radius, 
containing 6 subunits in the top and bottom monomer. The inner ring is organised 
around a hollow centre. The larger outer ring extends to ~15 nm from the core and is 
made of 12 catalytic domains (Morris and Torok, 2001). 
In that early study of Morris and Tӧrӧk, 2001, they found that the single 
partial EM images gave a less defined outer ring in αCaMKII obtained from the rat 
brain compared when purified from recombinant baculovirus expressed cell-lines  
The authors suggest that the rat brain purified αCaMKII exhibits a higher degree of 
disorder because of basal autophosphorylation, as well as the contribution of 
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Figure 1.20 Illustration of αCaMKII structure and 
regulation. (a) An illustration depicting the primary structure 
of αCaMKII, with the variable linker domain being subject to 
alternative splicing as indicated with a triangle. Functionally 
important residues are indicated, with phosphorylation sites in 
red. (b) A structural model of αCaMKII is shown in two 
different views angles. The 12meric holoenzyme model is 
derived from several partial crystal structures (Rosenberg et 
al., 2006, Hoelz et al., 2003, Rosenberg et al., 2005). (c) The 
amino acid sequence of the regulatory domain, with 
autoinhibitory and CaM-binding regions are shown in dark 
and light green, respectively. The oxidation site – M281 is 
represented in black. The green arrow indicates the N 
terminus of the core CaM-binding region (R296) and is 
carried forward in panel (d); which shows the structural 
transition of the regulatory domain upon Ca
2+
/CaM binding 
(Rellos et al., 2010). (e) Crystal structure of the basal state of 
the human γ-CaMKII regulatory domain (identical to 
αCaMKII), which is held in place partly by T-site (yellow) 
interaction, resulting in blocking access to the S-site, 
substrate binding regions (orange). The phosphorylation (red) 
and oxidation sites that generate autonomous activity (T286) 
are shown (Hudmon and Schulman, 2002a, Coultrap et al., 
2010, Erickson et al., 2008). Also, the inhibition of CaM-
binding (T305/306) sites are marked (Hudmon and Schulman, 
2002a, Colbran and Soderling, 1990, Hanson and Schulman, 
1992a, Colbran, 1993). Representations in panels d and e are 
based on Protein Data Bank (PDB) files 2VN9 and 2WEL 
(Rellos et al., 2010). Obtained with permission from Elsevier 
B.V. (license number - 3298510548633) [as reviewed in 
(Coultrap and Bayer, 2012). 
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1.5.2. T286 autophosphorylation 
The binding of Ca
2+/
CaM to αCaMKII induces T286 autophosphorylation in a 
inter subunit fashion and stabilises flanking hydrophobic residues that enables the 
regulatory domain to separate from the S-site (Yang and Schulman, 1999, Lisman et 
al., 2002, Colbran, 2004). The autophosphorylation of T286 confers onto αCaMKII a 
~1,300-fold increase in affinity for Ca
2+
/CaM and gives the interaction a positive 
cooperativity, which essentially means grouped activation of the catalytic domains 
by Ca
2+
/CaM (Waxham et al., 1998). Furthermore, T286 autophosphorylation is 
thought to endow αCaMKII with autonomous activity i.e. Ca
2+
/CaM independent 
activity (Colbran, 2004).  
However, Tzortzopoulos and colleagues (2004) found that the activity of 
T286 autophosphorylated αCaMKII in low Ca
2+
 represented ~5% of maximal 
activity (Tzortzopoulos et al., 2004). The perplexing question therefore is; how is it 
possible for αCaMKII to be active in the absence of Ca
2+ 
(autonomous activity) and 
be almost inactive in the presence of low Ca
2+
? One possible way to consolidate 
these two observations may come from the CaM trapping hypothesis. CaM 
dissociation from αCaMKII is ~0.4 seconds, however, CaM dissociation from T286 
autophosphorylated αCaMKII is several minutes (Meyer et al., 1992, Torok et al., 
2001). Therefore, T286 autophosphorylated αCaMKII protomers may interact with 
other proteins, like CaM to convey autonomous activity. 
1.5.3. T305/306 autophosphorylation 
The inhibitory T305/306 autophosphorylation site is firmly within the 
Ca
2+
/CaM binding domain of αCaMKII (Hashimoto et al., 1987, Miller and 
Kennedy, 1986). Furthermore, the autophosphorylation is thought occur in an intra-
subunit fashion (Mukherji and Soderling, 1994). The rate of T305/306 
autophosphorylation is similar to the rate of enzyme inactivation, which was 
previously determined to be ~1 minute at 37ºC (Jama et al., 2009, Lee and Yasuda, 
2009). Other reports have demonstrated that Ca
2+
/CaM binding inhibits T305/306 
autophosphorylation (Patton et al., 1990, Meador et al., 1993, Hanson and Schulman, 
1992a). This is corroborated with observations that EGTA induces a ‘burst’ of 
T305/306 autophosphorylation (Lou and Schulman, 1989, Jama et al., 2009). Taken 
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together, these studies suggest that αCaMKII catalytic activity is regulated by 
T305/306 autophosphorylation and Ca
2+
/CaM binding.  
1.5.4. Other posttranslational modifications  
The well-studied mechanisms of αCaMKII regulation are Ca
2+
/CaM binding 
and the above mentioned autophosphorylation events. However, several other less 
studied mechanisms may contribute to αCaMKII regulation. For example the T253 
phosphorylation is thought to target αCaMKII to the post synaptic density without 
altering its enzyme activity (Migues et al., 2006). In vitro S314 phosphorylation has 
been demonstrated, but no function has been shown to date (Colbran and Soderling, 
1990, Hanson and Schulman, 1992a). Recent studies have shown M281 oxidation, 
which like T286 is thought to impart Ca
2+
/CaM independent activity (autonomous 
activity) (Erickson et al., 2008). M281 oxidation has pathological roles in smooth 
muscle and cardiomyocytes (Luo et al., 2013, Scott et al., 2012, He et al., 2011, 
Swaminathan et al., 2011). 
1.5.5. αCaMKII binding GPCRs  
There are more than 100 proteins in the genomic database that contain the 
αCaMKII consensus sequence of Arg-X-X-Ser/Thr (Pearson et al., 1985, White et 
al., 1998)(Pearson et al., 1985; White et al., 1998). The role of these possible 
substrates is of particular interest in understanding the Ca
2+
 transduction pathway. 
Among these putative interactions is thought to contain GPCRs. One example of 
GPCR regulation by αCaMKII is the Ca
2+
 dependent phosphorylation of the M4 
muscarinic acetylcholine receptor (M4R) (Guo et al., 2010). The Gαi/o-coupled 
M4Rs inhibits adenylyl cyclase and therefore lowering the cAMP production (Wess, 
1996, Nathanson, 2000). The increase in cytoplasmic Ca
2+
 activates αCaMKII, 
thereafter phosphorylating T145 M4R (intracellular loop 2). The phosphorylation 
potentiates M4R efficacy in suppressing cAMP production (Guo et al., 2010). 
Another example is αCaMKII phosphorylation of the limbic dopamine receptor 
(D3R) at S229 (intracellular loop 3). D3R is similar to M4R in that they are both 
Gαi/o-coupled GPCRs. However, unlike the reported M4R potentiation, the 
αCaMKII dependent phosphorylation of D3R reduces D3R efficacy in suppressing 
cAMP production (Liu et al., 2009). 
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1.6. Aims and Objectives 
Previous reports have shown that some GPCRs are regulated by CaM and 
αCaMKII. Herein I address the mechanisms by which CaM and αCaMKII confer 
onto the KISS1R temporal sensing of cytoplamic Ca
2+
 concentrations before the 
stages of receptor desensitisation. I have discovered CaM-binding and αCaMKII 
consensus motifs in the primary amino acid sequence of the human KISS1R. I 
attempt to answer fundamental questions. For example, does CaM bind to the 
KISS1R and if so where? What is the functional relevance of the potential 
interaction? Also, the hypothesis was investigated whether αCaMKII can 
phosphorylate the KISS1R. This thesis provides, in my opinion, convincing evidence 
for the existence of a negative feedback loop regulating KISS1R activity. The vision 
of this thesis is to propose novel concepts in the development of co-agonists that may 
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2. Materials and Methods 
2.1. Introduction 
This chapter includes the materials and the laboratory techniques used in the 
research project presented within this thesis. All used materials that were obtained 
from external sources and any work that was not performed by me have been 
acknowledged. 
2.2. Peptides and Proteins 
The derived peptides from the kisspeptin receptor (KISS1R), gonadotropin 
releasing hormone receptor (GnRHR), the C-terminal regions of G-protein α 
subunits, and the kisspeptin-10 ligand were synthesised by EZbioLab, USA with >95 
% purity. Alpha-Ca
2+
/calmodulin dependent protein kinase II (αCaMKII) was 
expressed using the baculovirus expression system and was kindly provided by Dr K. 
Török, St Georges University of London. Pyruvate kinase (PK), Syntide-2 and 
lactate dehydrogenase (LDH) proteins were purchased from Sigma-Aldrich Inc. 
Wild-type calmodulin (CaM) and fluorescently tagged CaM probes were first 
expressed, FLPC purified, labelled and then HPLC purified. The CaM probes that 
were used were DA-CaM and TA-CaM which were kindly provided by Dr K. Török. 
The CaM
 C34
-badan was created in Dr K. Török’s lab. The point mutants CaM1, 
CaM2, CaM3, CaM4, CaM12, CaM34, and CaM1234 were obtained from Dr. Nael 
Nadif Kasri, Catholic University of Leuven, Belgium. CaM mutants were generated 
by mutation of the first coordinating Asp of the Ca
2+
 binding EF-hand motifs to Ala. 
2.3. Transforming of competent cells  
DNA constructs were transformed into ultra-competent E.coli cells XL-10 
(obtained from Stratagene, Cheadle, UK). Briefly, the cells were first thawed on ice 
and incubated with 1.5 μL β-mercaptoethanol for 10 minutes, followed by 30 minute 
incubation on ice with 10 ng of the DNA vector. The cells were then heat shocked at 
42°C for 35 seconds and allowed to cool on ice. After cooling (~3 minutes), 450 µL 
of S.O.C medium (Invitrogen, Paisley) was added into the tubes containing bacteria 
and incubated at 37°C in the shaker for 1 hour. Finally, the bacteria were streaked out 
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on to LB-agar (Luria Broth) plates containing 100µg/mL of ampicillin or 40 µg/mL 
of kanamycin and incubated at 37°C overnight.  
2.4. Preparation of DNA plasmids 
The LB-agar plates were removed from the 37°C incubator and a single 
bacterial colony was picked with a sterile toothpick and placed into a 5 mL LB 
medium starting culture containing 100 µg/mL of ampicillin or 40 µg/mL of 
kanamycin. The bacterial cultures were grown at 37°C in the shaker for ~8 hours. 
Then 1mL of the starting culture was inoculated into 250 mL of LB medium 
containing the necessary concentrations of antibiotics (100g/mL of ampicillin and 
50g/mL of kanamycin) and incubated for ~16 hours at 37°C in the shaker.  The 
bacterial cells were harvested by centrifugation at 6000 x g for 15 minutes at 4°C, 
followed by purifying the DNA vectors using Qiagen maxi-preparation columns 
(Qiagen, Crawley, UK) according to the provided protocol and eluted in distilled and 
deionised H2O. A Nanodrop spectrophotometer (Nanodrop Technologies, Delaware, 
USA) was used to determine DNA vector concentration and purity. The DNA 





) and the purity was determined using the ratio absorption of 
260/280 nm wavelength.  
2.5. Preparation of glycerol stocks  
The transformed bacteria were preserved using Glycerol stocks. To do this 
300 µL of 80% (w/v) glycerol was mixed into 700 µL of bacterial culture, frozen on 
dry ice and stored at -80°C. In order to recover the transformed bacteria, the frozen 
glycerol stock vials was placed into dry-ice and a small piece was scraped off the 
surface of the frozen culture and streaked onto LB-agar plates containing the 
necessary concentrations of antibiotics and incubated overnight at 37 °C.  
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2.6. Agarose gel electrophoresis 
Agarose gels were prepared with 1 % (w/v) agarose in TAE buffer (320 mM 
acetic acid, 40 mM Tris, 1 mM EDTA, pH7.2). DNA samples were separated at 120 
V for 40 minutes and stained with ethidium bromide and visualised under ultraviolet 
light using a GeneFlash transilluminator (Syngene Bio Imaging, Cambridge, UK). 
The DNA material was excised from the agarose gels and processed using a 
QIAquick gel extraction kit (Qiagen, Crawley, UK) according to supplied protocol.  
2.7. KISS1R cDNA victors and Site-directed mutagenesis   
The FLAG-KISS1R cDNA that was used in this project was kindly provided 
by Dr Andy V Babwah, The University of Western Ontario, Canada. Briefly, the 
human KISS1R cDNA was obtained from OriGene Technologies (Rockville, MD – 
NM_032551.3) and a FLAG-epitope was introduced at the amino terminus of 
KISS1R. The FLAG-KISS1R was cloned into NheI and NotI sites of a pEGFP-C 
vector backbone obtained from Invitrogen (Pampillo et al., 2009).  
The Wt-CaM cDNA contained in the pAED 4 vector and cloned into NdeI 
and PstI restriction sites was kindly provided by Dr Katalin Tӧrӧk, St George’s 
University of London. All the FLAG-KISS1R and CaM mutations were introduced 
using the Site-Directed Mutagenesis Kit from Agilent Technologies (Cheshire, UK) 
and validated by di-deoxy sequencing (Lu et al., 1997).  
2.8. Co-immunoprecipitation  
  FLAG-KISS1R expressing cells were stimulated with KP-10 using 150 mm 
dishes. After stimulation the cells were washed with Ca
2+
 free PBS and placed on ice 
for 30 minutes. This was followed by lysing the cells with NP40 lysis buffer (0.7 
mL) containing NaCl 250 mM, K
+
-HEPES (pH7) 5 mM, Glycerol 10 % (w/v), NP-
40 0.5 % (w/v), EDTA 2 mM, Phenylmethylsulfonyl fluoride (PMSF) 1 mM and 
Leupeptin 1mg/mL. The lysed cells were sonicated at 6 amplitude microns for 30 
seconds. Heavier cellular organelles were separated from whole cell lysates by 
centrifugation at 14,000 rpm for 10 minutes.  40 µL ANTI-FLAG M2 affinity Gel 
(Sigma-Aldrich) was incubated with the lysates on a rotating wheel overnight in the 
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cold room. The samples were then spun down at 5,000 rpm for 30 seconds. The 
supernatant was removed with a narrow Hamilton syringe. At this stage the samples 
were washed with 0.5 ml of TBS. The process of spinning and washing was repeated 
three times. The elution was carried out using 3 X FLAG peptide (Sigma-Aldrich) at 
150 ng/μL and incubated with gentle agitation for 30 minutes 2-8ºC. Afterwards the 
samples were spun at 8200 x g for 30 seconds and the supernatant was removed liked 
before. The samples were then stored in -20ºC . The pellets were dissolved in SDS 
sample buffer and were resolved by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to PVDF membrane (NEN Life Sciences) for protein 
immunoblotting.  PVDF membranes were blocked in 4% bovine serum albumin, 50 
mM Tris-HCl, pH 7.0, 0.05% Tween-20 and 0.05 %  NP40  blocking solution.  
  The primary antibodies of rabbit FLAG were purchased from Sigma-Aldrich. 
Mouse calmodulin antibodies were purchased from Millipore. Both antibodies were 
used at 1:1000. These were visualised by complementary anti-rabbit and anti-mouse 
secondary antibodies at a dilution of 1:5000 (Upstate). The imaging was carried out 
using a LiCor machine. 
2.9. Expression and purification of calmodulin  
A starter culture of 10 mL of 2xTY medium (16 g/L bacto-tyrptone, 10 g/L 
yeast extract, and 5 g/L of NaCl) containing 100 μg/mL ampicillin was inoculated 
with one bacterial colony of BL21 – Gold transformed with pAED4-CaM vector. The 
starter culture was incubated in a shaking incubator, shaking at 125 revolutions per 
minute (RPM) for 8 hours at 37C until bacterial growth reached an absorbance of 
0.6- 0.8 (A600) per mL. Thereafter, 200 μL of the starter culture was aliquoted into 2 
L culture flasks containing 500 mL 2XTY medium with 100 μg/mL ampicillin and 
incubated at 37C at 80 RPM overnight. In order to induce CaM expression 300 μM 
of isopropyl β-D-1-thiogalactopyranoside (IPTG) was added into the 2 L culture 
flasks and allowed to incubate for a further 150 minutes at 37ºC, 125 RPM. 
Afterwards, the bacterial cultures were pelleted by centrifugation at 16000 g for 30 
minutes at 4ºC. The pellet was suspended in 20 mL of 50 mM Tris-HCl pH 7.5, 1 
mM ethylene glycol tetraacetic acid (EGTA), 10 mM dithiothreitol (DTT), 10 μg/mL 
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tert-amyl methyl ether (TAME), 10 μg/mL N-tosyl-l-phenylalanine chloromethyl 
ketone (TPCK), 10 μg/mL trypsin inhibitor, 10 μg/mL leupeptin, 10 μg/mL pepstatin 
A and 10 μg/mL N-benzoyl-l-arginine ethyl ester (BAEE). All chemicals were 
bought from Sigma-Aldrich Inc, UK. Afterwards, the re-suspended pellet was 
freeze/thawed three times and then centrifuged 64000 g for 30 minutes at 4ºC, 
followed by adding into the supernatant 5 mM CaCl2.  
The purification of CaM from the supernatant was carried out using phenyl 
sepharose CL-4B resin. (Sigma-Aldrich Inc, UK). 100 mL of the resin was washed 
using 10 L of 20 mM Tris/HCl pH 7.5 followed by a 2 L wash with Tris/HCl pH 7.5 
containing 5 mM CaCl2 and 500 mM NaCl and then the resin was heated and stirred 
at 35ºC for 20 minutes. After the washing process the resin was equilibrated with 2 L 
20 mM Tris/HCl pH 7.5 containing 1 mM CaCl2. It was at this stage that the 
supernatant containing CaM protein was mixed with the equilibrated resin and the 
mixture was heated and stirred at 35ºC for 20 minutes in order to increase the 
efficiency of the CaM-resin binding. The supernatant-resin mixture was cooled to 
4ºC and then packed into a fast protein liquid chromatography (FPLC) column 
(Pharmcia Biotech, XK26). The FPLC machine that was used was the GE ÄKTA 
explorer (Amersham Pharmacia) system. The column was run using two buffers, 
both containing 20 mM Tris-HCl pH 7.5, 2 mM EGTA, 1 mM DTT, 0.2 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 μg/mL of leupeptin and 1 μg/mL of 
pepstatin A. However, the first buffer contained 1 mM CaCl2 and the second buffer 
contained 2 mM EGTA. The column was run in a gradient from a 100 % 1 mM 
CaCl2 and 0 % 2 mM EGTA containing buffer to 0 % 1 mM CaCl2 and 100 % 2 mM 
EGTA containing buffer in a total volume of 500 mL and collecting in 5 mL 
fractions/minute.  
A second purification was carried out using a Q-sepharose column 
(Amersham Pharmacia) equilibrated with 10 column volumes of buffer containing 20 
mM Tris-HCl pH 7.5, 2 mM EGTA, 1 mM DTT, 0.2 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 μg/mL of leupeptin, 1 μg/mL of pepstatin A, and 2 mM EGTA. 
The protein solution was allowed to flow into the column and was eluted with two 
buffers both containing 20 mM Tris-HCl pH 7.5, 2 mM EGTA, 1 mM DTT, 0.2 mM 
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phenylmethylsulfonyl fluoride (PMSF), 1 μg/mL of leupeptin and 1 μg/mL of 
pepstatin A. However, only one of the buffers contained 2 mM EGTA. The elution 
run was carried out with a gradient from a 100 % buffer and 0 % buffer + 2 mM 
EGTA to 100 % buffer + 2 mM EGTA and 0% buffer. This was carried out in a total 
volume of 50 mL and collecting in 1 mL fractions/minute. The fractions containing 
CaM were determined at 278 nm (A278 0.18 = 1 mg/mL CaM). In order to desalt the 
protein solution a PD10 column (Pharmacia Biotech, UK) was used. The 
equilibration of the column was carried out with 25 mL H2O, followed by running 
the purified CaM solution through the column. The elution was carried out using 3.5 
mL H2O. The desalted CaM sample was then freeze-dried and stored in -20ºC.  
2.10. Determination of protein concentration 
To determine protein concentrations of cell lysates, the Bradford Assay (Bio-
Rad Laboratories, Hertfordshire, UK) was used. To do this, BSA standards were 
prepared in a total of 200 uL of Bradford dye and appropriate PBS volumes with the 
following concentrations 0 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.5 mg/mL, 
0.75 mg/mL, 1 mg/mL, 1.5 mg/mL and 2.0 mg/mL. The standards were vortexed and 
left for 5 minutes. The absorbance was measured at 595 nm wavelength using a 
spectrophotometer. Using the standard curve the ‘unkown’ samples were calculated 
from the equation of the line. 
2.11. Site-directed fluorescence labelling of calmodulin  
The Wt CaM cDNA cloned in the pAED4 vector, between NdeI and PstI 
sites, was mutated to generate CaM T34C mutant with the use of site-directed 
mutagenesis (see section 2.7) This vector construct was overexpressed in Escherichia 
coli (BL21 strain). The fluorophore – 6-bromoacetyl-2-dimethylaminonaphthalene 
(badan) was used to label CaMT34C. This was carried out by reacting 100 g 
CaMT34C and 2 mM badan in a total volume of 1 mL solution of 150 mM KCl, 2 
mM tris (2-carboxyethyl) phosphine (TCEP), and 20 mM MOPS (pH 7.2). This 
reaction was allowed to incubate for 2 hours at 22 ºC in the dark. Afterwards the 
reaction was stopped by 30 mM β-mercaptoehanol. In order to purify the CaM
C34
-
badan, the reaction mixture was run through a Sephadex G-15 column. This was 
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followed by two rounds of purification using high-performance liquid 
chromatography (HPLC) purification steps. The fraction containing CaM
C34
-badan 
was used for the spectroscopic experiments. The concentration of the purified 
CaM
C34
-badan was determined using the extinction coefficient (molar absorbance of 




 at 386 nm. 
2.12. Reverse phase HPLC 
Further purification of wild-type CaM and fluorescence-labelled CaM were 
carried out by using reverse phase high pressure liquid chromatography (HPLC). 
Proteins were separated with a linear gradient of the organic solvents. The gradient 
was 70% H2O (containing 0.1 % trifluoroacetic acid, TFA) and 30% acetonitrile 
(0.082 % TFA) to 70% acetonitrile (0.082 % TFA) and 30% H2O (0.1 % TFA).  
2.13. Calmodulin-binding experiments 
  The fluorescently labelled CaMs (TA-CaM and DA-CaM) were kindly 
provided by Dr K. Török, St. George’s, University of London, UK. CaM
 C34
-badan 
was created in Dr K. Tӧrӧk’s lab (see section 2.11). The TA-CaM is fluorescently 
labelled at lysine 75 to form 2-chloro-(epsilon-amino-Lys75)-[6-[4-(N,N-
diethylamino)phenyl]- 1,3,5-triazin-4-yl]CaM. TA-CaM was excited at 366 nm 
wavelength and the emission was determined at 415 nm wavelength. 
The DA-CaM had two native threonines replaced with cysteine 
(T34C/T110C) and randomly labelled with the donor 5-((((2-
iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic acid (1,5-IAEDANS) and the 
acceptor dimethylamino-3,5-dinitrophenyl (DDP). The fluorescent intensity depends 
on the distance between the donor and the acceptor. The quenching of fluorescence 
corresponded to a decrease in distance between the two Ca
2+
 -binding domains of 
CaM (which the 1, 5-IAEDANS and DDP are located). The DA-CaM used for this 
project has been fully characterized and exhibits undistinguishable kinetic 
characteristics to wild-type CaM  (Török et al., 2001). DA-CaM excitation is 340 nm 
and the emission is 500 nm. The Absorbance was monitored at 250 nm.  
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All the labelled CaMs were double purified using high performance liquid 
chromatography (HPLC) and were experimented with using an assay buffer 
containing 1 mM MgCl2, 100 mM NaCl, 50 mM K
+
-PIPES (pH 7) in order to  mimic 
physiological ionic strengths and pH. All the fluorometric experiments were carried 
using SLM spectrofluorimeter (8100 model) and the data was analysed using GraFit 
7 (Erithacus Software Ltd, West Sussex, UK) and GraphPad Prism 5.0 (GraphPad 
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2.14. Free Ca2+ calculation  
The determination of the Ca
2+
 binding of CaM
C34
-badan requires the precise 
control of free Ca
2+
 concentrations. This is achieved with an in vitro assay that has a 
high buffering capacity, utilising the chelating agent ethylene glycol tetraacetic acid 
(EGTA). Additionally, the calculation of free Ca
2+
 concentrations is dependent on 
the buffer’s ionic strength, pH, and temperature. The dissociation constants (Kd) of 
EGTA for Ca
2+
 is 376 nM and for Mg
2+
 is 33.9 nM in a solution of pH 7 and at 20ºC 
(Tsien and Pozzan, 1989). This fundamental understanding allows for the 
determination of free Ca
2+
 concentration using the following equations:  
Ca
2+
 + EGTA       Ca
2+
.EGTA 




















Replacing [EGTA]free and [Ca
2+







]Total – [EGTA]Total – Kd)  [Ca
2+
]free – Kd  [Ca
2+
]Total = 0 
 
This is a quadratic equation of the general form x
2
 + x + = 0. Upon solving this 
equation for [Ca
2+
]free transforms into:  
[Ca
2+
]free = - [([Ca
2+
]Total – [EGTA]Total – Kd)  

/2  1 (equation) 
where  =β
2
-4αγ  = ([Ca
2+
]Total – [EGTA]Total – Kd)
2
 – 4  1  (– Kd  [Ca
2+
]Total) 
Therefore the equation above is used for the calculation of the free Ca
2+
 
concentration when the total Ca
2+
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In order to determine the free Ca
2+





 binding experiments, an automated syringe pump (ALADDIN 
1000, WPI) was used. The pump contained 325 mM CaCl2 that was diluted at a 10 
μL/min flow rate into a 3 mL cuvette containing 100 nM CaM
C34
-badan, 50 mM K
+
-
HEPES (pH 7.5), 100 mM KCl, 2 mM MgCl2, 5 mM EGTA. The flow rate values 
were converted into free Ca
2+
 concentrations using a two-chelator Maxchelator 
program. Validation checks of free Ca
2+
 concentrations were performed with the use 
of Fluo3 at Kd 325 nM. This was similar to the previously reported Ca
2+ 
affinity for 
Fluo3 at Kd 390 nM in 100 mM KCl, 10 mM MOPS (pH 7.2) and at 22 ºC.(Haugland 
et al., 2005). 
2.15. Steady state kinase activity assay  
A derived quantitative description of enzyme catalysis is known as specific 
activity. This is calculated by a continuous spectrofluorimetric assay which is based 
on an ADP calibration (Török et al., 1998). The amount of substrate (syntide-2) 
phosphorylation is equal to the amount of ADP production from the enzymatic 
reaction (in vitro). This in turn is coupled to an NADH fluorescence assay, which 
decreases in fluorescence upon oxidation of NADH to NAD
+
. The change in 
fluorescence is a direct correlation to syntide-2 phosphorylation. Consider the initial 
biochemical reaction (reaction 1); 
 
Reaction 1      
αCaMKII + Ca
2+ 
+ CaM + Syntide-2 + ATP → Ca2+.CaM.αCaMKII + Syntide-2-Phos. + ADP 
 
The αCaMKII in the presence of CaM, Ca
2+
 and ATP will result in a complex 
of. Ca
2+
.CaM.αCaMKII, which phosphorylates syntide-2 (syntide-2
-Phos
), this 
reaction results in ADP production. However, the amount of substrate 
phosphorylation and ADP production is unquantifiable in real-time. To overcome 
this, a naturally fluorescent NADH assay is coupled to the above reaction 1. Now 
consider the NADH assay below; 
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Reaction 2  PEP + PK + ADP → Pyruvate + PK + ATP  
Reaction 3  Pyruvate + LDH + NADH → Lactate + LDH + NAD+ 
Pyruvate kinase (PK) catalyses the transfer of a phosphate group from 
phosphoenolpyruvate (PEP) to ADP, yielding one molecule of pyruvate and one 
molecule of ATP (reaction 2). Lactate dehydrogenase (LDH), which is a NADH 
dependent enzyme, converts pyruvate to lactate resulting in NADH oxidation to 
NAD
+
 (reaction 3). The combined reactions of 1, 2, and 3 constitute the continuous 
spectrofluorimetric steady state coupled enzyme reaction (Figure 2.1). This provided 
continuous monitoring of NADH oxidation and thus a sensitive measurement of 
syntide-2 phosphorylation, ADP production and thus αCaMKII specific activity 












Figure 2.1 Steady state coupled enzyme reaction. The amount of substrate 
phosphorylation is equal to the amount of ADP produced by the enzyme reaction. 
The constant production of ADP corresponds to the constant fluorescence decrease 
of NADH upon oxidation to NAD
+















Lactate Pyruvate PEP 
Reaction 1 
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The NADH fluorescence was measured using two spectrofluorimeter, the first was 
SLM spectrofluorimeter 8100 model consisting of a Xenon arc lamp (450 W) or 
mercury arc lamp (100 W). The excitation measured used in this instrument was 340 
nm and the emission was 460 nm. Slit widths were 2, 2 nm for excitation and 16, 16 
nm for emission. The other spectrofluorimeter used (and stated in the relevant results 
sections) was the FluroLog-3, manufactured by HORIBA scientific. Slit width was 2, 
2 for excitation and 2, 2 for emissions.  
All assays of steady state enzyme activities were carried with an assay buffer 
(MgCl2 1 mM, NaCl 100 mM, K
+
-PIPES pH7 50 mM) containing 5 mM DTT, 50 
M syntide-2, 4 U/mL PK, 9 U/mL LDH, 2 mM PEP and 22 M NADH. CaM, 
αCaMKII and Ca
2+
 concentrations were varied as indicated. The data analysis was 
carried out using GraFit 7 (Erithacus Software Ltd, West Sussex, UK). 
T286 autophosphorylation was carried out using 1 μM αCaMKII, 6 μM CaM, 
(exception; CaM34, which was 60 μM in 220 μM CaCl2), and 1 mM ATP in the 
presence of 50 mM K
+
-PIPES, pH 7.0, 100 mM KCl, 2 mM MgCl2, 5 mM DTT, and 
0.05 mM CaCl2 at 21 °C. At the indicated times, the reaction was stopped with 4 x 
SDS sample buffer. The samples were then run on a SDS-PAGE 4-12 % precast gels 
(Invitrogen). T286 phosphorylation was determined with western blotting and 
phospho-T286-αCaMKII-specific monoclonal antibody and fluorescent secondary 
antibody (IRDye 800CW goat antimouse IgG). Odyssey infrared imaging system 
(LI-COR Biotechnologies) was used to acquire the digital images. The densitometry 
values of the images obtained using ImageJ software (National Institutes of Health). 
The analysis was as follows: Densitometry values were taken from each band and 
time 0. The time 0 reaction was stopped before the addition of ATP. The following 
formula was used on an inverted scale: (Dmax — Dt)/(Dmax — DB), where Dmax 
represents the average density of the most fluorescent band, Dt – the average density 
of a time point, and DB – time 0 average density. By subtracting individual values 
with the highest densitometry value the scaling was inverted. The relative density is 
Chapter 2: Materials and Methods 
 
  68 
represented with respect to the highest density. The data was fitted to an exponential 
function using GraFit software program, version 4.0. 
2.16. ADP calibration  
The ADP calibration is critical to the effectiveness of the steady state coupled 
enzyme reaction. It is derived by measuring the NADH fluorescence with reaction 2 
and 3 (materials and methods – section 2.15) without ADP as a control and 
correlating the 2 μM ADP additions to fluorescence change. A typical ADP 
calibration would be:- 1 μM ADP corresponds to 1131 fluorescence counts.  An 
ADP calibration was done every day preceding a steady state coupled enzyme 
activity experiment.  
2.17. Calculation of CaMKII specific activity 
After the ADP calibration an enzyme activity experiment was carried out. An 
assay mixture containing reactions of 1, 2, and 3 (reactions in section 2.15), 
excluding αCaMKII from reaction 1 was measured in the spectrofluorimeter. An 
average gradient of fluorescence change is derived by using a PC with OS\2 
operating system and SLM Aminco software attached to the SLM spectrofluorimeter. 
A typical value of an active enzyme is 300 fluorescence counts per second (fc/s). 
This value is then divided by a typical ADP calibration value of 1131 fluorescence 
counts per 1 μM ADP to give 26.5 x 10
-3
 μM ADP per second. At this stage of 
quantifying enzyme activity, the enzyme is producing 26.5 x 10
-3
 μM ADP and 
substrate phosphorylation per second. Finally, the formula below was used to 
calculate the specific enzyme activity.  
 
 
𝑀𝑜𝑙𝑒𝑠 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 × (𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑒𝑛𝑧𝑦𝑚𝑒 𝑢𝑠𝑒𝑑)−1  × (𝑚𝑖𝑛 )−1
= 𝜒 𝑛𝑚𝑜𝑙𝑒𝑠 𝑚𝑖𝑛−1  𝑚𝑔−1 
The ‘moles of product’ was calculated in nmoles/L of ADP. The ‘amount of enzyme 
used’ was expressed as milligrams, and the ‘min’ was 1 minute. 
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2.18. Cryopreservation and resurrection of cell-lines 
Cell-lines were stored in liquid nitrogen (-196°C) containing a cryoprotectant 
of 10 % (v/v) dimethylsulphoxide (DMSO) and 90 % (v/v) foetal calf serum. The 
recovery procedure involved thawing the vials containing cell-lines in a 37°C water 
bath prior to being re-suspended in growth medium and seeded into culture flasks. In 
order to cryopreserve cell-lines, confluent cultures were passaged and harvested by 
centrifugation at 500 x g for 3 minutes. The culture medium was removed and the 
pellet was re-suspended in the cryoprotectant and slowly frozen using ‘Mr Frosty’ 
(Nalgene, Hereford, UK) container prefilled 100 % isopropanol and stored at -80 
o
C. 
After 24 hours, the vials were transferred to the liquid nitrogen tank.  
2.19. Cell culture  
  The four different cell-lines used for this project were HEK-293, COS-7, 
GT1-7, and GnV3 cells.  All the cell-lines were available in the laboratory of Dr Zhi-
Liang Lu, Human Reproductive Science Unit, University of Edinburgh. The HEK-
293, COS-7, and GT1-7 cells were maintained in Dulbecco’s modified Eagles 
medium (DMEM; Sigma, UK) supplemented with 10% foetal calf serum, 2% 
glutamine and 1% penicillin (10,000units/mL)/streptomycin (10,000mg/mL). The 
GnV3 cells were maintained with Neurobasal A medium (Sigma, UK) containing 
0.04 % B27 supplement (Gibco, UK),
 
500 µM glutamine, 25 µM glutamate, and
 
1% 
penicillin/streptomycin (Sigma, UK). All the cells were maintained at 37ºC in a 
humidified 5 % CO2 atmosphere.  
  The cell-lines were passaged regularly with the use of trypsin/EGTA. To do 
this, the medium was removed from cell-line cultures approaching 80-100 % 
confluency and washed once in phosphate-buffered saline (PBS). To detach cells 
from the monolayer, 2 mL trypsin was added to 162 cm
2
 cell culture flasks (Fisher 
Scientific, Leicestershire, UK) and allowed to incubate in the 37°C incubator for 5 
minutes. Once the cells had fully detached, 8 mL of growth medium was added into 
the culture flask to terminate the trypsin action. The cell-lines were regularly 
passaged to 1:3 dilutions. In order to determine the cell number, a Neubauer 
haemocytometer was used. Briefly, the detached cells were diluted 1:10 in PBS and 
injected into the indicated inlets of the haemocytometer. The four counting areas 
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were utilised and an average was taken. The cell number was represented in x 
10
5
/mL. The dilution factor was also taken into consideration. 
2.20. Confocal laser scanning microscopy 
Confocal microscopy was used to characterise CaM-CFP interactions with 
KISS1R-YFP. The cDNA constructs were electroporated into HEK-293 cells (see 
materials and methods 2.21). The cDNA concentration used was 15 µg in the case of 
CFP-CaM only expressing cells and 15 µg for KISS1R-YFP only expressing cells. 
The combined co-transfection of CFP-CaM and KISS1R-YFP was carried out at 7 
µg each. After electroporation the cells were placed into 3.5 cm plastic plates with 
glass cover bottoms (World Precision Instrument Inc, USA) and were left for 48 
hours to reach 70 % confluency. Cell density when seeded was 1 x 10
6
 cells/plate. 
Prior to imaging the cells were washed with Ca
2+
 free PBS and new medium was 
placed on the cells. The YFP was excited at 517 nm and the emission was measured 
at 528 nm wavelength. The CFP was excited at 436 nm and the emission was 
measured at 488 nm wavelength. The GnV3 cells were electroporated with 15 µg of 
cDNA GPR54-GFP (see materials and methods 2.21).  
2.21. Transient transfection by electroporation  
  The transient expression of KISS1R in COS-7, HEK-293, GT1-7, and GnV3 
cells was achieved using the electroporation method. All the cell-lines were 
electroporated using a Bio-rad Gene Pulser with cold (4 
o
C) Opti-MEM medium 
(Sigma-Aldrich Inc, UK). The HEK-293 cells were electroporated using 300 voltage 
(V) and of capacitance 950 µF. COS-7 cells were electroporated with 230 V and with 
950 µF. GT1-7 cells were electroporated with 350 V and 960 F and, while GnV3 
cells were electroporated with 240 V and 700 μF. All the cells were electroporated 
with 4 mm cuvettes (Bio-Rad, UK) with infinite resistance.  
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2.22. KP-10 iodination and whole cell competitive radioligand 
binding assay 
The iodination of kisspeptin-10 (KP-10) was carried out by Dr Kevin Morgan 
and Mr Robin Sellar. The KP-10 (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2) 
was radiolabeled using the Chloramine-T method as described for GnRH (Flanagan 
et al., 1998). KP-10 (10 μL from 1 mM stock) was suspended into 50 µl PBS (pH7.2) 
and mixed with 10 μL (100 μCi/μL) of carrier-free Na
125
I. Thereafter, 10 µl 
chloramine T (2 mg/ml) was added and the reaction was allowed to proceed for 10-
15 seconds. Sodium metabisulfate (2 mg/ml) was added to terminate the reaction. 
The reaction was diluted into 1 ml running buffer (50 mM sodium acetate pH4.0, 50 
mM N-acetylmethionine, 5 % sucrose, 2.5 % BSA, 0.1 % sodium azide) and then 
loaded onto a QAE Sephadex G25 size exclusion column. Fractions were collected in 
1 ml vials and 10 µL was collected from each fraction and counted for 1 minute 
using a gamma counter to obtain the elution profile and identify fractions containing 
the radiolabelled peptide. The fractions to be kept were above 4,000 gamma counts. 
All the gamma counts in the peak (P) was added up and the ‘specific activity’ was 
calculated= 𝑃 ×  1,000 ÷ (𝑇𝐶 × 0.05)𝜇𝐶𝑖/𝜇𝑀𝑜𝑙. Because we did not use a HPLC 
to gain > 99 % pure radiolabelled fraction, the ‘specific activity’ calculated is 
therefore an estimate for the purpose of standardisation between iodination batches. 
  With the use of the labelled KP-10, whole cell competition radioligand 
binding assay was performed using the method as previously described for GnRH 
(Flanagan et al., 1998). COS-7 cells were electroporated (see section 2.21) with 
KISS1R cDNA (see section 2.7) and seeding into 12-well plates. The peak KISS1R 
expression in COS-7 cells was optimised using confocal microscopy and western 
blotting. 48 hours post-transfection the media was aspirated and the cells were 
incubated for 4 hours at 4
o
C in 0.5 mL binding media (DMEM supplemented with 10 
mM HEPES and 0.1 % BSA) containing 100,000 cpm/well and increasing 
concentrations of unlabelled KP-10 ranging from 0 to 1μM. The estimated 
concentration [I
125
]-KP10 tracer that was used in each well was about 25 pM. Hence, 
the tracer amount used in the experiments had little effect on the Cheng-Prusoff shift 
as determined for the GPCR – GnRH receptor (Flanagan et al., 1998) Non-specific 
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binding was determined in the presence of 1 μM unlabelled KP-10. After the 
incubation period unbound ligand was removed with two washes of cold PBS, 
followed by lysing the cells with 0.5 mL 0.1 NaOH. The radioactivity was measured 
using a  counter. The raw data was represented as counts/minutes 
2.23. Radioimmunoassay 
The radioimmunoassay (RIA) was employed for the measurement of GnRH 
secretion in the characterisation of GV-3 and GT1-7 cell-lines, a cell model for 
GnRH neurons. To do this, 150 L buffer (100 mM phosphate buffered saline 
gelatine pH 7.4), 100 L primary anti-GnRHII antibody (1:10,000 dilution) and 50 
L of sample or standards was pre-mixed into 10 x 75 mm polypropylene test-tubes 
(Sarstedt Ltd., Leicester, UK) and incubated overnight at 4°C. On the second day, 
100 µL of tracer was added and incubated for an additional 24 hours at 4°C. The 
tracer used was radioactively labelled GnRHII ligand with iodine-125 (I
125
) at 20,000 
cpm. The third day, 100 µL of normal rabbit serum (1:100 dilutions) was added and 
allowed to incubate for another 24 hours at 4°C. Finally, the fourth day, 1 mL of 
wash buffer was added into the tubes (polyethylene glycol 4%, saline 0.9%, triton 
0.2%), and were centrifuged at 3000 rpm at 4ºC for 30 min. The supernatant was 
carefully decanted and the tubes were measured using a Wizard 1470 Automatic 
Gamma Counter (Perkin-Elmer Inc., MA, USA) which gave a reading in γ counts per 
minute. The raw data was analysed using the software AssayZAP (Biosoft, 
Cambridge, UK). The software generates a standard curve and calculates the 
unknown sample GnRH concentration. 
2.24. Measurement of inositol phosphate turnover 
  HEK-293 and COS-7 cells were electroporated with DNA constructs (see 
section 2.21) and cultured 12 well culture dishes in complete DMEM. After 24 
hours, the cells were washed twice with phosphate-buffered saline (PBS) prior to 
incubating the cells with special inositol free DMEM (Invitrogen, Paisley, UK) 
supplemented with 50 IU/mL penicillin-streptomycin, 1 % (v/v) dialysed foetal calf 
serum and 1 Ci/mL myo-D-[
3
H] inositol (GE healthcare, Buckinghamshire, UK) in 
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a total volume of 500 µL for 16 hours. Thereafter, the cells were washed three times 
and then incubated with 500 L of HEPES-DMEM containing 0.1 % BSA and 10 
mM LiCl for 30 minutes at 37ºC to block inositol phosphate breakdown.  After 
incubation, the medium was replaced with 500 µL of HEPES-DMEM/10 mM 
LiCl/0.1 % BSA containing varying concentrations of Kisspeptin-10 (10 pM – 1 
mM) to stimulate the cells for 1 hr at 37 ºC. The cells were then lysed with 10 mM 
formic acid at 4ºC for 1 hr in order to extract the radioactive inositol phosphate.  The 
lysates were transferred to plastic tubes containing 500 µL Dowex AGI-X8 ion 
exchange resin (Bio-Rad Laboratories, Hertfordshire, UK) in order to bind the 
radioactive inositol phosphate. The bound [
3
H]inositol phosphate  was washed with 1 
mL deionised H2O, then further washed with 60 mM ammonium formate / 5 mM 
sodium tetraborate. The resin bound [
3
H]inositol phosphates was eluted with 1M 
NH4 formate / 100 mM Formic acid.  Finally, 800 µL of the eluted solution was 
transferred to vials containing 2.5 mL scintillation fluid and the radioactivity was 
measured on a Beta counter for 5 minutes. 
2.25. Preparation of cell extracts  
In order to carry out co-immunoprecipitation experiments, transfected or 
untransfected HEK-293 cell-lines were seeded onto a 150 mm cell culture dish (3 x 
10
5
 cells/1 mL) with 10 mLs of complete medium (DMEM supplemented with 10 % 
FCS, 2 mM glutamine, 50 IU/mL penicillin, 50 IU/mL streptomycin and 10 mM 
HEPES) and kept in the 37°C incubator. After 48 hours the medium was removed 
and replaced with 10 mL of fresh medium with or without the presence of kisspeptin 
ligand and inhibitors for durations that were indicated in the results figure legends. 
After the stimulation (indicated in the results figure legends) the medium was 
removed and the culture dishes were placed on ice and washed three times with cold 
PBS (10 mLs). Followed by adding the lysis buffer; nonidet P-40 solubilisation 
buffer (50 mM K
+
-HEPES (pH8), 250 mM NaCl, 0.5 % (v/v) Nonidet P-40, 2 mM 
EDTA, 10 % (v/v) glycerol) that was supplemented with 1 mM 
phenylmethylsulfonyl floride (PMSF), 10 ug/mL leupeptin and 1 mM sodium 
orthovanodate fluoride. The lysate slurry was clarified by centrifugation at 4 °C, 
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20,000 x g for 15 minutes and the nuclear contents were sheared by sonication. The 
protein concentration was measured as described above. 
2.26. Western blotting  
Solubilised protein samples were mixed with sample buffer, Laemmli 2 x 
concentrated (LSB- 4% (v/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2-
mercaptoethanol, 0.004% (v/v) bromophenol blue and 0.125 M Tris-HCl, pH 6.8. 
The samples were then heated to 100
o
C for 5 minutes. The protein samples were 
resolved using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) obtained from Invitrogen Life Technologies, Paisley, UK (20% Tris-Gly 
gels). Protein separation was carried out using SDS-PAGE running buffer (25 mM 
Tris, 192 mM glycine, 1 % (w/v) SDS) at 45 mA for 1 hour. 
  After the 1 hour of SDS-PAGE electrophoresis the gels were placed onto 
polyvinylidene difluoride (PVDF) membranes (NEN Life Science, Buckinghamshire, 
UK). The PVDF membranes were previously washed with 100 % methanol followed 
by several washes of distilled H2O and equilibrated in semi-dry transfer buffer (20 
mM Tris, 192 mM glycine, 20 % (v/v) methanol, 0.1 % (w/v) SDS) for 30 minutes. 
Also, six blotting papers (Bio-Rad Laboratories, Hertfordshire, UK) were pre-soaked 
in the transfer buffer for 30 minutes. A sandwich was created by placing three 
blotting papers onto the anode plate and the PVDF membrane placed on top of it. 
This was followed by placing the Tris-Gly gel onto the stack and another three 
blotting papers on top. Any trapped air bubbles were removed by rolling the 
sandwich with a glass test tube. The cathode plate was placed on top. The proteins 
were transferred from the gel to the PVDF membrane at 25 V for 1 hour.  
  The PVDF membranes were then washed with 3 x 10 minutes TBS-T (100 
mM Tris (pH 7.0), 150 mM NaCl, 0.05% (v/v) Tween 20, 0.05% (v/v) Nonidet P-40) 
and blocked 3 x 10 minutes in 10 mL of blocking buffer (4 % (w/v) BSA, TBS-T) on 
the rocker. After the indicated times the blocking buffer was removed and the 
primary antibody (1:1000 dilutions in 10 mL blocking buffer) was incubated onto the 
PVDF membranes over night at 4 °C. The next day, the PVDF membranes were 
washed three times in TBS-T for 10 minutes after which the primary antibodies were 
detected with Goat IRDye800 conjugated anti-mouse antibodies (Rockland) and 
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Goat Alexa Fluor 680/700 conjugated anti-rabbit antibodies (Invitrogen Molecular 
Probes) at a 1:5000 dilution. The western blots were imaged using the Odyssey Li-
Cor infrared imaging system (software version 2.1.12).  The band intensities were 
quantified using Image J 1.46. 
2.27 Software and data analysis  
All the experiments shown in this thesis were repeated at least three 
independent times. The inositol phosphate and radio-ligand binding assays were 
carried out in triplicates of individual repeats. The data of these assays were 
represented as mean values and the standard error of the mean (SE). The statistically 
significant results were indicated by asterisks in the figures. The data analysis was 
performed using Students t-test or One-Way Anova with Dunnett’s test using 
GraphPad Prism 5.0 (GraphPad Software, San Diego, USA). Sigmoidal dose 
response curves were fitted to the relevant data sets and the EC50 and Emax values 
were determined. The expression levels of the mutant KISS1R were expressed 
relative to wild-type KISS1R control included in the individual experiments. The 
αCaMKII activity data was fitted to a Michaelis-Menten equation using GraFit 7 
(Erithacus Software Ltd, West Sussex, UK). 
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3. The physical association of calmodulin with kisspeptin 
receptor 
The regulatory mechanisms that enable KISS1R to sense increased intracellular 
Ca
2+
 concentration and avoid Ca
2+
 excitotoxicity are unclear. In this chapter, the 
hypothesis is investigated whether an interaction between the KISS1R and the Ca
2+
 
binding protein, calmodulin (CaM) may exist. The binding of CaM to KISS1R was 
tested by three different approaches. Firstly, spectrofluorimetric experiments were 
performed to see if CaM binds to intracellular loops IL1, IL2, IL3 or the C-
terminal tail of KISS1R. Secondly, co-immunoprecipitation experiments were 
conducted using FLAG-KISS1R expressed in HEK-293 cells and immunoblotting 
for endogenous CaM. Thirdly, it was tested if in HEK-293 cells, CFP-CaM co-
localises with YFP- KISS1R. The results of this chapter will be discussed in the 
context of how KISS1R is likely to function in high Ca
2+
 intracellular 
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3.1. Introduction 
The kisspeptin receptor (KISS1R) is a 7-transmembrane G-protein coupled 
receptor (GPCR) that is critical for mammalian fertility and some endocrine cancers 
[as reviewed (Oakley et al., 2009)]. Upon KISS1R activation, its coupling partner, G-
protein q/11 promotes cytosolic Ca
2+
 increase (Constantin et al., 2009, Kotani et al., 
2001, Liu et al., 2008, Muir et al., 2001, Stafford et al., 2002). However, this linear 
set of events will lead to Ca
2+
 excitotoxicity if left un-regulated, thus we must 
determine the proteins that bind and regulate KISS1R function.  
Like other GPCRs, the KISS1R contains three intracellular loops (IL1 to 3) 
and an intracellular C-terminal tail that function, in part, as contact sites for protein-
protein interactions. GPCRs signal by forming macromolecular protein complexes 
consisting of G-proteins and other proteins (Davare et al., 2001, Venema et al., 1998, 
Kim et al., 2005, Guhan and Lu, 2004, Sjogren et al., 2013, Mahon and Segre, 2004). 
Proteins other than G-proteins that interact with GPCRs are known as GPCR-
interacting proteins (GIPS). GIPs have been shown to directly interact with IL2 and 
IL3 of GPCRs, regulating their trafficking, function, and desensitisation [as reviewed 
in (Ritter and Hall, 2009, Bockaert et al., 2004). A detailed study of GIPs will 
increase our understanding of GPCR regulation mechanisms and potentially enable 
us to develop therapeutic drugs to modulate disease states.  
In this regard, an increasing interest is being paid to – calmodulin (CaM), a 
Ca
2+
 regulated GIP that is known to modulate the functional properties of a variety of 
GPCRs [as reviewed in (Ritter and Hall, 2009). Binding of Ca
2+
 to CaM induces 
conformational changes that expose hydrophobic regions and enable CaM to bind to 
various target proteins. CaM binding motifs are highly variable, with secondary 
structure properties being critical for CaM binding. The Ca
2+
/CaM binding motif is 
characterised by the existence of hydrophobic amino acids (F, W, I, L, or V) 
separated by basic residues (H, K, and R) in a 1-10, 1-12, 1-14 or 1-16 motif and 
governed by amphipathic α-helical feature. This criterion is derived from numerous 
structural studies of CaM binding to target proteins (Yap et al., 2000, Hultschig et al., 
2004).  
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CaM is known to interact and regulate some GPCRs. These include the 
metabotropic glutamate receptor, -opioid receptor, angiotensin II AT1A receptor, D2 
dopamine receptor, V2-vasopressin receptor, 5-hydroxytryptamine receptor, 5-HT2A, 
and 5-HT2C receptors (O'Connor et al., 1999, Dev et al., 2001, El Far et al., 2001, 
Minakami et al., 1997, Ishikawa et al., 1999, Choi et al., 2011, Wang et al., 1999, 
Thomas et al., 1999, Nickols et al., 2004, Turner and Raymond, 2005, Labasque et 
al., 2008). The CaM binding regions of the above mentioned GPCRs vary. In the 
case of the -opioid and 5-HT1A receptors, CaM binding is reported to occur via IL3 
(Wang et al., 1999, Turner et al., 2004). Binding of CaM to IL2 and the C-terminal 
tail is observed in the 5-HT2C receptor (Turner and Raymond, 2005). The general 
observation is that when CaM binding occurs via the intracellular loops of GPCRs 
then there is an attenuation of G-protein coupling [reviewed in (Ritter and Hall, 
2009)]. 
The purpose of this chapter was to determine whether the repertoire of CaM-
binding GPCRs extends to KISS1R. The work described in this chapter supports the 
role of CaM binding to KISS1R. However, the reader is directed to chapter 4 in order 
to appreciate the functional relevance of CaM binding to KISS1R.  
3.2. Aim and hypothesis  
The aim of this chapter is: 
 Determine whether CaM binds to KISS1R, and if so, characterise the 
site(s) of interaction. 
The hypothesis of this chapter is: 
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3.3. Results  
3.3.1. Ca2+/CaM binding to KISS1R intracellular loops  
Several research groups have demonstrated that CaM can modulate the activity of a 
hand full of GPCRs [as reviewed in (Ritter and Hall, 2009)]. However, our 
knowledge is severely constrained as to the type and number of likely CaM binding 
GPCRs. Therefore, I have selected two GPCRs that are critical for reproductive 
health – the human kisspeptin receptor (KISS1R) and gonadotropin releasing 
hormone receptor (GnRHR). In order to determine whether CaM binds KISS1R 
and/or GnRHR, peptides that correspond to the intracellular loops of GnRHR and 
KISS1R, and the C-terminal tail (in the case of KISS1R) were titrated against 
fluorescently labelled CaM using a spectrofluorimetric CaM binding assays (see 
section 2.13).  
Peptides that correspond to the intracellular loops (IL 1-3) of KISS1R and 
GnRHR, and the C-terminal tail (C-tail) of KISS1R were synthesized by EZBiolab, 
USA at > 95% purity (the peptide sequences are shown in Figures 3.1, 3.2, 3.4, and 
3.6). These peptides were then reacted with two different CaM probes containing 
chemical fluorophores. The first of these probes was TA-CaM (see section 2.13), 
which allowed for the measurement of the hydrophobic conformational change of 
K
75
. The probe is positioned in the flexible linker region of CaM. Another 
fluorescent probe termed DA-CaM was used. Briefly, double mutants (T34C/T110C) 
of CaM was generated and chemically labelled with IAEDANS and DDP 
fluorophores. The two probes form a Förster resonance energy transfer (FRET) pair. 
Upon DA-CaM binding to target peptide the donor IAEDANS fluorescence is 
quenched by the acceptor DDP, indicating close proximity of the probes, i.e. the 
closure of  the N- and C- lobes of CaM (see section 2.13). Both the DA-CaM and 
TA-CaM had high basal fluorescence intensities, which decreased upon binding to 
target peptide.  
The KISS1R intracellular loop 1 (IL1
67-80
) peptide is 14 amino acids long and 
contains 4 basic residues positioned mainly in the N-terminus and 4 bulky 
hydrophobic residues mostly positioned at the C-terminus. The peptide sequence 
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contains a proline amino acid towards the half-way point (6
th
 amino acid) of 
KISS1R-IL1
67-80
 (Figure 3.2A). The titration of KISS1R-IL1
67-80
 peptide (titration 
range: 0 to 100 M) against TA-CaM gave little fluorescence reduction (Figure 
3.2B). However, the titration of KISS1R-IL1
67-80
 peptide against DA-CaM (titration 
range: 0 to 50 M) gave an initial fluorescence reduction of approximately 10 % 
with the addition of 10 M KISS1R-IL1
67-80
 peptide, and gave no further 
fluorescence reduction with increased peptide concentration (Figure 3.2C). These 
observations were contrasted with the use of a high affinity CaM binding peptide 
called Trp peptide (RRKWQKTGHAVRAIGRL; single-letter amino acid code), the 
sequence is derived from the CaM binding domain of (residue 797-813) of smooth 
muscle myosin light chain kinase (MLCK) (Torok et al., 1998). The Trp peptide at 5 
M reduced DA-CaM fluorescence by approximately 85 % (Figure 3.2C).  
The GnRHR-IL1
59-78
 peptide is 20 amino acids long with 3 bulky 
hydrophobic residues spread along the full length of the peptide and 9 basic residues 
dispersed between them. This peptide sequence contains a glycine residue at the 12
th
 
amino acid position (Figure 3.2D). The GnRHR-IL1
59-78
 peptide titrated against DA-
CaM (titration range: 0 to 50 M) gave undetectable fluorescence reduction, this was 
in stark contrast to the observation that 5 M Trp peptide gave approximately 80 % 
fluorescence reduction of DA-CaM (Figure 3.2E)  
The left shift of the spectral peaks of DA-CaM observed in panel C compared 
to panel E of figures 3.2, 3.3, and 3.5 were attributed to an instrumental artefact. Two 
different instruments were used, panel E was generated using FluroLog-3, 
manufactured by HORIBA scientific, and the remaining figures were generated using 
SLM aminco series spectrofluorimeter (8100 model).  
The KISS1R intracellular loop 2 peptide (IL2
139-258
) contains 20 amino acids 
with 8 bulky hydrophobic residues mostly positioned at the N-terminus and 6 basic 
residues mostly positioned at the C-terminus. This peptide sequence (KISS1R- 
IL2
139-258




 amino acid positions 
(Figure 3.3A). The titration of KISS1R- IL2
139-258 
peptide against TA- and DA-CaM 
(titration range: 0 to 500 nM) resulted in consistent reduction of fluorescence 
intensities (Figure 3.3B and 3.3C). The fluorescence intensity reduction observed for 
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peptide (Figure 3.3). These levels were significantly lower than that of the 
5 M Trp peptide and DA-CaM mixture, which gave fluorescence reduction of 
approximately 80 %. The changes of the fluorescence intensities of TA-/DA-CaM 
were further analysed by plotting the emission fluorescence intensity values at 415 
nm for TA-CaM and 480 nm for DA-CaM against peptide concentration (Figure 3.4 
and Table 3.1). The obtained results show that KISS1R- IL2
139-258 
peptide bound to 
DA-CaM with binding affinity of 23 ± 4 nM Kd and to TA-CaM at 82 ± 15 nM Kd 
(Table 3.1). 
The GnRHR intracellular loop 2 (IL2
138-145
) peptide contains 18 amino acids 
with 5 bulky hydrophobic and 4 basic residues dispersed among the sequence. The 
GnRHR-IL2
138-145
 peptide contains a proline in the 9
th
 amino acid position (Figure 
3.3D). The DA-CaM mixed with GnRHR-IL2
138-145 
peptide (titration range 0 to 50 
M) gave markedly less fluorescence intensity reduction (approx.  5 %) than that of 
5 M Trp peptide, which gave approximately 70 % reduction in fluorescence 
intensity (Figure 3.3E).   




peptide contains 37 amino acids 
with 8 basic residues and 9 bulky hydrophobic residues spread throughout the length 
of the peptide. This sequence contains two proline amino acids at positions 12 and 
14, and 3 glycine residues at positions 6, 21, and 29 (Figure 3.5A).The titration of 
KISS1R-IL3
227-263 
peptide against TA-CaM and DA-CaM led to the largest reduction 
in fluorescence intensity (Figure 3.5C & D) compared with the other peptides tested 
(Figures 3.2, 3.3, and 3.7). Furthermore, 17 M of KISS1R IL3
227-263
 peptide was 
sufficient in quenching DA-CaM fluorescence similar to the extent with the addition 
of 5 M Trp peptide (Figure 3.5D). The analysis of the changes of the fluorescence 
intensities of the spectral peaks (emission fluorescence values taken at 415 nm for 
TA-CaM and 480 nm for DA-CaM) showed a biphasic binding of the CaM probes to 
the KISS1R-IL3
227-263
 peptide (Figure 3.6). Both TA-CaM and DA-CaM bound 
KISS1R-IL3
227-263
 at two independent sites, with the first site having an affinity of 
142 ± 65 nM for TA-CaM and 133 ± 98 nM for DA-CaM (Table 4.1). The second 
site of interaction was significantly lower in affinity for TA-CaM (12 ± 5 M) and 
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DA-CaM (9 ± 3 M). The level of the fluorescence reduction of TA-CaM binding to 
the first site of KISS1R-IL3
227-263
 was 32 ± 2 % and the second site was 47 ± 4 %. 
The fluorescence reduction of DA-CaM to KISS1R-IL3
227-263
 was 23 ± 5 % for the 
first site and 54 ± 4 % for the second site of KISS1R-IL3
227-263
. Upon normalising 
the fluorescence reduction to saturating KISS1R-IL3
227-263
 peptide concentrations, 
the Bmax for TA-CaM binding to the first site was 41 ± 6 % and the second site was 
60 ± 5 %. The Bmax for DA-CaM binding to the first site of KISS1R-IL3
227-263 
peptide 
was 30 ± 8 % and the second was 73 ± 6 % (Table 4.1).  
The GnRHR intracellular loop 3 (IL3
230-270
) peptide is composed of 40 amino 
acids with 12 bulky hydrophobic amino acids and 9 basic residues spread throughout 
the length of the peptide. The GnRHR-IL3
230-270 
peptide contains 2 proline residues 
at amino acid positions 16 and 32 (Figure 3.5B). The addition of GnRHR-IL3
230-270 
peptide against DA-CaM (titration range: 0 to 50 M) gave approximately 15 % in 
fluorescence reduction and resulted in a left shift of the spectral peaks (Figure 3.5E)  
The KISS1R C-terminal tail (C-tail
340-360
) peptide is composed of 21 amino 
acids with 7 basic residues that mostly form 3 repeating motifs of PRR. This peptide 
sequence contains 7 proline residues in the amino acid position of 3, 6, 9, 12, 14, 17, 
and 20. Also contained in the KISS1R- C-tail
340-360 
is a glycine residue in the 13
th
 
amino acid position. The titration of this peptide against TA- and DA-CaM gave 
undetectable change in fluorescence intensity (Figure 3.7)   





DA-CaM binding to KISS1R-IL3
227-263
 in the presence or absence of CaCl2 was 
measured. In 100 M CaCl2, DA-CaM mixed with 100 M KISS1R-IL3
227-263
 
reduced the fluorescence intensity by approximately 80 % and regained fluorescence 
intensity with the addition of 5 mM EGTA (Figure 3.8). This revealed that DA-CaM 
binding to KISS1R-IL3 peptide was Ca
2+
 dependent.  
Next, I wanted to know whether peptides derived from the C-terminal region 
of the Gα-subunit of the heterotrimeric G proteins can displace the DA-CaM bound 
KISS1R-IL3
227-263
 complex. To do this, C-terminal peptides from four different Gα-
subunit of the heterotrimeric G proteins (Figure 3.9) were synthesized (EZBiolab) at 
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> 95 % purity. None of the heterotrimeric G protein peptides at 50 M or less were 
found to displace DA-CaM bound to KISS1R-IL3
227-263
 peptide (Figure 3.9). 
In summary, the probes of TA- and DA-CaM gave significant fluorescence 
changes predominantly when titrated against KISS1R-IL3 and to a lesser extent -IL2, 
but not to -IL1 or -C-terminal tail (tested region). Nor did TA- and DA-CaM give 
significant fluorescence intensity change when titrated with intracellular loops of 
GnRHR. Furthermore, the binding of DA-CaM to KISS1R-IL3 was observed to be 
Ca
2+
 dependent. It was interesting to note that the Gα peptides did not displace the 
CaM.KISS1R-IL3 complex; this will later be evaluated in the discussion section of 
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Figure 3.1 Schematic depiction of the human KISS1R primary amino acid sequence. This diagram 
shows the transmembrane domains embedded into the plasma membrane in yellow and connected by 
extracellular loops (EL1-3) and intracellular loops (IL1-3). The amino acid sequence is identifiable in 
green and the most highly conserved residues are indicated in red. 
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Figure 3.2 Emission fluorescence spectra of TA- and DA-CaM titrated against 
intracellular loop 1 peptides from KISS1R & GnRHR. The amino acid sequence of 
intracellular loop 1 (IL1) peptides derived from human KISS1R (A) and GnRHR (D) was 
synthesised; red indicates bulky hydrophobic amino acids, while blue depicts basic residues 
and the amino acid (aa) number is identifiable with numbering above the boxed letters. IL1 
peptides were titrated against 100 nM TA-CaM (B) or 1 M DA-CaM (C & E) in the 
presence of assay buffer (see section 2.13) containing 100 M CaCl2. TA-CaM (B) 
fluorescence was determined at excitation wavelength 366 nm and emission wavelength 410-
430 nm. (C & E) DA-CaM fluorescence was measured at excitation wavelength 365 nm and 
emission wavelength 450-540 nm. 
      KISS1R-IL1 (aa)  67           72        77    80     
                             ICRHKPMRTVTNFY 
GnRHR IL1 (aa) 59             64                70      75     
             KLQKWTQKKEKGKKLSRMKL 
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Figure 3.3 Emission fluorescence spectra of TA- and DA-CaM titrated against 
intracellular loop 2 peptides from KISS1R & GnRHR. The amino acid sequence of 
intracellular loop 2 (IL2) peptides derived from human KISS1R (A) and GnRHR (D) was 
synthesised; red indicates bulky hydrophobic amino acids, while blue depicts basic residues 
and the sequence is identifiable with numbering above the boxed letters. IL2 peptides were 
titrated against 100 nM TA-CaM (B) or 1 M DA-CaM (C & E) in the presence of assay 
buffer (see section 2.13) containing 100 M CaCl2. TA-CaM (B) fluorescence was 
determined at excitation wavelength 366 nm and emission wavelength 410-430 nm. DA-
CaM (C & E) fluorescence was measured at excitation wavelength 365 nm and emission 
wavelength 450-540 nm. 
KISS1R IL2 (aa) 139                   145      250              255      258  
                                                                   DRWYVTVFPLRALHRRTPRL 
 GnRHR IL2 (aa) 138                  145            150      145 
                                                                     DRSLAITRPLALKSNSKV 
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Figure 3.4 TA/DA-Calmodulin binding to KISS1R- IL2. (A) 100 nM TA-CaM or 
(B) 1  DA-CaM and 100  CaCl2 were reacted with increasing concentrations 
of IL2 peptide. Fluorescence was determined at excitation wavelength at (A) 366 nm, 
(B) 365 nm and emission wavelength (A) 415 nm, (B) 480. The average values of 
three repeats were plotted and the error bars show the S.E.M. The data was fitted to a 
one-site model. The values are displayed in Table 4.1.  
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Figure 3.5 Emission fluorescence spectra of TA- and DA-CaM titrated against 
intracellular loop 3 peptides from KISS1R & GnRHR. The amino acid sequence 
of intracellular loop 3 (IL3) peptides derived from human KISS1R (A) and GnRHR 
(B) was synthesised; red indicates bulky hydrophobic amino acids, while blue depicts 
basic residues and the sequence is identifiable with numbering above the boxed 
letters. IL3 peptides were titrated against 100 nM TA-CaM (C) or 1 M DA-CaM (D 
& E) in the presence of assay buffer (see section 2.13) containing 100 M CaCl2. TA-
CaM (C) fluorescence was determined at excitation wavelength 366 nm and emission 
wavelength 410-430 nm. DA-CaM (D & E) fluorescence was measured at excitation 
wavelength 365 nm and emission wavelength 450-540 nm. 
KISS1R IL3 (aa) 227   230              240              250              260   263  
     MLRHLGRVAVRPAPADSALQGQVLAERAGAVRAKVSR 
GnRH IL3 (aa)   230       235               240      245      250        255      260           265             270            
                                                                            CNAKIIFTLTRVLHQDPHELQLNQLNQSKNNIPRARLKTLK  
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Figure 3.6 TA/DA-Calmodulin binding to KISS1R-IL3. (A) 100 nM TA-
Calmodulin or (B) 1  DA-Calmodulin and 100  CaCl2 was reacted with 
increasing concentrations of IL3 peptide. The experiments were carried out at 21
o
C, 
pH 7.0 in an assay buffer containing 100 mM KCl, 50 mM K
+
- PIPES, and 2 mM 
MgCl2. Fluorescence was determined at excitation wavelength at (A) 366 nm, (B) 
365 and emission wavelength (A) 415 nm, (B) 480. The average values of three 
repeats were plotted and the error bars show the S.E.M. The data was fitted to a two-
site model. The values are displayed in Table 4.1.  
 
 
Chapter 3: CaM Binding to KISS1R 
 











































































Figure 3.7 Emission fluorescence spectra of TA- and DA-CaM titrated against 
C-terminal tail fragment peptide of KISS1R. The amino acid sequence of the C-
terminal fragment peptide (C-tail) derived from human KISS1R (A) was synthesised; 
red indicates bulky hydrophobic amino acids, while blue depicts basic residues and 
the sequence is identifiable with numbering above the boxed letters. The C-tail 
fragment peptide was titrated against 100 nM TA-CaM (B) or 1 M DA-CaM (C) in 
the presence of assay buffer (see section 2.13) containing 100 M CaCl2. TA-CaM 
(B) fluorescence was determined at excitation wavelength 366 nm and emission 
wavelength 410-430 nm. DA-CaM (C) fluorescence was measured at excitation 
wavelength 365 nm and emission wavelength 450-540 nm. 
 
KISS1R (aa)  340               350              360     
  CAPRRPRRPRRPGPSDPAAPH 
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Table 3.1 Summary of TA/DA-CaM binding to KISS1R-IL2 and IL3. This table shows the values of the plotted graphs shown in 







Kd  Bmax 
Site -1 (nM)  Site-2 (M)  Site -1 (%)  Site-2 (%) 










IL 2  82 ± 15 23 ± 4  - -  100  100  - - 
IL 3  142 ± 65 133  ± 98  12 ± 5 9 ± 3  41 ± 6 30 ± 8  60 ± 5 73 ± 6 
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 dependent DA-CaM binding to KISS1R-IL3. DA-CaM 1M, in 
the presence of assay buffer (see section 2.13) containing 100 M CaCl2 was 
preincubated at 21 °C; DA-CaM fluorescence intensity was normalised to 1. At the 
point indicated by an arrow, 100 M KISS1R-IL3 was added, resulting in substantial 
quenching of DA-CaM fluorescence, indicating a conformation in where the two 
globular domains of DA-CaM are compacted around KISS1R-IL3. As indicated by 
the second arrow, at 335 s, 5 mM EGTA was added, resulting in unquenching of 
DA-CaM fluorescence. This indicated the stretching of DA-CaM to an extended 
conformation and presumably releasing KISS1R-IL3. The excitation wavelength was 
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Figure 3.9 Peptides derived from the Gα-subunit of the heterotrimeric G proteins do 
not antagonise the CaM.KISS1R-IL3 complex. The G protein derived C-terminal peptides 
with variable amino acid sequences (table 3.2) were synthesised and titrated against 1 M 
DA-CaM in the presence of assay buffer (see section 2.13) containing 100 M CaCl2. DA-
CaM fluorescence was measured at excitation wavelength 365 nm and emission wavelength 
480 nm. (A) Gqα peptide (B) G13α peptide (C) Gi3α peptide (D) Gsα peptide 
 
Table 3.2 Human G protein α-subunits derived C-terminal peptides 
The amino acid sequence of the peptides used in Figure 3.9. All the peptides were 
synthesised from EZ Biolabs at > 95 % purity. 
 
 
Gα protein peptide Amino Acid Sequence NCBI Reference 
Sequence  
(A)  Gqα-C-Terminus   (349-359) LQLNLKEYNLV P29992.2 
(B)  G13α-C-Terminus (272-282) LHDNLKQLMLQ NP_001269354.1 
(C)  Gi3α-C-Terminus  (344-354) IKNNLKECGLY AAM12621.1 
(D)  Gsα-C-Terminus   (384-394) QRMHLRQYELL P63092.1 
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3.3.2. Ca2+ and KP-10 dependent CaM binding to KISS1R 
  The selective binding of CaM to IL2 and IL3 peptides derived from the 
KISS1R, raised the important question of whether CaM can bind to the intact 
KISS1R expressed in cells, and whether the interaction is ligand and/or Ca
2+
 
dependent. To answer this question, HEK-293 cells were used in co-
immunoprecipitation experiments, transiently expressing FLAG-KISS1R and 
immunoblotting for endogenous CaM. Also, colocalisation experiments were carried 
using YFP-Chimeric-KISS1R and CFP-CaM co-expressed in HEK-293 cells. 
  To test the putative interaction between CaM and KISS1R in cells co-
immunoprecipitation (Co-IP) experiments were carried out (see section 2.25). The 
cDNA vector of the N-terminal FLAG-tagged KISS1R was transiently transfected 
into HEK-293 cells. The FLAG-tag did not affect kisspeptin-10 (KP-10) binding or 
the signalling properties as compared to wild-type KISS1R (Figure 3.10, Table 3.3, 
Figure 3.11 and Table 3.4). The expression of FLAG-KISS1R was confirmed by the 
observation that the transfected-non-stimulated (TNS) band intensities were 
significantly (P < 0.05) increased relative to the non-transfected (NT) cells (Figure 
3.12). Furthermore, the FLAG-KISS1R band intensities showed no significant (P > 
0.05) change between KP-10 stimulated and TNS samples (Figure 3.12). These 
experiments revealed that FLAG-KISS1R could be detected when expressed and 
showed little variation in band intensity upon KP-10 stimulation. All the kisspeptin 
ligands bind to the KISS1R with nanomolar affinities and have indistinguishable 
signalling efficacies (Kotani et al., 2001). Therefore, the KP-10 ligand was used in 
further experiments because it was the shortest and the most stable peptide (Kotani et 
al., 2001). As expected, endogenous CaM was found to interact with the FLAG-
KISS1R in Co-IP complex (P < 0.05) only upon KP-10 stimulation (Figure 3.12). 
This was determined by immunoblots with specific monoclonal anti-calmodulin 
antibody and the molecular weight was verified with purified calmodulin (Figure 
3.12) as an indicator (Ind).  
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  To test whether Ca
2+ 
can promote CaM binding to FLAG-KISS1R expressed 
HEK-293 cell lysates, exogenous CaCl2
 
was added into the lysate slurry (Figure 
3.13). When the cells were not stimulated by KP-10 agonist, FLAG-KISS1R did not 
Co-IP with endogenous CaM, but did with exogenous addition of CaCl2
 
concentrations (Figure 3.13). This interaction was disrupted by addition of the CaM 
inhibitor, calmidazolium (Figure 3.13).  
  To further validate the interaction between CaM and the KISS1R, co-
localisation experiments were carried out using CFP-CaM and YFP-Chimeric-
KISS1R transiently expressed in HEK-293 cells (Figure 3.14 and Figure 3.16). The 
YFP-Chimeric-KISS1R has the N-terminal region replaced with that of the Galanin 
receptor N-terminal region. The YFP-Chimeric-KISS1R was chosen for its properties 
of right-shift dose response curve (Figure 3.11), this enabled for the study of a 
receptor form that existed more in the inactive state than wild-type KISS1R, which 
had been shown to have constitutive activity (Pampillo and Babwah, 2010). The 
obtained confocal images showed that in CFP-CaM expressing cells the fluorophore 
appeared to be ubiquitously expressed throughout the cell (Figure 3.14). The YFP-
Chimeric-KISS1R expressing cells appeared to be localised to the cell membrane and 
around what was presumed to be the nucleus (Figure 3.15). However, when both 
constructs were co-expressed in the same cell, a high degree of co-localisation in the 
membrane was observed. This basal colocalisation of CaM and KISS1R was 
observed in some populations of cells (Figure 3.16). However, the majority of cells 
did not express co-localisation. 
  Taken together, these results provided the first evidence that CaM selectively 
binds to IL2 and IL3 peptides derived from the KISS1R, and that CaM bind to the 
intact KISS1R expressed in HEK-293 cells in a KP-10/Ca
2+
 dependent manner. 
Additionally, the three independent methods of spectrofluorimetry, confocal 
microscopy, and co-immunoprecipitation, all validate each other. However, it 
remains to be further confirmed by testing the underlying sites of interaction(s) and 
the functional relevance of the interaction. In the following chapter these questions 
were experimentally addressed.  
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Figure 3.10 KP-10 binding to Wt-KISS1R and FLAG-KISS1R. COS-7 cells were 
transiently transfected with Wt-KISS1R ( ) or N-terminal tagged FLAG-KISS1R (
) 48 hours prior to the binding assay (see section 2.22). A representative trace of 
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Table 3.3 KP-10 binding to Wt-KISS1R and FLAG-KISS1R. The analysed data 
of Figure 3.10 shows the IC50 values of KP-10 binding to wild-type KISS1R FLAG-






















Construct IC50 [M] S.E.M [M] 
    Wt-KISS1R 7.44 x 10
-9
 0.91 x 10
-9
 
    FLAG-KISS1R 5.21 x 10
-9
 0.62 x 10
-9
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Figure 3.11 KP-10 induced IP3 accumulation in COS-7 cells expressing KISS1R 
with or without tags. COS-7 cells were transiently transfected with different 
KISS1R constructs 48 hours prior to the IP3 accumulation assay (see section 2.24). 
Wt-KISS1R ( ), N-terminal fused FLAG-KISS1R ( ), and N-terminal YFP- 
Chimeric-KISS1R ( ) in where the N-terminal is replaced for the Galanin receptor. 
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Table 3.4 Comparison of KP-10 potency of the different tagged KISS1R 
constructs. Analysed data of Figure 3.11 show the EC50 values of KP-10 in 
stimulating IP3 turnover transfected with different tagged KISS1R constructs. 




















Construct EC50 [M] S.E.M [M] 
  Wt-KISS1R 3.4 x 10
-9
 1.7 x 10
-9
 
  FLAG-KISS1R 5.27 x 10
-9
 0.85 x 10
-9
 
   YFP-Chimeric-KISS1R 9 x 10
-8
* 5.5 x 10
-8 
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Figure 3.12 KP-10 dependent binding of FLAG-KISS1R to endogenous CaM. 
FLAG-KISS1R was transiently transfected into HEK-293 cells. At 48 hours post 
transfection the cells were stimulated with 100 nM KP-10 at 1 minute intervals and 
processed using the Co-IP method (see section 2.25). The samples were later 
immunoblotted (IB) with anti-FLAG M2 and anti-CaM antibodies. Lane NT denotes 
non-transfected cells and TNS is transfected non-stimulated stimulated cells. 
Purified CaM from bovine testes was used as the positive control (indicator, Ind.). A 
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 dependent binding of FLAG-KISS1R to endogenous CaM. 
HEK-293 cells were transiently transfected with FLAG-KISS1R 48 hours before 
incubation in lyses buffer containing indicated Ca
2+
 concentrations and 
Calmidazolium inhibitor. CaM and FLAG were detected via immunoblotting (IB). A 











    
           NT +   - - - - - - -  
           NS - + - - - - - -  
           CaCl2 10M - - + - - - - -  
           CaCl2 100M - - - + - - + -  
           CaCl2 1mM - - - - + - - -  
           CaCl2 10mM - - - - - + - -  
           Calmidazolium 1 M - - - - - - + -  
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Figure 3.14 Ubiquitous expression of CFP-CaM in HEK-293 cells. Live cell 
imaging was made by using HEK-293 cells that were transiently transfected with 
CFP-CaM (Cyan colour) 48 h before confocal imaging. The right column is the 
fluorescence channel, the middle column is bright field and the left column is merged 
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Figure 3.15 YFP-Chimeric-KISS1R expression in HEK-293 cells. Live cell 
imaging was obtained using HEK-293 cells that were transiently transfected with 
YFP-Chimeric-KISS1R (Yellow colour) 48 h before confocal imaging. The right 
column is the fluorescence channel, the middle column is bright field and the left 
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Figure 3.16 Colocalisation of CFP-CaM and YFP-Chimeric-KISS1R in HEK-
293 cells. Live cell imaging of HEK-293 cells were carried out by transiently 
transfection of YFP-Chimeric-KISS1R (Yellow colour) and CFP-CaM (Cyan colour) 
48 h before confocal imaging. From the left, CFP-CaM fluorescence channel, then 
the YFP-Chimeric-KISS1R fluorescence channel, followed by the bright field 
channel (with exception of the bottom image), and finally the merged images.   
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3.4 Discussion 
Calmodulin (CaM) is a multifunctional signalling adaptor protein that 
transduces Ca
2+
 signals by binding Ca
2+
 ions and then interacts with target proteins to 
modify their structure and function. These include several GPCRs, which have been 
shown to interact with CaM [Reviewed in (Ritter and Hall, 2009)]. However, 
whether the CaM binding GPCRs extends to the kisspeptin receptor (KISS1R) was 
not known. Therefore, following the reductionist approach, this study set out to 
determine the affinity of CaM binding to the intracellular regions of KISS1R. Indeed, 
there was CaM binding to IL2 and IL3 and not to IL1, or C-terminal tail (tested 
region) of the KISS1R, or to IL1-IL3 of GnRHR. Further validation was carried out 
with confocal imaging, which appeared to show that CaM and KISS1R colocalise in 
the periphery of the cell in some cells. Also, KISS1R was found to interact with 
endogenous CaM in a ligand and Ca
2+
 dependent manner by assays. 
The binding of CaM to the intact KISS1R in cells was confirmed by co-
immunoprecipitation (Co-IP) experiments. In HEK-293 cells, endogenous CaM and 
transiently transfected FLAG-KISS1R were found to Co-IP in an agonist- and Ca
2+
-
dependent manner at a time of ≤ 1 minute post stimulation (Figure 3.10 and 3.11). 
The rapid binding of CaM to the KISS1R upon agonist stimulation was deemed to be 
faster than the initiation of KISS1R internalization, which was shown to be ~ 5 
minutes by Pampillo and Babwah (Pampillo and Babwah, 2010). Therefore, CaM 
binding to the KISS1R occurs before the initiation of the agonist-induced KISS1R 
internalization. Furthermore, the KISS1R has been shown to exhibit basal 
constitutive activity and internalization (Pampillo and Babwah, 2010). It was thus 
unclear whether CaM binds the inactive state of the KISS1R.  
In an attempt to address this, a chimeric KISS1R was utilised, where the N-
terminal of KISS1R was replaced with that of the Galanin receptor and the C-
terminal was fused with YFP. The YFP-chimeric-KISS1R construct exhibited a (10-
fold) right-shifted dose-response curve (Figure 3.11), implying that the chimeric 
receptor has decreased ligand potency and signalling efficacy, but remains functional 
in terms of activating G-proteins. The expressed protein was observed to colocalise 
with CFP-CaM in the cell periphery of HEK-293 cells (Figure 3.14). The basal 
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colocalisation was observed in some cells and not all. The cells that showed 
colocalisaiton were abnormal in shape and large in size implying that these cells are 
perhaps undergoing cell division or apoptosis. Apoptosis is known require increased 
cytosolic Ca
2+
 (Mattson and Chan, 2003). Therefore, if the cells are apoptotic the 
increased Ca
2+
 may drive the colocalisation. Another explanation may be due to the 
inherent Ca
2+
 dynamics in the cell throughout the mammalian cell-cycle, and 
especially during early G1 and G1/S and G2/M transitions (Roderick and Cook, 
2008). The first major Ca
2+
 transient occurs before cells enter mitosis, and the second 
is during the metaphase-anaphase transition (Roderick and Cook, 2008, Groigno and 
Whitaker, 1998). Additionally, the downstream protein targets for Ca
2+
 are also 
implicated in the cell cycle (Patel et al., 1999, Rasmussen and Means, 1989). 
Therefore, the basal colocalisation that is observed in some population of cells may 
be the result of those cells undergoing cell division or apoptosis and thus increased 
cytosolic Ca
2+
 that promotes CaM binding to KISS1R.  
Although supported by Figure 3.13, showing the Ca
2+
 dependent binding of 
CaM to KISS1R in Co-IP, the confocal imaging results have significant limitations, 
these include; that the minority of cells that showed colocalisation were also of poor 
viability. The study examined the basal interaction and not the KP10 stimulated 
interaction. KP10 stimulation was attempted but exhibited technical difficulties in 
terms of simultaneous stimulation and imaging and the high KP10 concentration that 
was required to activate the YFP-chimeric-KISS1R. YFP-chimeric-KISS1R may 
have altered trafficking properties because of the replaced N-terminal. The Wild-type 
KISS1R-YFP was created to address some of these issues but the expression was 
poor, possibly due to the pEYFP vector. Immunohistochemistry (IHC) was 
considered but ruled out because the real-time dynamic interaction will not be 
appreciated and direct protein-protein interactions cannot be determined even with 
IHC-FRET, as the spatial distance of the probes via primary and secondary 
antibodies will increase the measured distance of the interaction significantly to ~140 
Å, and are substantially flexible to influence their absolute positions (Snapp and 
Hegde, 2006). Future experiments should entail the optimisation of Wild-type 
KISS1R-YFP expression, the use of CFP-CaM in a FRET study with and without 
KP10 stimulation, and a perfusion culture chamber to properly administer the KP10 
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while simultaneously imaging the live-cells. This approach will determine the spatial 
distance of CaM and KISS1R to < 100 Å and image the real-time dynamic 
interaction (Selvin, 2000). This approached although desirable will have limitation in 
the photobleaching of CFP and YFP and therefore increased the signal-to-noise ratio. 
Furthermore, the probes may interfere with the structural interaction between 
KISS1R and CaM. 
These results are in concurrence with other research showing CaM Co-IP 
with some GPCRs. For example, CaM has been shown to interact with 5-
Hydroxytryptamine 2A and 2C (5-HT2A and 5-HT2C) receptors in a Ca
2+
 and agonist 
dependent manner (Labasque et al., 2008, Turner and Raymond, 2005). Also, CaM 
Co-IP with the Vasopressin (V2) receptor has been shown to be Ca
2+
 dependent 
(Nickols et al., 2004). These results are in contrast with the finding that CaM Co-IPs 
with the 5-HT1A and Dopamine D2 receptor in a constitutive, agonist-independent 
manner (Turner et al., 2004). However, intracellular Ca
2+
 signalling is complex and 
this constitutive interaction may partially be the result of ‘cross-talk’ from other 
signalling pathways, which may in turn promote CaM binding to D2 and 5-HT1A.  
The inherent limitations of Co-IP experiments involving CaM and GPCRs 
cannot exclude the potential of indirect protein-protein interactions. For instance, one 
argument that may challenge CaM.KISS1R Co-IP is the following logic; CaM has 
been shown to bind G protein-coupled receptor kinases (GRKs) and β-arrestin 
(Pronin et al., 1997, Levay et al., 1998, Wu et al., 2006). Both β-arrestin and GRK-2 
in turn have been shown to bind KISS1R (Pampillo et al., 2009). Thus, β-arrestin and 
GRK-2 may function to mediate CaM interaction with KISS1R.  
However, upon careful consideration these arguments are refuted with the 
following explanations; CaM binds to the concave surface of the C-domain and a 
finger loop in the middle of the ß-arrestin molecule. These CaM-binding sites on the 
β-arrestin also overlap with receptor and microtubule binding sites. In fact, CaM 
binds ß-arrestin with a Kd of ~ 7 M, and ß-arrestin binds its cognate receptors in the 
nanomolar affinity range. This means that ß-arrestin cannot bind to CaM and 
receptor simultaneously because these two interactions are mutually exclusive, 
making CaM an ineffective competitor for ß-arrestin binding in the presence of 
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highly expressed receptors (Wu et al., 2006). Therefore, ß-arrestin is unlikely to 
function as an intermediary interacting protein linking CaM and KISS1R.  
Ca
2+
 bound CaM has been shown to inhibit the catalytic activity of all the 
GRKs (GRK2, -3, -4, -5, and -6) except GRK1 (Chuang et al., 1996). With GRK5 
being the most sensitive to CaM (IC50 40-50 nM) and GRK2 being the least sensitive 
(IC50 ~2 M) (Chuang et al., 1996, Pronin et al., 1997). Pampillo (Pampillo et al., 
2009) showed GRK2 interacted with KISS1R in the absence and presence of KP-10 
agonist, implying that GRK2 and KISS1R form basal interaction. In addition, myc-
GRK2 was found to interact predominantly with GST-IL2 of KISS1R, but in this 
thesis CaM was found to bind to IL3 of KISS1R (Figure 3.5 and 3.6). In addition, 
Pampillo overexpressed myc-GRK2 and FLAG-KISS1R in HEK-293 cells which 
may artificially increase KISS1R-GRK2 interactions. Thus, further studies involving 
Co-IP of FLAG-KISS1R and endogenous GRK2 are required to determine whether 
there is an actual basal interaction. However, other unknown intermediary proteins 
linking CaM and KISS1R Co-IP complex were not ruled out. 
In order to circumvent the inherent limitations of the Co-IP method, cell-free 
spectrofluorimetric CaM binding assays were utilized to study the physical 
interactions between CaM and KISS1R intracellular regions. In those studies, 
fluorophore labelled CaM was found to bind exclusively to IL2 and IL3 derived 
peptides of the KISS1R, but not to the peptides of IL1, the C-terminal tail (tested 
region) or any of the three intracellular loops of GnRHR (Figure 3.2-3.7). As far as 
one can tell from the literature, the biphasic nature of CaM binding to IL3 is the first 
reported case of CaM biphasic binding to target peptide. The two distinct DA-CaM 
binding sites of IL3 are both within physiological concentrations, as HEK-293 cells 
have been shown to contain intracellularly available CaM at a concentration of 8.8 ± 
2.2 M (Black et al., 2004). The binding of TA/DA-CaM to IL2 and IL3 (Table 3.1) 
were in agreement with published data of CaM binding to other GPCRs. 
Fluorescence labelled dansyl-CaM has been shown to bind to IL3 of 5-HT1A in two 
separate peptide regions (Kd - 87 nM ± 23 nM and 1.7 M ± 0.16 M), D2 
Dopamine receptor (Kd ~100 nM ), and Opioid receptor (IC50 42 nM ± 3 nM). The 
binding of dansyl-CaM has also been shown to bind to IL2 of the 5-HT2A (Kd 65 ± 30 
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nM). Also, all these interactions are Ca
2+
 dependent (Turner et al., 2004, Bofill-
Cardona et al., 2000, Wang et al., 1999, Turner and Raymond, 2005). Furthermore, 
numerous studies have indicated IL3 of GPCRs as being critical for G-protein 
activation (Cai et al., 2001, Kang et al., 2005, Geiser et al., 2006, Nanoff et al., 2006, 
Johnston and Siderovski, 2007). Additionally, Gq coupling was found occur at IL2 of 
the KISS1R (Wacker et al., 2008). Taken together, KISS1R IL2 and IL3 constitute 
significant sites for Gq activation and therefore CaM binding to those sites is 
proposed to compete with Gq.  
This chapter set out to determine whether CaM binds the KISS1R, and if so 
where were the sites of interaction(s). The three independent experiments of 
spectrofluorimetry, confocal imaging and co-immunoprecipitation all validate each 
other to provide the first evidence of the physical interaction between CaM and 
KISS1R via IL2 and IL3. The intracellular loop regions are also critical sites of 
heterotrimeric Gq binding, implying that CaM binding may function to attenuate Gq 
coupling. In the next chapter, the amino acid sequence of IL2 and IL3 of KISS1R 
will be analysed for CaM binding motifs and then the critical amino acids will be 
replaced by alanine to determine whether KISS1R/Gq coupling can be enhanced. 
This approach will allow for closer examination of the sites of interaction and at the 
same time determine the function of these sites in KISS1R function. 
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4. The functional relevance of calmodulin binding to 
kisspeptin receptor  
Having established that CaM binds to IL2 and IL3 of KISS1R, the functional 
importance of this interaction was studied with alanine substitution by site-directed 
mutagenesis of the putative critical binding residues. This method revealed the 
importance of bulky hydrophobic amino acids at the juxtamembrane regions of 
IL3. These results were used to model CaM binding to KISS1R-IL3 peptide. The 
site-directed mutagenesis and modelling data was validated with site-directed 
fluorescence labelling of CaM to determine the importance of the juxtamembrane 
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4.1. Introduction 
There is increasing evidence to suggest that the kisspeptin (KP) pathway is a 
therapeutic target for the potential treatment for hypogonadotropic hypogonadism 
(HH), delayed puberty, and many endocrine cancers (Nash et al., 2007, Clarkson et 
al., 2008, Makri et al., 2008, Roa et al., 2009). However, two main hurdles must be 
overcome to realise this potential. Firstly, KISS1R will internalise through the 
process of endocytosis to desensitise against the stimulation of KP ligands (Pampillo 
and Babwah, 2010). Secondly, the endogenous expression levels of KISS1R vary in 
space and time and may limit the potential KP ligand-based hormone therapy (Ohtaki 
et al., 2001). A solution might be to determine the structural features of KP ligands in 
order to engineer more potent analogues, but this approach poses considerable 
challenges. As noticed by Shin et al., 2009, the KP-54 in sodium dodecyl sulphate 
(S.D.S) micelles “exhibits greater than 90 % random coil content, with no significant 
β sheet or α-helical content” as studied by nuclear magnetic resonance (NMR) 
techniques (Shin et al., 2009). The authors conclude that the lack of distinguishable 
structural elements in KP-54 make it difficult to engineer more potent analogues 
(Shin et al., 2009). Nevertheless, promising work carried out by Orsini et al., 2007, 
revealed that the shorter KP-13 in detergent (S.D.S micelles) adopted a stable helical 
structure in the last seven residues using NMR spectroscopy (Orsini et al., 2007).  
With this information the authors generated full agonists, but with reduced potency 
compared to KP-13 (Orsini et al., 2007). However, Tomita and colleagues of 2006 
were more successful in generating agonists with increased potency (compound 34), 
albeit with reduced maximum agonistic activity relative to KP-10 (Tomita et al., 
2006).  
Engineering ligands that target the extracellular regions of KISS1R may one day 
prove useful in disease modulation, but currently considerable challenges exist, 
therefore other approaches need to be considered. Thus, the intracellular regions of 
KISS1R were explored in our search for novel drug targets against protein-protein 
interactions. A number of studies utilising site-directed or alanine scanning 
mutagenesis approaches have suggested that the intracellular loops 2 and 3 (IL2 and 
IL3) of GPCRs are paramount for G–protein coupling and activation (Moro et al., 
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1993, Blin et al., 1995, Arora et al., 1995, Burstein et al., 1998, Zhou et al., 1999, 
Gaborik et al., 2003, Cai et al., 2001, Kang et al., 2005, Geiser et al., 2006, Nanoff et 
al., 2006, Johnston and Siderovski, 2007, Audet and Bouvier, 2012). Furthermore, it 
was previously shown that in the class A GPCRs, a sequence element that was 
termed DRY (E/DRY) motif played a role in receptor activation. Numerous 
structural studies have revealed the presence of a polar interaction between the 
arginine of the above mentioned motif positioned at the bottom of transmembrane 3 
(TM3) and a glutamate located in TM6. The ionic lock that is formed between TM3 
and TM6 involves IL2 and IL3 and is proposed to stabilise the inactive state of 
GPCRs [as reviewed in (Audet and Bouvier, 2012)]. This would therefore imply that 
IL2 and IL3 function as conduits for transducing the activation of GPCRs into the 
modulation of the multi-domain GPCR-G protein interface, and thus regulating G-
protein activity. 
One particular GPCR interacting protein that has drawn increasing interest lately 
is calmodulin (CaM), because of its direct involvement in attenuating G-protein 
activation via interactions with IL2 and IL3 of GPCRs [as reviewed in (Ritter and 
Hall, 2009)]. Consistent with this, I have shown that CaM binds to KISS1R via IL2 
and IL3 (see chapter 3). Herein, I aim to determine the functional relevance of CaM 
binding to IL2 and IL3 of KISS1R. The method used was alanine substitution by 
site-directed mutagenesis of the putative CaM binding motifs of KISS1R, as well as 
modelling the KISS1R.CaM interaction. This approach aims to advance our 
understanding of the KISS1R.CaM complex with the strategic vision to develop 
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4.2. Aims and hypotheses  
The aims of this chapter are: 
 To test the hypothesis that calmodulin binding motifs regulate G-protein 
coupling/activation. 
 Propose a testable structural model of CaM.KISS1R complex  
 Test the CaM.KISS1R model.  
 
The hypotheses of this chapter are: 
 The putative CaM binding motifs  in KISS1R-IL3 regulateKISS1R-CaM 
interactions  
 The interaction of KISS1R with CaM via the putative CaM binding motifs in 
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4.3. Results 
4.3.1. The critical sites of KISS1R-CaM binding motifs  
KISS1R IL2 and IL3 contain CaM-binding motifs and thus may constitute the 
foundation of the CaM.KISS1R interactions. In order to test this, alanine substitution 
by site-directed mutagenesis was used to replace the putative crucial amino acids that 
make up the CaM binding motifs of the KISS1R (Figure 4.1), and followed by 
studying the effects of mutation on ligand binding and receptor functional activity 
(see section 2.22 and 2.24, respectively). This approach might be useful in the 
identification of specific CaM binding sites of KISS1R. The experimentally 
proposed CaM binding sites were then used to validate an in silico model of the 
CaM-IL3 complex.  
The IL3 region of KISS1R contains 6 complete CaM binding motifs and 4 
more binding motifs extended into the transmembrane domains (TM) 5 or 6. The IL2 
in contrast contains only 1 CaM binding motif (Figure 4.1). The bulky hydrophobic 
amino acids and the basic residues that are characteristic of the CaM binding motifs 
were mutated into alanine (Ala) using site-directed mutagenesis (Figure 4.1). The 
Ala mutants were transiently transfected into COS-7 cells and the receptor 
expression level was measured using radio-ligand binding assay (see section 2.22). 
The expression profile of the Ala mutants showed reduced expression level (relative 
to wild-type KISS1R) in KISS1R-IL2 mutants W141A (12.59 % ±10.54 %), Y142A 
(11.19 % ± 2.15 %). Also the KISS1R-IL3 N-terminus mutants were also reduced, 
these were R229A (10.97 % ± 1.81 %), V236A (5.10 % ± 5.31 %), as well as the 
KISS1R-IL3 C-terminus mutants of R253A (34.30 % ± 2.27 %), R258A (31.00 % ± 
6.20 %), K260A (25.02 % ± 3.04 %), and K263A (23.52 % ± 2.84 %). All these low 
expressing mutants were statistically significant (ranging from P<0.001 to P<0.05) 
from wild-type KISS1R expression levels (Figure 4.2, Table 4.1).  
The KP-10 ligand bound to wild-type KISS1R with an IC50 value of 5.21 ± 
0.62 nM, and this was similar to most of the KISS1R Ala mutants that ranged 
between an IC50 value of 2.37 ± 0.24 nM (R237A) and 8.44 ± 2.18 nM (V234A). 
Unfortunately, the IC50 values of W141A, Y142A, and V236A were undetectable 
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(Figure 4.3 and Table 4.1), due to their low expression levels (Figure 4.2 and Figure 
4.3, respectively). 
Next, the effect of KP-10 ligand induced IP3 turnover in cells expressing 
KISS1R alanine mutants was studied. The Ala mutants were transiently expressed in 
COS-7 cells and then functionally analysed by IP3 accumulation assays (see section 
2.24). The relative maximum responsiveness was calculated by the ratio of Emax/Rexp 
relative to KISS1R wild-type KISS1R, where the receptors were saturated and the 
ligand binding affinity became unimportant. Interestingly, only one mutant (L245A) 
displayed a 6-fold reduction in the relative maximum responsiveness (Figure 4.1) 
with also a 4-fold increase in EC50 value (Table 4.1). In contrast, two mutants 
(W141A and Y142A) of IL2 gave a 4 to 5-fold increase in relative maximum 
responsiveness. Mutations to KISS1R-IL3 revealed that the N-terminal region 
residues of R229A and V236A gave a 4 and 16-fold increase in relative maximum 
responsiveness, respectively (Figure 4.5 and Table 4.1). However, all the mutants 
tested did not show significant increases in basal activity (Figure 4.6).  
The Ala mutagenesis studies were complemented with computational 
modelling of the CaM-IL3 interaction. To do this, the amino acid sequence of IL3 
and the flanking regions (P216– P278) of KISS1R was aligned to their comparative 
regions of bovine rhodopsin, using the highly conserved proline residues positioned 
in transmembrane 5.50 (TM) and TM 6.50 (Figure 4.7) using www.tcoffee.org. This 
was then homology-modelled against the determined structure of bovine rhodopsin 
(PDB 2X72) using easy modeller GUI. In addition to this, the CaM structure (1CM1) 
was obtained from the determined structure of CaM binding to the auto inhibitory 
domain of CaMKII. Both these structures were then uploaded onto the 
www.cluspro.bu.edu protein-protein docking web server for predicting the CaM-IL3 
interaction. The third highest scoring model was chosen as it fitted the Ala 
mutagenesis results (Figure 4.7). The CaM-IL3 model showed CaM binding to the 
juxtamembrane regions KISS1R-IL3, with the N-terminal of IL3 binding to the C-
terminal of CaM (Figure 4.7).  
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Taken together, these results supported the hypothesis that the CaM binding 
motifs of KISS1R participates in regulating receptor activity, and in particular the 
juxtamembrane regions of KISS1R-IL3 and the N-terminal region of KISS1R-IL2 
Alanine mutations of IL2 and IL3 of KISS1R had little effect on the binding affinity 
of KP-10, suggesting little global structural disturbance by the alanine mutations, 
which simply delete the side-chain beyond the -carbon. The marked increase in the 
signalling efficacy of the mutants, especially R229A and V236A, may be caused by 
the abolishment of the mutant receptor interaction with CaM. Unfortunately this 
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Figure 4.1 Putative Calmodulin-binding motifs of KISS1R-IL2 and IL3. The amino 
acid sequences of KISS1R-IL2 (A-C) and -IL3 (D-F) have many basic amino acids 
(blue) dispersed between flanking bulky hydrophobic residues (red) that are 
characteristic of CaM binding motifs. IL2 has only one putative CaM binding motif 
(highlighted in yellow, B). However, IL3 contains 6 full-length putative CaM binding 
motifs with 4 more motifs extending into transmembranes 5 and 6 (E). Alanine 
substitution by site-directed mutagenesis to the suggested crucial CaM binding residues 
was carried out in order to investigate the role of these CaM binding motifs (C and F, 
highlighted in black). 
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Figure 4.2 Cell surface expression levels of KISS1R mutants. COS-7 cells were 
transiently transfected with KISS1R 48 hours prior to the radio-ligand binding assay 
(see section 2.22). The average values of three experimental repeats are shown with 
the error bars (S.E.M.) Asterisks (*) denote statistical significance (* P<0.05, ** 
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Figure 4.3 KP-10 binding properties of KISS1R-mutants. COS-7 cells were 
transiently transfected with KISS1R 48 hours prior to the radio-ligand binding assay 
(see section 2.22). The average values of three repeats are shown with the error bars 
denoting standard error of the mean (S.E.M.). The mutations showed little effect on 
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Figure 4.4 The signalling potency of KP-10/KISS1R-mutants. COS-7 cells were 
transiently transfected with wild-type and mutant KISS1Rs 48 hours before 
stimulation with KP-10 for 60 minutes, and the IP3 accumulation was measured (see 
section 2.24). The average EC50 values of the three repeats are shown with the error 
bars constituting S.E.M. Asterisks (*) denote statistical significance (* P<0.05, ** 
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Figure 4.5 The relative maximum responsiveness of KP-10/KISS1R-mutations.  
COS-7 cells were transiently transfected with KISS1R wild-type and mutant 
receptors 48 hours before stimulation with KP-10 for 60 minutes, and the IP3 
accumulation was measured (see section 2.24). The average of three repeats is shown 
with the error bars constituting S.E.M. Asterisks (*) denote statistical significance (* 
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Figure 4.6 Effects of mutations of R229 and V236- KISS1R to Ala on IP3 
production.  COS-7 cells were transiently transfected with KISS1R wild-type and 
mutant receptors 48 hours before stimulation with KP-10 for 60 minutes, and the IP3 
accumulation was measured (see section 2.24). A representative trace of three 
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Table 4.1 Alanine substitution of putative sites of the CaM-binding motifs of KISS1R. COS-7 cells were transiently 
transfected with wild-type and mutant receptors 48 hours prior to the binding assay and IP3 assay (see section 2.22 and 2.24 
respectively). The shaded section depicts IL2 mutations. 
a 
Normalised to itself 
b 
Normalised to the average of the experimental 
repeats Asterisks (*) denote statistical significance (* P<0.05, ** P<0.01, *** P< 0.001) as calculated by One-Way Anova with 
Dunnett’s test. –‡ denotes - could not be measured accurately.  
Mutant Binding  IP3 Responses  Relative Maximum 
Responsiveness  
 Rexp IC50  Emax EC50  Emax/Rexp 
 % WT (nM)  % WT (nM)  Fold Change 
WT 100a 5.21 ± 0.62  100a 5.27 ± 0.85  1.00 ± 0.13b 
W141A 12.59 ± 10.54*** –‡  61.62 ± 12.24 123.64 ± 37.23***  4.89 ± 0.97*** 
Y142A 11.19 ± 2.15*** –‡  47.60 ± 3.62 195.15 ± 33.27***  4.25 ± 0.40*** 
F146A 43.63 ± 1.21 4.99 ± 2.40  53.58 ± 6.64 7.42 ± 3.58  1.23 ± 0.15 
L151A 110.89 ± 4.64 7.06 ± 2.67  48.57 ± 15.98 24.76 ± 11.40  0.44 ± 0.14 
R229A 10.97 ± 1.81*** 6.51 ± 1.91  47.82 ± 22.73 36.17 ± 13.62**  4.36 ± 2.07*** 
V234A 63.79 ± 10.52 8.44 ± 2.18  64.52 ± 7.59 12.32 ± 7.10  1.01 ± 0.12 
V236A 5.10 ± 5.31*** –‡  81.02 ± 16.72 13.84 ± 4.98  16.10 ± 2.55*** 
R237A 41.46 ± 6.41 2.37 ± 0.24  67.45 ± 4.87 15.46 ± 7.90  1.63 ± 0.14 
L245A 94.75 ± 6.97 6.49 ± 0.38  15.83 ± 4.08** 22.98 ± 5.64*  0.16 ± 0.07 
V249A 100.11 ± 6.93 8.12 ± 0.58  88.51 ± 13.58 5.15 ± 1.84  0.71 ± 0.2 
R253A 34.30 ± 2.72 7.26 ± 1.32  38.76 ± 6.31 39.82 ± 19.30*  1.13 ± 0.18 
R258A 31.00 ± 6.20* 6.48 ± 0.83  49.35 ± 18.66 53.19 ± 15.03***  1.59 ± 0.60* 
K260A 25.02 ± 3.04* 5.75 ± 0.55  54.83 ± 7.18 23.10 ± 6.50*  2.08 ± 0.39* 
R263A 23.52 ± 2.84** 6.31 ± 0.99  56.01 ± 17.71 63.10 ± 22.91***  2.38 ± 0.75** 
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Figure 4.7 A proposed model for CaM-IL3 complex. The amino acid alignment of bovine 
rhodopsin and human KISS1R (A) is shown with the full alignment in grey and the selected IL3 
sequence in black & white. Space filled CaM (B) has unique amino acid characteristics (C) and is 
identifiable with C- and N- terminal domains connected by the linker region. The IL3 peptide 
amino acid sequence (C) is represented in rainbow colour to better identify the cartoon structure 
docked in the centre of CaM (B). The amino acids of IL3 that were identified of having a role in 
modulating KISS1R activity are pointed out. A zoomed image of specific sites of interest is 
shown in D 
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4.3.2. The functional relevance of KISS1R-IL3 juxtamembrane 
regions 
The site-directed mutagenesis study suggested that the CaM binding motifs of 
KISS1R particularly that of the juxtamembrane regions of IL3 may play an important 
role in CaM binding. Furthermore, modelling (Figure 4.7) the CaM.IL3 interaction 
revealed the interaction of CaM with the juxtamembrane regions of IL3. However, 
these experiments do not constitute a direct evidence of CaM.IL3 interactions, thus 
further experiments were conducted to validate these observations. In order to 
measure the importance of CaM binding to the juxtamembrane regions of KISS1R-
IL3 (227-263 aa) a shortened version termed KISS1R-IL3
short 
(234-254 aa) was 
synthesized by EZbiolabs with > 95 % purity (Figure 4.8). Da-CaM was used to test 
whether the two CaM globular domains come in close proximity to one another in 
the presence of KISS1R-IL3
short
. Da-CaM has its endogenous T34 and T110 replaced 
for the amino acid Cys. This double mutant (T34C/T110C) CaM was chemically 
labelled with IAEDANS and DDP fluorophores. The two probes form a Förster 
resonance energy transfer (FRET) pair. Upon DA-CaM binding to target peptide the 
donor IAEDANS fluorescence is quenched by the acceptor DDP, indicating close 
proximity of the probes, i.e. the closure of the N- and C- lobes of CaM (see section 
2.13). I also tested the Ca
2+
 dependency of CaM binding with KISS1R-IL3 and 
KISS1R-IL3
short
 peptides using CaM
C34
-badan, in which the amino acid T34 was 
replaced for Cys and then labelled with badan, an environmentally sensitive 
fluorescent probe.  
The KISS1R-IL3 (227-263)
 
peptide contains 37 amino acids with 8 basic 
residues dispersed between 9 bulky hydrophobic residues that form 6 complete CaM 
binding motifs. The KISS1R-IL3
short
 (234-254 aa) peptide contains 2 basic residues 
and 5 bulky hydrophobic residues that form 4 complete CaM binding motifs. The 




 amino acid 
positions, as well as 3 glycine residues at positions 6, 21, and 29. The KISS1R-
IL3
short
 peptide lacks the two glycine residues of KISS1R-IL3 at positions 6 and 29 
(Figure 4.8).  
Chapter 4: The Function of CaM Binding to KISS1R 
 
   126 
The reaction mixture of KISS1R-IL3
 
peptide with DA-CaM in an assay buffer 
(see section 2.13) containing 100 μM CaCl2 led to a large reduction in fluorescence 
intensity as compared to the addition of KISS1R-IL3
short 
(Figure 4.9). The level of 
fluorescence reduction of DA-CaM upon adding 20 μM KISS1R-IL3
short
 was 7% and 
upon adding an equal amount of 20 μM KISS1R-IL3 peptide the fluorescence 
reduction was. 61 %. With the use of the high affinity Trp peptide the fluorescence 
reduction was reduced further to 82 % (Figure 4.9).  
The proposed in silico model revealed the possible role of the C-terminal 
domain of CaM in its interaction with the juxtamembrane regions of IL3 (Figure 
4.7). In order to test this experimentally, a site-directed fluorophore called badan was 
attached to the N-terminal domain of CaM (CaM
C34
-badan) (see section 2.11). This 
construct was previously shown to be a powerful tool to monitor CaM 
conformational changes and the interaction interface between CaM and target 
proteins (Gangopadhyay et al., 2004). The CaM
C34
-badan construct was sensitive to 
Ca
2+





-badan was increased by the pre-incubation of KISS1R-IL3 (Kd 
398 ± 25.21 nM and n- 5.60 ± 0.63). However, the Ca
2+





 with gave a similar affinity to CaM
C34
-badan without 
peptides with an affinity of Kd  802 ± 15.07 nM and n of 4.74 ± 0.22 (Figure 4.10 
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Figure 4.8 Peptide sequence KISS1R-IL 3 fragments. Two related peptides were 
synthesised; the first was KISS1R- intracellular loop 3 (IL3) (227-263 aa), and the 
second was KISS1R-IL3
short
 (234-254 aa). Red indicates bulky hydrophobic amino 
acids, while blue depicts basic residues, and the green represents flexible residues. 
The amino acid (aa) number is identifiable with numbering above the boxed letters. 
The scissor symbol represents the juxtamembrane regions that were removed from 
KISS1R-IL3 to generate KISS1R IL3
short
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Figure 4.9 Emission fluorescence spectra of DA-CaM titrated against KISS1R-
IL 3 peptides fragments. KISS1R derived intracellular loop 3 (IL3) peptide 
fragments were titrated against 1 M DA-CaM in the assay buffer (see section 2.13) 
containing 100 M CaCl2. DA-CaM fluorescence was measured at excitation 
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 dependence of CaM
C34
-badan in the presence of KISS1R-IL3 
fragments. Equilibrium Ca
2+
 binding assay was carried out with 100 nM CaM
C34
-
badan (black line) in assay buffer (see section 2.14). The addition of KISS1R-IL3 
(green line-227-263 aa) and KISS1R-IL3
short
 (red line-234-254 aa) peptides were 
premixed with CaM
C34
-badan prior to experimentations. CaM
C34
-badan fluorescence 
was measured at excitation wavelength 368 nm and emission wavelength 455 nm. 
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 dependencies in the presence of KISS1R-IL3. 
This table shows the values of the plotted graphs shown in Figures 4.10. The 




-badan mix Kd (nM) Hill coefficient 
CaM
 C34
-badan only 792 ± 40 4.58 ± 0.22 
KISS1R-IL3 398 ± 25 5.60 ± 0.63 
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4.4. Discussion 
This chapter aimed to characterise the interactions between CaM and the 
KISS1R. The approaches used were alanine mutagenesis of the putative CaM-
binding motifs of KISS1R, molecular modelling of the CaM.KISS1R complex, and 
spectrofluorimetric CaM binding assays using KISS1R derived peptides. Herein, 
evidence is provided for the binding of CaM to KISS1R via the juxtamembrane 
regions of IL3, resulting in the attenuation heteromeric G protein activation. 
Calmodulin (CaM) regulates a wide array of cellular processes via its 
interaction with specific binding motifs of proteins. These include several GPCRs 
that have been shown to interact with CaM [Reviewed in (Ritter and Hall, 2009)]. 
Therefore, following the tradition of identifying CaM binding regions, this study set 
out to examine the primary amino acid sequence of KISS1R and to determine 
whether there exist CaM-binding motif(s). Indeed, there were CaM-binding motifs in 
IL2 and IL3 of KISS1R (Figure 4.1). The putative CaM-binding motif of IL3 (245-
263aa) was confirmed with the use of the Calmodulin Target Database search engine 
(http://calcium.uhnres.utoronto.ca/ctdb/ctdb/sequence.html). However, the search 
engine did not identify IL2, even though there is a “1-10” CaM-binding motif (142-
151aa). This is thought to be due to the lack of alpha-helical propensity of the CaM-
binding motif of IL2, a critical criterion for the identification of putative CaM-
binding motifs. Another explanation might be due to the selective criterion of the 
search engine, which was derived from numerous structural analyses of CaM binding 
to none-GPCR proteins (Yap et al., 2000). 
The solved structures of CaM bound proteins gave potential to the idea of 
determining the structure of CaM bound to KISS1R-IL3. In light of this, 
crystallisation trials were carried out; however, no crystals were observed. The 
reason for this may be due to the non-homogenous nature of the biphasic binding of 
CaM to KISS1R-IL3 (Figure 3.5), and the significant unstructured region of 
KISS1R-IL3. Future crystallisation trails should detail the use of optimised KISS1R-
IL3 peptides. Nevertheless, a new approach was sought in determining the CaM 
binding sites of KISS1R.  
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KISS1R IL2 and IL3 are the only intracellular regions that contain CaM-
binding motifs, and they have been shown to bind CaM exclusively (see chapter 3). 
With this in mind, an in-depth understanding of the CaM.KISS1R interaction via IL2 
and IL3 was sought by alanine mutagenesis of the CaM binding motifs (Figure 4.1), 
homogenous competition ligand binding and inositol phosphate accumulation 
studies.  
4.4.1 Ligand binding assay with radiolabeled KP-10 
Although saturation ligand binding assay is the most appropriate approach to 
measure receptor expression and ligand binding affinity, it is often infeasible for 
labelled peptide ligands (Mamputha et al., 2007, Kuohung et al., 2010). The KISS1R 
saturation ligand binding assays presented a technical problem because of its high 
non-specific binding of 
125
I-leballed kisspeptin peptides and KP-10 forming 
aggregates (Kuohung et al., 2010, Nielsen et al., 2010). Furthermore, my colleague 
Kevin Morgan has previously found that increasing the concentrations of 
radiolabeled KP-10 in binding assays leads to increased non-specific binding, which 
makes it difficult to distinguish between specific and non-specific binding. 
Consequently, it is not technically feasible to use increased tracer concentrations or 
saturation binding assays to determine ligand binding affinities of the wild-type and 
mutant KISS1R receptors. As a result, a competition ligand binding assay was 
carried out as that previously described for GnRH (Flanagan et al., 1998). The 
concentration of used radioligand is about 25 pM.  Hence, it is likely to have little 
effect on the Cheng-Prusoff shift. Furthermore, homogenous competition binding 
experiments of 
125
I-KP-10 on intact cells transiently transfected with wild-type and 
mutant receptors demonstrated little or only marginal shift in affinity for any of the 
mutants compared to the wild type receptor. Therefore, in most cases, the Bo values 
of the specific binding measured in the absence of competitive ligands reflect the 
relative expression levels (Rexp) of receptors on the cell surface. 
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 4.4.1.1 Receptor Reserve and Responsiveness. 
It is important to take into account the spare receptors when calculating 
efficacy. Our lab has previously used irreversible antagonists to estimate receptor 
reserve (Lu et al., 1997). However, due to the lack of irreversible antagonists for 
KISS1R, it is difficult to estimate the receptor reserve for KISS1R. However, the 
little change between the IC50/Kd and EC50 values of KP-10 for wild-type KISS1R 
suggests little presence of a receptor reserve. Hence, the relative maximum signalling 
efficacy of KP-10 was estimated by normalization of the maximum IP responses to 
the cell surface receptor binding sites as the receptor population is saturated, and the 
affinity is not an issue (Takino et al., 2003, Kenakin, 2002a). The decreases in KP-10 
potency for mutant receptors are potentially the product of combined decreased 
coupling efficiency/activation with decreased affinity of the mutant receptor. The 
low expressing mutants often show a decreased potency (larger EC50 values, (Lu et 
al., 1997). However, mutation of certain constrained amino acids may increase 
signalling potency/efficacy, as the mutants become super-active (Lu et al., 2005, Lu 
et al., 2007). The increased relative maximum responsiveness (relative to wild-type 
KISS1R) of KISS1R mutations of the N-termini of IL2 (W141A and Y142A) and 
IL3 (R229A, V236A), as well as the C-terminus of IL3 (R258A, K260A and K263A) 
may indicate super-coupling and/or the inhibition of intramolecular constraints. In 
contrast the decreased efficacy of the mutants may indicate that they may be 
involved in receptor G protein coupling such as L151A, L245A and V249A. 
However, KP-10 IC50 of KISS1R W141A, Y142A and V236A could not be 
accurately measured and require future investigation. As with all such mutagenesis 
studies, there remains the possibility that hypothetical changes in the receptor’s cell 
surface expression, G protein interactions or desensitization could have some 
influence on observations. 
Due to the inherent complexity involved in the folding and trafficking of 
seven-transmembrane proteins, GPCRs must fulfil stringent quality control 
mechanisms that will enable them to express normally at the cell surface (Conn et al., 
2006). It was therefore not surprising that most of the KISS1R mutants showed 
decreased receptor expression on the cell surface (Figure 4.2). One explanation to 
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this might be due to an increase in intracellular retention, due to KISS1R misfolding 
and subsequently becoming misrouted within the cell. Intracellular retention is the 
most prevalent mechanism by which clinical mutations of GPCRs cause disease 
(Meyer et al., 1992, Tan et al., 2004). For example, of the 21 clinical mutations 
recorded in the gonadotropin-releasing hormone receptor, ~17 are shown to be the 
result of intracellular retention (Conn et al., 2007). Another explanation to why some 
KISS1R mutants showed decreased receptor expression on the cell surface might be 
due to increased constitutive activity and thus increased constitutive internalisation. 
This explanation is supported with the evidence that the KISS1R mutants with 
decreased expression levels on the cell surface positively correlated with an observed 
increase in the relative maximum responsiveness (Figure 4.5). Future experiments 
should entail dissecting these two explanations by immunocytochemistry and 
internalisation assays. 
The KISS1R mutants with increased EC50 values (decreased potency) (Figure 
4.2, Figure 4.3, and Table 4.1) is likely the result of the markedly decreased receptor 
expression level on the cell surface. This conclusion is reached because those 
KISS1R mutants also had increased relative maximum responsiveness, and a similar 
phenomenon was observed by Lu and colleagues 1997 when performing mutation 
studies on the m1 muscarinic receptor. 
GPCR intracellular loops undergo large conformational changes as part of 
ligand binding and receptor activation, implying high conformational flexibility 
(Rasmussen et al., 2011a, Lebon et al., 2011, Xu et al., 2011, Standfuss et al., 2011, 
Choe et al., 2011, Park et al., 2008, Scheerer et al., 2008). Mutations in the 
intracellular regions of KISS1R showed little effect on ligand binding affinity (IC50 
values) of all the KISS1R mutants tested (Figure 4.3, Table 4.1). Additionally, the 
disease causing mutant L148S of KISS1R also showed a markedly reduced ligand 
potency, but unchanged ligand binding affinity (Wacker et al., 2008).  
The intracellular-transmembrane regions (IC-TM) harbour many functionally 
important features that are conserved in class A GPCRs [as reviewed in (Katritch et 





, as according to the Ballesteros/Weinstein numbering (Ballesteros 
et al., 1998)] located at the bottom of TM3 in which R
3.50
 may interact with a E
6.30
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 is thought to stabilise the inactive state of GPCRs through a 
mechanism known as ’ionic lock’, which brings together TM3 and TM6 in close 
proximity (Rovati et al., 2007). The KISS1R contains the highly conserved R
3.50
 (in 
the aa position 140, Figure 3.1), as indeed do 96 % of class A GPCRs (Mirzadegan et 
al., 2003). However, in the KISS1R, the equivalent position 6.30 is occupied by a 
positive charged residue (R258) (Figure 3.1), which is unlike 32 % of class A 
GPCRs (Springael et al., 2007). Therefore, the KISS1R is unlikely to form an ionic 
lock. Indeed, most peptide GPCRs (> 90%) cannot form an ionic lock due to the lack 
of an acidic residue in position 6.30 (Mirzadegan et al., 2003). Therefore, the 
increased EC50 values of W141A and Y142A (C-terminus to TM3) and R253A, 
R258A, K260A, and R263A (N-terminal to TM6) is not related to the ionic lock 
concept.  
GPCRs are known to act as guanine nucleotide exchange factors (GEF) and 
drive G-protein activation, however the structural basis for GPCR-catalysed 
nucleotide exchange is presently unclear (Oldham and Hamm, 2008). Nevertheless, 
important crystallographic studies have suggested that G-protein activation requires 
conformational changes of the Gα switch I, II, III to relieve a GDP clamp formed 
between the GTPase and α-helical domains (Oldham and Hamm, 2006). In the 
inactive Gαβγ heterotrimer, the Gα switch II region is sequestered by Gβγ and in 
theory GPCRs utilise Gβγ as a lever against the Gα switch II region to relieve the 
GDP clamp (Iiri et al., 1998). More recently, the structure of active β2 adrenergic 
receptor (β2AR) in complex with Gαs protein was solved (Rasmussen et al., 2011b, 
Chung et al., 2011). The β2AR-Gαs interface is formed by IL2 and the 
juxtamembrane regions IL3 (Rasmussen et al., 2011b). Therefore, the KISS1R 
mutants of IL2 and the juxtamembrane regions of IL3 with increased relative 
maximum responsiveness are likely the result of Gq/11 super-coupling.  
In that regard, the increased relative maximum responsiveness observed in 
the juxtamembrane regions of KISS1R-IL3; R229A, V236A, R258A, K260A, and 
R263A are likely to be the result of impaired CaM binding and increased G-protein 
activation. These observations were similar to Lu and colleagues, 2005, where they 
show super coupling after rescuing GnRH mutant receptors (Lu et al., 2005). These 
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results complements previous reports that GPCRs interact with Gα via the basic 
residues of the juxtamembrane regions of IL3 [as reviewed in (Denis et al., 2012)]. 
This would suggest that removing the biochemical basis for CaM binding increases 
KISS1R maximum efficacy. Furthermore, this finding agrees with the report that 
CaM competes with 
35
S-labeled guanosine 5’-3-O-(tio)triphosphate binding to G-
proteins, in membranes containing OP3 and D2 receptors (Bofill-Cardona et al., 2000, 
Wang et al., 1999). 
In order to further validate these observations I carried out 
spectrofluorimetric CaM binding experiments with KISS1R-IL3 peptide lacking the 
juxtamembrane regions. The KISS1R-IL3 contains landmarks in the form of specific 
amino acids strategically positioned to convey flexibility, i.e., G 232 and G 255 
flanking the central region of IL3 (Figure 4.8). The central region of IL3 contains 2 
Pro and 1 Gly residues that provide more flexibility. The removal of the 
juxtamembrane regions around the landmarks, created KISS1R-IL3
short
 peptide. The 
KISS1R-IL3
short
 peptide did not lead to FRET produced by the proximity of the 
globular domains due to CaM binding to peptides (Figure 4.9). This was in stark 
contrast to the KISS1R-IL3 peptide that gave a significant reduction in DA-CaM 
fluorescence, which means that the N- and C-terminal lobs of CaM come in close 
proximity, wrapping around KISS1R-IL3 (Figure 4.9). I therefore conclude that the 
juxtamembrane regions of KISS1R-IL3 constitute distinct binding sites critical for 
CaM binding, which support the proposal derived from the site-directed mutagenesis 
study. A similar observation exists in the binding of CaM to the IL3 of 5-HT1A, 
which also involves two distinct bindings sites positioned in the N- and C-terminal 
region of 5-HT1A-IL3 (Turner et al., 2004).  
The Ca
2+
 affinity for CaM
C34
-badan was determined to be 792 ± 39.53 nM, 
which is similar to the previous report of ~700 nM (Gangopadhyay et al., 2004). The 
increased Ca
2+
 affinity of CaM
C34
-badan pre-mixed with KISS1R-IL3 peptide 
revealed an interesting possibility that the KISS1R-IL3 induces conformational 
changes of CaM
C34
-badan that favours the EF-hand regions to bind Ca
2+
more 
efficiently. Therefore, it may be possible that Ca
2+
CaM binding to KISS1R-IL3 
juxtamembrane regions may create a Ca
2+/
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Although CaM binding to GPCRs has been known since the 1990s, the 
literature lacks a testable model. Herein is proposed the first such model of CaM 
binding to the juxtamembrane regions of IL3 (Figure 4.7). The model aims to initiate 
the realistic and testable conceptualisation of an important interaction. The model 
consolidates the site-directed mutagenesis data and the spectrofluorimetric CaM 
binding experiments. Notably, IL2 is absent from model, the reason is as follows: 
Firstly, IL2 titration against TA/DA-CaM gave a relatively small amplitude change 
(see Figure 3.3), implying a non-conventional binding. Secondly, the site-directed 
mutagenesis data revealed that only the N-terminus of the CaM-binding motif of IL2 
increased KISS1R activity. This would imply that a very small portion of the CaM 
binding motif of IL2 is involved. Furthermore, these residues are very close to the 
membrane, while TM5 and TM6 have extended alpha-helical structures (Standfuss et 
al., 2011). Therefore, I propose that CaM binding occurs mainly to IL3 and with a 
peripheral contact to IL2. 
In conclusion the site-directed mutagenesis study and molecular modelling 
revealed the functional importance of CaM binding motifs present in the 
juxtamembrane regions of KISS1R-IL3 and the N-terminal region of KISS1R-IL2. In 
addition, the relative maximum responsiveness of KISS1R mutants varied, but the 
ligand binding (IC50) remained similar. This would therefore suggest that the 
receptor-G protein coupling may be fine-tuned by Ca
2+
/CaM.  
The knowledge gained from chapters 3 and 4 is integrated into a CaM.IL3 
model. This model and subsequent validations revealed how CaM is likely to interact 
with the juxtamembrane regions of IL3. It is therefore proposed that CaM binding to 
KISS1R IL3 attenuates G-protein activation via steric hindrance.  
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5. αCaMKII targets kisspeptin receptor to down-regulate the 
HPG axis 
This thesis has so far provided evidence for the role of Ca
2+
/CaM in the regulation 
of KISS1R function. However, can a closely related kinase also regulate KISS1R 
function? Α-Ca
2+
/calmodulin-dependent protein kinase II (αCaMKII) 
phosphorylates substrates possessing specific consensus sequences. Therefore, the 
KISS1R amino acid sequence was examined for αCaMKII consensus sequence. 
Indeed, there was such a motif and subsequent kinase assays were performed with 
IL1, IL2, IL3, and C-terminal tail peptides. Phosphomimetic mutations of KISS1R 
revealed the potential importance of the phosphorylation event in the regulation of 
KISS1R function. These in vitro data were validated with in vivo experiments from 
my collaborator, which involved perturbation studies of rat HPG axis using a 
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5.1. Introduction 
Mammalian Kisspeptins (KPs) are important regulators of the hypothalamic-
pituitary-gonadal axis (HPG) (Oakley et al., 2009). KPs activate KISS1R expressed 
on the surface of hypothalamic GnRH neurons, leading to the consequent increase in 
intracellular Ca
2+
 which drives GnRH pulsatile secretion (Constantin et al., 2009, Liu 
et al., 2008). However, researchers do not know to the full extent by which the 
multifarious effects of Ca
2+
 cause GnRH pulsatile secretion (Liu et al., 2008). 
Nevertheless, GnRH stimulates gonadotropic cells of the pituitary to secrete 
luteinising hormone (LH) and follicle stimulating hormone (FSH) into the blood 
stream, which in turn orchestrates the reproductive processes of mammals (Sisk and 
Foster, 2004).  
Ca
2+
/calmodulin-dependent protein kinase II (αCaMKII) is a multifunctional 
Ser/Thr protein kinase that is abundant in brain cells, particularly at neuronal 
dendritic spines (Hudmon and Schulman, 2002b, Schulman and Greengard, 1978a, 
Schulman and Greengard, 1978b). Binding of Ca
2+
/CaM to αCaMKII exposes the 
substrate binding regions of the catalytic domain and facilitates T286 
autophosphorylation (Lisman, 1994, Meyer et al., 1992, Torok et al., 2001). The 
function of T286 autophosphorylation is to stabilise the active state of CaMKII 
(Ishida et al., 1996, Tzortzopoulos and Torok, 2004). Thereafter, the enzyme auto-
inactivates in ~1 minute due to T305/306
 
autophosphorylation (Jama et al., 2009, Lee 
et al., 2009). As such, αCaMKII functions as a Ca
2+
 frequency decoder, integrating 
the diverse forms of Ca
2+
 transients and decoding it into various forms of 
phosphorylation states that leads to neuronal synaptic plasticity (Eshete and Fields, 
2001, Dupont and Goldbeter, 1998, Lisman et al., 2012, Jama et al., 2011). For 
instance, αCaMKII has been shown to phosphorylate α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptor (AMPA) to increase channel conductance and 
thus neuronal synaptic strength (Benke et al., 1998). Another example is the 
important role of αCaMKII in GPCR functional regulation. Both the inhibitory 
phosphorylation of dopamine D3 receptor (D3R) and the stimulatory phosphorylation 
of M4 muscarinic acetylcholine receptor (M4 mAChR) by αCaMKII contributes to 
dopamine homeostasis (Liu et al., 2009, Guo et al., 2010). 
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The highly expressed neuronal αCaMKII is believed to target multifarious 
substrates containing the basic consensus sequence of K/R-X-X-S/T (Pearson et al., 
1985, White et al., 1998). Currently, a limited number of substrates have been 
identified (Colbran, 2004). This limits our understanding of how cytoplasmic Ca
2+
 
synchronises the panoply of signalling events through CaMKII. In search for new 
CaMKII substrates, the KISS1R amino acid sequence was examined for the 
consensus sequences, followed by kinase assays to determine the catalytic 
relationship between CaMKII and KISS1R derived peptides. The in vivo role of 
CaMKII inhibition was studied with perturbation studies of rat HPG axis. Taken 
together, this chapter reveals the mechanism by which αCaMKII targets KISS1R to 
down-regulate the HPG axis.  
5.2. Aims and hypothesis  
The aims of this chapter are: 
 To determine whether αCaMKII phosphorylates the consensus 
sequences of the KISS1R derived peptides. 
 To identify the function of the phosphorylation of KISS1R by the 
αCaMKII  
 
The hypothesis of this chapter is: 
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5.3. Results  
5.3.1. CaMKII phosphorylates T77 of KISS1R 
-Ca
2+
/calmodulin-dependent protein kinase II (αCaMKII) is a 
serine/threonine protein kinase that is known to recognise and phosphorylate the 
consensus sequence – K/R-X-X-S/T (White et al., 1998, Pearson et al., 1985). A 
similar sequence exists in the intracellular loop 1 (IL1) and the C-terminal tail (C-
tail) of the human KISS1R (Table 5.1). To explore whether these sites are substrates 
for αCaMKII, the intracellular loops (IL1, IL2 and IL3) and the putative 
phosphorylation sequence of the C-terminal tail (C-Tail) of KISS1R (Table 5.1) were 
synthesised at > 95% purity from EzBiolabs. A steady state kinase assay was used to 
determine the specific activity of CaMKII in the presence of synthetic peptides (see 
section 2.15). Furthermore, the activation mechanisms αCaMKII by Ca
2+/
CaM 
dynamics were investigated by mutation of Ca
2+
 binding sites in different lobes, in 
order to put into the context of the possible role of αCaMKII phosphorylation of the 
putative sites of KISS1R.  
As expected (Jama et al., 2011, Jama et al., 2009), the specific activity of 
CaMKII in the presence of saturating Syntide-2 (a well-known positive control) 




. The velocity of CaMKII 
phosphorylation for IL1 peptide was lower than that of Syntide-2, giving a specific 




. The speed of CaMKII phosphorylation was 
at undetectable level (i.e. extremely reduced) with the pre-mixing of 80 M IL2, IL3 
or C-Tail peptides (Figure 5.1 and Table 5.1). The phosphorylation affinity (Km) of 
CaMKII for IL1 was 19 ± 1 M, which was similar to Syntide-2 at 12 ± 2 M 
(Table 5.1). The six-fold difference in specific activities of IL1 and Syntide-2 and 
their comparable Km values imply that αCaMKII may favour a longer interaction 
with IL1 as opposed to Syntide-2. It was observed that IL1 contains two T residues 
separated by a V. To determine the site of phosphorylation, two different peptides 
were synthesised (IL1-T75A and IL1-T77A). CaMKII was found to phosphorylate 





implying that T77 of IL1 is the site of phosphorylation (Figure 5.2 and Table 5.1). 
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However, the catalytic activity of αCaMKII was ~11-fold lower for IL1-T75A 
relative to the parent IL1 (Table 5.1). Thus, the side chain of T75 in IL1 may be 
configurationally important in supporting T77 phosphorylation. Interestingly, IL1 
and IL1-T75A phosphorylation exhibited positively cooperative kinetics with a Hill 
coefficient (n) of 4.4 ± 0.83 and 3.3 ± 0.15, respectively. This was in stark contrast to 
Syntide-2 phosphorylation, which was observed to have non-cooperative kinetics. 
GPCRs are known to form receptosomes, consisting of macromolecular 
protein complexes with divergent roles (Bockaert et al., 2004). Moreover, the 
activation of the KISS1R is thought to activate the canonical transient receptor 
potential (TRPC) channel (Zhang et al., 2013). Thus, the KISS1R may function in a 
unique microenvironment with local Ca
2+
 dynamics. In order to understand the role 
of Ca
2+
 in the activation of αCaMKII, T286 autophosphorylation experiments were 
carried with wild type and CaM mutants with submaximal Ca
2+
 binding.  
The C-terminal domain of CaM is thought to have an inherently higher 
affinity for Ca
2+
 than the N-terminal domain (Martin et al., 1985). This would imply 
that CaM C-terminal domain is populated by low amplitude/frequency Ca
2+
 whereas 
CaM N-terminal domain is populated with high amplitude/frequency Ca
2+
 (Jama et 
al., 2011). With this in mind, CaM mutants deficient in the Ca
2+
 binding sites of the 
N-terminal domain (CaM1 and CaM2) and the C-terminal domain (CaM 3 and CaM 
4) were generated by single site mutation of the first coordinating Asp of the Ca
2+
 
binding EF-hand motifs to Ala (CaM1-D21A, CaM2-D56A, CaM3-D93A and 
CaM4-D131A). Because calcium ions are coordinated in a pentagonal configuration 
around the EF-hand motif, the first Asp and the last Glu of the motif provides two 
oxygen atoms, each for binding calcium. Additionally, the negatively charged Asp 
and Glu will make a charge-interaction with the positively charged calcium ion. Thus 
replacing the first Asp and/or last the Glu to Ala will remove the functionality of the 
respective EF-hand motif (Martin et al., 1992, Babu et al., 1985).  
The rate of αCaMKII Thr
286
 autophosphorylation by wild-type CaM was 
previously determined to be very fast at ~ 5 s-
1
 by quenched flow (Bradshaw et al., 
2002). In another study, manual mixing experiments showed that wild-type CaM 
induced complete Thr
286
 autophosphorylation in less than 15 s (Tzortzopoulos et al., 
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2004). However, when following the reaction for 1 hour, a second slower phase 
became apparent (Figure 5.3, Table 5.2).  
Wild-type and mutant CaMs were reacted with αCaMKII in the presence of 
assay buffer (see section 2.15) and the time course of the reaction was determined by 
western blotting (see section 2.26). The fastest possible sampling time was 15 s, at 
this time point the reaction was ~ 50 % complete. Therefore, we decided to plot the 
data with two phases, the first being constrained to 5 s
-1
, in line with the previously 
determined fast rate (Bradshaw et al., 2002). This enabled the deconvolution of the 
second phase of the Thr
286
 autophosphorylation rates. Wild-type CaM induced the 
second rate Thr286 autophosphorylation by 0.006 s
-1
 (Table 5.2). With regards to 
CaM2 and CaM3, the T286 autophosphorylation rates were similar to the time 
courses of wild type CaM. This was in stark contrast to the T286 
autophosphorylation time courses of CaM1, CaM4, CaM12, and CaM34, which 
showed a much diminished fast phase, and a significantly slower second phase at 
0.0014, 0.002, 0.0024, and 0.0008 s
-1
 (p < 0.05), respectively (Figure 5.3 and Table 
5.2). 
In summary, the steady state kinase assay revealed that αCaMKII selectively 
phosphorylates IL1 of the KISS1R and that the phosphate group is likely attached to 
T77. Additionally, the phosphorylation of IL1 by αCaMKII exhibited cooperative 
kinetics unlike Syntide-2. Furthermore, the role of Ca
2+ 
dynamics in αCaMKII T286 
autophosphorylation was determined to involve both CaM domains and thus suggests 
that αCaMKII activation and the subsequent KISS1R-IL1 phosphorylation requires 
local and global Ca
2+
 dynamics. 
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Figure 5.1 KISS1R-IL1 and syntide-2 phosphorylation by αCaMKII. 6 M 
Calmodulin and 50 M CaCl2 were reacted with varying concentrations of IL1 
peptide in the presence of (A) 50 nM αCaMKII or (B) 35 nM αCaMKII. The 
experiments were carried out at 21
o
C, pH 7.0 in the spectrofluorimetry-coupled 
enzyme reaction assay containing 100 mM KCl, 50 mM K
+
- PIPES, and 2 mM 
MgCl2, 2 mM PEP, 1 mM ATP, 22 μM NADH, 5 mM DTT. NADH fluorescence 
was determined at excitation wavelength 346 nm and emission wavelength 460 nm. 
The average of three repeats was plotted and the error bars show the S.E.M. The data 
was fitted to a Michaelis-Menten model. The standard error displayed in Table 5.1 
shows the error of the fit. 
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Figure 5.2 KISS1R-IL1 T75A phosphorylation by αCaMKII. 50 nM αCaMKII, 6 
M Calmodulin and 50 M CaCl2 were reacted with varying concentrations of IL1-
T
75A
 peptide. The experiment was carried out at 21
o
C, pH 7.0 in the 
spectrofluorimetry-coupled enzyme reaction assay containing 100 mM KCl, 50 mM 
K
+
- PIPES, and 2 mM MgCl2, 2 mM PEP, 1 mM ATP, 22 μM NADH, 5 mM DTT. 
NADH fluorescence was determined at excitation wavelength 346 nm and emission 
wavelength 460 nm. The average of three repeats was plotted and the error bars show 
the S.E.M. The data was fitted to a Michaelis-Menten model. The standard error 
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Table 5.1 Summary of CaMKII catalyzed phosphorylation kinetics of the synthesized peptides derived from the intracellular regions 
of KISS1R. Bold A letters represent the introduced mutations. Blue represents the initiation of the CaMKII consensus sequence. Red denotes 













Peptide Sequence Km Hill 
coefficient 
Specific Activity 
Vmax (nmol of ADP) 
   n min
-1 mg-1 
Syntide-2 PLARTLSVAGLPGKK 12 ± 2 - 5506 ± 297 
IL1(I67-Y80) ICRHKPMRTVTNFY 19.6 ± 1.4 4.4 ± 0.83 922 ± 37.4 
IL1-T75A (I67-Y80) ICRHKPMRAVTNFY 25.9 ± 0.6 3.3 ± 0.15 80.7 ± 1.4 
IL1-T77A (I67-Y80) ICRHKPMRTVANFY - - Undetectable   




- - Undetectable   
C-Tail (C340-H360) CAPRRPRRPRRPGPSDPAAPH - - Undetectable   
C-Tail (A361-A371) AELHRLGSHPA - - Undetectable   
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Figure 5.3 Time courses of αCaMKII T286 autophosphorylation induced by 
wild type and mutant CaMs. A–G, Densitometric analysis of the western blots 
(immunoblots shown in H and described in section 2.15) for wild type CaM (A), 
CaM1 (B), CaM2 (C), CaM3 (D), CaM4 (E), CaM12 (F), and CaM34 (G) were 
performed as previously described (see section 2.15) and fitted an exponential 
function. The rate constant amplitudes are shown in Table 5.2. The error bars 
represent the S.D. from three repeats. 
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Table 5.2 Summary of the rates of αCaMKII T286 autophosphorylation by 
CaM mutants. The time courses were fitted to a double exponential. The amplitudes 
(A) and rates (k) for each phase is given. The values are the mean of three 
measurements. The standard errors are the S.E.M.  
‡ Denotes statistically significant 
(P > 0.05) values compared to the second phase (s
-1
) of wild-type CaM Thr
286
 











CaM 5 ± 0 0.6 ± 0.1 0.006 ± 0.002 0.4 ± 0.1 
CaM1 5 ± 0 0.1 ± 0.03 0.0014 ± 0.0001‡ 0.9 ± 0.02 
CaM2 5 ± 0 0.6 ± 0.1 0.006 ± 0.003 0.4 ± 0.1 
CaM3 5 ± 0 0.4 ± 0.1 0.003 ± 0.001 0.6 ± 0.1 
CaM4 3 ± 0 0.2 ± 0.11 0.002 ± 0.001‡ 0.8 ± 0.1 
CaM12 5 ± 0 0.2 ± 0.1 0.0024 ± 0.0003‡ 0.8 ± 0.1 
CaM34 5 ± 0 0.14 ± 0.06 0.0008 ± 0.0002‡ 0.86 ± 0.07 
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5.3.2. Phosphomimetic mutations of KISS1R-T77. 
The functional significance of phosphorylated KISS1R-T77 was investigated. To do 
this, phosphorylation-deficient KISS1R-T77A and the phosphomimetic KISS1R-
T77D and KISS1R-T77E mutants were generated (see section 2.7). The effect of the 
mutations was studied with radio-ligand binding and inositol phosphate (IP3) 
turnover assays (see sections 2.22 and 2.27, respectively). The results showed that 
the phosphomimetic mutations abolished IP3 turnover, but had unchanged ligand 
binding affinity (IC50) (Figure 5.4, Figure 5.5, and Table 5.3). In addition, co-
transfection of GFP-CaMKII and KISS1R in COS-7 cells led to a reduced KP-10 
Emax as compared to KISS1R only transfected COS-7 cells (Figure 5.6). 
CaMKII selectively phosphorylates T77 KISS1R (see section 5.3.1). 
Therefore, the role of this residue in receptor function was investigated by replacing 
it with phosphomimetic aspartic acid (D) and glutamic acid (E). Furthermore, 
phosphorylation deficient KISS1R-T77 was studied with alanine (A) substitution, 
which deletes the side-chain beyond the -carbon. The KISS1R constructs were 
transiently transfected into COS-7 cells and their function was studied with radio-
ligand binding and IP3 turnover assays (see section 2.22 and 2.24, respectively). The 
expression levels of the KISS1R mutants were moderately reduced relative to wild-
type KISS1R. The expression level of T77A (48 % ± 4 %), T77D (56 % ± 2 %) and 
T77E (65 % ± 11 %) were however sufficiently expressed to measure KP-10 binding 
affinity, which showed IC50 values ranging from 3.2 ± 0.4 to 5.3 ± 0.2 nM and were 
similar to wild-type KISS1R with an IC50 value of 5.2 ± 0.6 nM (Figure 5.4 and 
Table 5.3). The IP3 turnover study of these mutant KISS1Rs showed that T77A had 
unchanged relative maximum responsiveness relative to wild-type (Figure 5.5 and 
Table 5.3). In contrast, KISS1R-T77D/E gave very little IP3 responses, (Figure 5.5 
and Table 5.3). This suggested that the phosphomimetic mutations may cause 
deleterious effects on the receptor-G protein coupling. Furthermore, of the three 
KISS1R mutants tested, only the T77A gave a moderate IP3 response to KP-10 
stimulation, showing a 2.2-fold increase in EC50 value and 50 % reduction in Emax. 
This was thought to be caused by the reduced receptor expression level on the cell 
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surface. The mutant T77A gave a relative maximum responsiveness that was similar 
to wild-type by taking into account receptor expression levels. 
The role of CaMKII in KISS1R mediated IP3 response was investigated 
further. Wild-type KISS1R and GFP-CaMKII were transiently co-transfected into 
COS-7 cells. The increased expression of CaMKII levels reduced the maximum IP3 
responses relative to the wild-type KISS1R co-transfected with vector DNA at the 
same amount of GFP-αCaMKII. The pre-incubation (30 minutes) of KN-93 inhibitor 
with cells co-expressing KISS1R and GFP-CaMKII reversed the reduced KP-10 
Emax (Figure 5.6). This indicated that inhibition of CaMKII increased KP-10 
induced IP3 response, suggesting an inhibitory role of CaMKII in KISS1R-elicited 
IP3 turnover. 
In conclusion, phosphomimetic mutations at T77 of KISS1R-IL1 nearly 
abolished IP3 responses without altering KP-10 binding affinity. In addition, 
increasing the expression of CaMKII decreases KISS1R elicited maximum IP3 
response. This suggested that the phosphorylation of KISS1R-T77 by CaMKII 
would inhibit KISS1R-Gq/11 coupling, and that CaMKII functions to desensitise 
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Figure 5.4 Effects of KISS1R-T77
 
mutation on KP-10 ligand binding. COS-7 
cells were transiently transfected with KISS1R constructs and incubated for 48 hour 
prior to processing with radio-ligand binding assay (see section 2.22). A 
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Figure 5.5 KP-10 induced IP3 response of KISS1R-T77 mutants. COS-7 cells 
were transiently transfected with KISS1R constructs 48 hours before stimulation with 
KP-10 for 60 minutes, and then by followed be measuring IP3 turnover (see section 
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Table 5.3 Effects of mutations of KISS1R-T77 on receptor binding functional response. COS-7 cells were transiently transfected 
with KISS1R constructs 48 hours prior to processing with radio-ligand binding IP3 assays (see section 2.22 and 2.24, respectively). 
a 
Normalised to itself 
b 
Normalised to the average of the experimental repeats Asterisks (*) denote statistical significance (* P<0.05, ** 









Mutant Binding  IP3 Responses  Relative Maximum 
Responsiveness 
 Rexp  IC50  Emax EC50  Emax/Rexp 
 % WT (nM)  % WT (nM)  Fold Change 
WT 100a 5.2 ± 0.6  100a 5.3 ± 0.62  1.00 ± 0.13b 
T77A 48 ± 4** 4.1 ± 0.5  50 ± 2 11.7 ± 6.4  1.04 ± 0.03 
T77D 
56 ± 2** 3.2 ± 0.4  4 ± 2   (undetectable)  
0.16 ± 0.01 
(uncoupled)*** 
T77E 
65 ± 11* 5.3 ± 0.2  19 ± 13 (undetectable)  
0.07 ± 0.03 
(uncoupled)** 
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Figure 5.6 Effect of CaMKII on KISS1R-elicited IP3 response. COS-7 cells 
were transiently co-transfected with KISS1R and GFP-CaMKII or vector DNA 48 
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5.3.3. Perturbation of CaMKII function in rat HPG axis 
The physiological significance of CaMKII in the regulation of hypothalamic-
pituitary-gonadal axis (HPG) by KPs was investigated. In order to do this, I 
collaborated with Professor Kevin O'Byrne of Kings College London, United 
Kingdom. The model organism we chose was ovariectomised (OVX). The OVX rats 
were intracerebroventricularly (ICV) treated with N-terminal myristoylated 
autocamtide-2 related inhibitory peptide (Myr-AIP) for 10 minutes prior to KP-10 
ICV administration. The obtained results revealed that Myr-AIP and KP-10 
administered rats exhibited augmented luteinizing hormone (LH) responses relative 
to KP-10 only treated rats, as measured by plasma LH concentrations.  
The full-length human KISS1R shares 80 % amino acid sequence homology 
with the rat KISS1R (Kotani et al., 2001). Furthermore, the intracellular loop 1 (IL1) 
of KISS1R, and particularly the phosphorylatable T77 of the human KISS1R is fully 
conserved among fish, amphibians and mammals (Figure 5.7). However, the R74 
residue at IL1 of the human KISS1R that is part of the CaMKII consensus motif is 
changed to Q in the rat KISS1R at the equivalent position. The consequence of this 
alteration is unknown. An attempt to study the effect of this change on CaMKII 
specific activity was made, but the synthesised rat IL1 peptide could not be dissolved 
in the assay buffer, presumably because it was too hydrophobic. This made the 
kinetic studies unfeasible. The significance of the amino acid change is discussed 
further in the discussion section of this chapter. 
In order to inhibit CaMKII in vivo, the AIP inhibitor was selected because of 
its characteristics of high specificity, potency, and high-affinity. AIP inhibits 
CaMKII with an IC50 value of 100 nM, but does not affect the catalytic activity of 
protein kinases A and C (PKA and PKC), and CaMKIV (Ishida et al., 1995). Myr-
AIP was used to increase cell permeability. The OVX rats showed unchanged LH 
pulses after ICV administration with 4 nmol Myr-AIP, indicating that Myr-AIP and 
the subsequent inhibition of CaMKII did not affect the basal LH responses (Figure 
5.8 C). The ICV administration of 1 nmol of KP-10 increased the plasma LH 
concentration (basal ~ 2 ng/ml: KP-10 5.6 ng/ml LH) (Figure 5.8 A). The ICV 
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administration of 4 nmol Myr-AIP 10 minutes prior to 1 nmol KP-10 treatment 
revealed an augmented LH spike (basal ~2 ng/ml: Myr-AIP+KP-10 8 ng/ml LH) and 
prolonged duration of the response  (Figure 5.8 B). This was observed in 4 repeats (a 
representative results is shown). Thus, the amplitude of LH spike in the KP-10 only 
treated rats had to be kept low in order to circumvent the ‘ceiling effect’ of Myr-AIP 
+ KP-10 synergistic effects.  
Interestingly, increasing the concentration of Myr-AIP treatment (40 nmol) 
prior to KP-10 (1 nmol) administration had an unexpected effect. The expected 
augmentation observed in 4 nmol Myr-AIP was not observed in the rats pre-treated 
with 40 nmol Myr-AIP (Figure 5.9). It is presently unclear why the increased 
concentration of Myr-AIP had this effect, but one explanation may be a side-effect. 
Taken together these results indicate that the human αCaMKII consensus 
sequence in IL1 is on the whole conserved amongst vertebrates with changes to R74 
to Q in rodents. Also, inhibiting αCaMKII prior to KP-10 administration augments 
LH secretion. However, increasing the concentration of Myr-AIP appears to exhibit 
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Figure 5.7 The amino acid sequence of KISS1R-IL1 is evolutionarily conserved 
among fish, amphibians and mammals. The amino acid sequences were obtained 
from Pubmed. The sequence alignments were performed with the full length 
sequences of KISS1R and only the IL1 region is shown. The blue represents identical 
amino acids.  The ‘Quality’ is calculated used the Blosum 62 score. The image was 
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Figure 5.8 ICV administration of Myr-AIP at 4 nmol augments KP-10 
stimulated LH spike in OVX rats. Ovariectomized (OVX) rats were 
intracerebroventricularly (ICV) treated with (A) 4 L artificial cerebrospinal fluid 
(aCSF, blue arrow, 165 minutes) followed by 1 nmol/4 L of the KP-10 (red arrow, 
175 minutes). (B) ICV treatment with 4 nmol/4 L of myristoylated autocamtide-2 
related inhibitory peptide (Myr-AIP, blue arrow, 165 minutes) followed by 1 nmol/4 
L of the KP-10 (red arrow, 175 minutes). (C) ICV treatment with 4 L aCSF (blue 
arrow, 165 minutes) followed by 4 nmol/4 L of Myr-AIP (blue arrow, 175 
minutes). All figure are representatives of at least three repeats with the exception of 
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Figure 5.9 Effect of ICV Myr-AIP at 40 nmol on KP-10 stimulated LH spike in 
OVX rats. Ovariectomized (OVX) rats were intracerebroventricularly (ICV) treated 
with 40 nmol/4 L Myr-AIP (blue arrow, 165 minutes) followed by 1 nmol/4 L of 
KP-10 (red arrow, 175 minutes). Myr-AIP denotes myristoylated autocamtide-2 
related inhibitory peptide and aCSF denotes artificial cerebrospinal fluid. Both 
figures are representatives of at least three repeats. 
 
Chapter 5: Inhibitory Phosphorylation of KISS1R by αCaMKII  
 
    161 
5.4 Discussion  
In this chapter I uncovered an inhibitory phosphorylation of KISS1R by αCaMKII. 
Although the human KISS1R contains two CaMKII consensus motifs positioned in 
IL1 and the C-terminal tail, it was determined that CaMKII cooperatively 
phosphorylates only IL1 at T77. The functional significance of a phosphate group 
attached to T77 was investigated with phosphomimetic mutations. The results 
revealed that KISS1R-T77D and KISS1R-T77E were functionally deficient in 
eliciting inositol phosphate turnover (IP3). Furthermore, the role of Ca
2+
 in the 
activation of αCaMKII was determined to require a diverse range of Ca
2+
 dynamics. 
In addition, the in vivo functional significance of CaMKII interactions with 
KISS1R was studied with OXV rats ICV treated with Myr-AIP prior to KP-10 
administration. The results showed that CaMKII inhibition augments the effects of 
KP-10 stimulated blood LH levels. The data of this chapter identifies a new link 
between KP-10/KISS1R and the reproductive axis via CaMKII. 
Notably, human KISS1R contains two RXXS/T motifs in the first intracellular 
loop and the C-terminal tail (Table 5.1). This sequence is consistent with the 
consensus substrate recognition motif (RXXS/T) for CaMKII (White et al., 1998). 
However, only IL1 was observed to be phosphorylated by CaMKII. It is plausible 
that CaMKII is unable to phosphorylate the C-terminal tail fragment (A361-A371) 
due to the bulky hydrophobic L363 and L365 flanking the crucial R365, and thus 
masking the initiation of the recognition motif. Furthermore, the S368 of the motif 
might be very flexible due to the presence of G367, making the recognition motif 
unable to be phosphorylated by CaMKII. Future studies should be carried out to 
determine whether these amino acids are factors in the inability of αCaMKII to 
phosphorylate the C-terminal tail fragment (A361-A371). In addition, the recognition 
motif (RXXS/T) is known to be a target for other kinases, such as protein kinase A, C 
(PKA and PKC) and Akt/PKB (Montminy, 1997, Pearson and Kemp, 1991). Thus, 
future studies to investigate whether these kinases can phosphorylate IL1 are 
required and may increase our understanding of the proteomic networks that are 
involved in down-regulating KISS1R activity. 
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The rat and human KISS1R share 80 % sequence homology, as well as 
similar KP ligand binding affinity and potency (Kotani et al., 2001). Nevertheless, 
the R74 of the human KISS1R, that is part of the CaMKII recognition motif, is 
changed to Q in the rat KISS1R. However, a valid CaMKII recognition motif still 
exists in IL1 of rat KISS1R in the form of HXXT motif. It is possible that histidine 
can replace arginine in the consensus sequence as long as it carries a positive charge. 
This corresponds to H72 and upon protonation at pH 6.5 it is possible that T75 
becomes the phosphorylatable residue. A similar observation is reported in the 
inhibitory phosphorylation of the human HMG-CoA reductase by CaMKII via the 
sequence H869-D-R-S872 (Clarke and Hardie, 1990). The authors show that 
CaMKII phosphorylation of HMG-CoA increases at pH 6.5 compared to pH 7.2 
(Clarke and Hardie, 1990). In this study, an attempt was made to verify this, 
however, the synthesised IL1 peptide was unable to be dissolved in assay buffer, 
because the peptide was too hydrophobic (see section 2.20). Future experiments 
should entail synthesising a peptide that can be dissolved in order to verify whether 
the rat KISS1R-IL1 can be phosphorylated by CaMKII and whether pH plays any 
role.  
The cooperative phosphorylation of the human KISS1R IL1 by CaMKII 
means that the initial catalytic domain involved in IL1 phosphorylation positively 
affects adjacent catalytic domains preferentially over those located more distantly 
within the dodecameric structure. Furthermore, the IL1-T75A peptide exhibited 
cooperative phosphorylation and thus the two threonine residues of IL1 (T75 and 
T77) were unlikely to be the cause of the cooperative phosphorylation. In contrast, 
Syntide-2 phosphorylation was non-cooperative, implying that one CaMKII 
catalytic domain does not sequentially affect another catalytic domain. It is presently 
unclear the exact cause of this kinetic phenomenon, but is likely due to the difference 
in the amino acid sequence of Syntide-2 and IL1 peptides. Also, the speed (velocity) 
at which αCaMKII phosphorylated IL1 was observed to be ~6 times slower than 
syntide-2 phosphorylation. Although αCaMKII’s Hill coefficient of (n) 4.4 ± 0.83 in 
the phosphorylation of IL1 may account partially for the reduced speed, it is possible 
that other contributing factor(s) exist. A similar observation was reported in the 
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phosphorylation of the limbic dopamine receptor (D2R) by αCaMKII. The authors 
report αCaMKII recognises a binding motif at the N-terminus of D2R IL3 and 
phosphorylates S229 at a speed of 4.0 ± 0.2 pmol/μg/min and affinity of Km 65.9 ± 
1.2 nM (Liu et al., 2009). The specific activity of αCaMKII in the phosphorylation 
D2R IL3 was 4-fold faster than the phosphorylation of KISS1R IL1. This may be 
explained by the observation that the D2R IL3 is non-cooperatively phosphorylated 
by αCaMKII (Liu et al., 2009). Thus αCaMKII’s Hill coefficient of (n) 4.4 ± 0.83 in 
the phosphorylation of IL1 may account for the reduced speed.  
The autophosphorylation of αCaMKII (T286) by Ca
2+
/CaM is critical for its 
in vivo function (Giese et al., 1998). The Ca
2+
 binding sites 1, 3, and 4 are sufficient 
in promoting αCaMKII T286 autophosphorylation. This is supported with the 
observation that CaM mutants with submaximal Ca
2+
 binding sites 1, 3, and 4 
significantly inhibited the rate of αCaMKII T286 autophosphorylation (Figure 3). 
Furthermore, CaM C-terminal domain is populated by low amplitude/frequency Ca
2+
 
whereas CaM N-terminal domain is populated with high amplitude/frequency Ca
2+ 
(Jama et al., 2011). With this in mind, Ca
2+
/CaM decode global and local Ca
2+
 
dynamics and transduce αCaMKII T286 autophosphorylation. Therefore, αCaMKII 
is likely to integrate a diverse Ca
2+
 dynamic into the phosphorylation of KISS1R IL1  
To date, very little is known about the significance of IL1 in the activation 
mechanisms of KISS1R. Herein, evidence is presented that IL1-T77 phosphorylation 
confers onto KISS1R the uncoupling of heterotrimeric G protein – Gq/11 and the 
inhibition of IP3 turnover. Whether a phosphate group at IL1-T77 is permanent or not 
is presently unknown. However, the KISS1R is known to physically interact with 
phosphatase 2A (PP2A-C). This interaction may enable the dephosphorylation IL1-
T77 (Evans et al., 2008).  
The inhibition of αCaMKII function by Myr-AIP in the hypothalamus of 
OVX rats revealed an expected augmentation of KP-10 induced role of the HPG 
axis. Unexpectedly however, the increased dose of 40 nmol Myr-AIP abolished the 
observed augmentation. This may be explained by the side-effect of the high dose of 
Myr-AIP. One such side-effect may be the unintended inhibition αCaMKII 
phosphorylation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
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(AMPA) receptor, and thus impairing synaptic functioning, which is critical for 
neuronal communication [as reviewed in (Derkach, 2011)].  
In conclusion, the human KISS1R was identified to contain two consensus 
motifs for CaMKII phosphorylation. They are located in the intracellular loop 1 
(IL1) and the C-terminal tail of KISS1R. Upon further examination CaMKII was 
found to selectively phosphorylate IL1 at residue T77. The phosphorylation of IL1 
was observed to be cooperative, which implied that the dodecameric αCaMKII must 
utilise several catalytic domains in that effort. Furthermore, decrypting the Ca
2+
 
dynamics that regulate αCaMKII function revealed that global and local Ca
2+
 
ooscillations have important roles. Phosphomimetic mutations (E/D) of KISS1R-T77 
revealed a significant reduction in inositol phosphate turnover following KP-10 
stimulation, but exhibited unchanged IC50 ligand binding. Micro-injections of the 
αCaMKII inhibitor – autocamtide-2 related inhibitory peptide (AIP) into the 
hypothalamus of ovariectomized rats exhibited augmented KP induced blood plasma 
LH surge, relative to KP-10 only administered rats. Taken together, these results 
reveal that αCaMKII down-regulates the activity of KISS1R through 
phosphorylation of the IL1, and thus participates in KP-LH homeostasis.   
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6. Conclusion   
The kisspeptin receptor (KISS1R), functioning as the metastasis suppressor and gate-
keeper of GnRH neurons, is a potent activator of intracellular Ca
2+
. Upon KISS1R 
activation, phospholipase C (PLC drives the production of inositol phosphate 
(IP3), which in turn promotes Ca
2+
 release from the endoplasmic reticulum. 
However, the regulatory mechanisms that enables KISS1R to sense the increased 
intracellular Ca
2+ 
concentration and avoid Ca
2+
 excitotoxicity via a signalling off-
switch remains unclear. In this thesis, evidence is provided for a novel protein-
protein interaction between KISS1R and the Ca
2+







/CaM dependent protein kinase II 
(αCaMKII).  
The interaction between CaM and KISS1R was determined with three 
independent methods of colocalisation with confocal microscopy, co-
immunoprecipitation (Co-IP), and cell-free spectrofluorimetric CaM binding 
experiments. The KISS1R in HEK-293 cells was found to colocalise with CaM, as 
well as Co-IP with endogenous CaM in a ligand/Ca
2+
 dependent manner. Moreover, 
the KISS1R derived intracellular loop 2 & 3 (IL2 and IL3) peptides were found to 
exclusively bind CaM (see chapter 3). Further examination of the sites of interaction 
revealed extensive CaM binding motifs mainly positioned in IL3 of KISS1R. The 
alanine substitution of critical residues of the juxtamembrane regions of IL3 created 
a KISS1R variant with increased relative maximum responsiveness, but unchanged 
ligand binding affinity. These experiments were further validated with the 
observation that the IL3 peptide lacking the juxtamembrane regions did not bind 
CaM in the cell-free spectrofluorimetric CaM binding experiments (see chapter 4).  
The knowledge gained from chapters 3 and 4 developed the hypothesis that 
αCaMKII, a closely associated kinase to Ca
2+
/CaM, may also interact with KISS1R. 
This theory was validated with the observation that CaMKII selectively 
phosphorylated T77 KISS1R-IL1. Interestingly, the kinetics of the phosphorylation 
was cooperative. The phosphomimetic mutations of KISS1R-T77D/E created a 
receptor that was unable to elicit IP3 production in COS-7 cells. Finally, in vivo 
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perturbation studies with ovariectomised rats revealed that the 
intracerebroventricularly administrated cell-permeable CaMKII inhibitor, 
autocamtide-2 related inhibitory peptide (AIP), augments the 1 nmol KP-10 
stimulation of plasma luteinizing hormone (LH) levels (see chapter 5). 
Taken together, these results suggest that KISS1R contains two distinct off-
switch mechanisms. The first of which is the dynamic binding of Ca
2+
/CaM to 
KISS1R-IL3. This is postulated to attenuate G-protein activity via steric hindrance. 
The second mechanism is theorised to involve the permanent inhibitory 
phosphorylation of KISS1R by CaMKII. The interplay between dynamic regulation 
vs permanent termination of KISS1R activity, is likely determined by intracellular 
Ca
2+
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8. Appendix  
8.1. Characterising cell-line models for GnRH neurons 
Physiologically relevant cell-line models that are similar to GnRH neurons 
and secrete GnRH would be good cell model candidates to study cellular physiology. 
To date, the best candidates are the GT1-7 and GnV3 cell-lines. Furthermore, GnRH 
neurons have been reported to express endogenous KISS1R and that when stimulated 
with KP-10 induce fast action potentials and secrete GnRH [as reviewed in (Oakley 
et al., 2009)]. Thus, in order to determine whether GT1-7 and GnV3 cells express 
endogenous KISS1R, 
125
I-KP-10 binding (see section 2.22), and inositol phosphate 
(IP3) turnover (see section 2.24) were examined. As a comparison, COS-7 cells were 
used, with and without transient expression (see section 2.21) of KISS1R.  
The GnV3 cell-line contains a Tet-On system which drives the transcription 
of v-myc (the immortalisation agent) upon doxycycline (DOX) administration. The 
proliferation of GnV3 cells is stimulated with DOX, while in DOX free medium 
GnV3 cells differentiate back into ‘GnRH neurons’ (Salvi et al., 2006, Mansuy et al., 
2011). GT1-7 constitutively expresses the immortalisation agent SV40 T-antigen 
(Mellon et al., 1990). 
The GT1-7 and GnV3 cells were determined to have undetectable 
endogenous KISS1R expression (GnV3 cells were cultured in the absence of DOX), 
as both cell types gave undetectable 
125
I-KP-10 binding and IP3 turnover. (Figure 6.1 
and Figure 6.2). In contrast, COS-7 cells, which are frequently used to express 
GPCRs, showed approximately 7-fold increase in the maximum 
125
I-KP-10 binding 
of transiently expressing KISS1R (P < 0.05) (Figure 6.1) Furthermore, the COS-7 
cells transiently expressing KISS1R gave a 20-fold increase in KP-10 induced IP3 
turnover relative to the vector control (P < 0.05) (Figure 6.2). 
In order to determine whether GT1-7 and GnV3 cells secrete GnRH upon 
potassium stimulation a radioimmunoassay was carried. It was observed that GT1-7 
and GnV3 cells were unable to secrete GnRH, or the levels below the methodological 
sensitivity of tens of pg/mL GnRH (Figure 6.3). 
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Figure 8.1 KP-10 binding to COS-7, GT1-7, and GnV3 cells. All cell-lines were 
prepared following the receptor binding assay protocol (see section 2.22) and the 
KISS1R cDNA transfection was carried out using the protocol in section 2.21. COS-
7 cells transiently transfected with KISS1R (blue line) or vector (pcDNA3.1+) (black 
line) were compared to untransfected native GT1-7 (red line) and GnV3 (green line) 
cells. The GnV3 cells were cultured in the absence of doxycycline (-DOX) 48 hours 
prior to the assay. The error bars are the standard error of the mean (S.E.M).  
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Figurer 8.2 KP-10 induced effects on IP3 response in COS-7, GT1-7, and GnV3 
cells. All cells were treated with KP-10 (1 μM) and processed using the IP3 
accumulation assay (see section 2.24). COS-7 cells were transiently transfected with 
control vector (pcDNA3.1+) or KISS1R cDNA and native GT1-7 and GnV-3 cells 
were used. GnV3 cells were incubated in the absence of doxycycline (-DOX) for 48 
prior the assay. Asterisks (*) denote statistical significance (** P<0.01) as calculated 
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Figure 8.3 GnRH secretion studies of GnV3, GT1-7, COS-7, and HEK-293 cell-
lines. Top; calibration curve using GnRH II concentration gradient to determine the 
sensitively of the radioimmunoassay. Bottom; indicated cell-lines were treated with 
60 mM of K
+
 for 30 minutes in their respective culture media. GnV3 cells were 
cultured in doxycycline 24 hours prior. 50 L of medium (from 10mL) was removed 
as sample for the radioimmunoassay (see section 2.23).  
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8.1.1. Discussion   
The aim of this section was to characterise GnV3 and GT1-7 cells for the purpose of 
studying KISS1R interacting proteins. To do this, a radio-ligand binding assay was 
used to determine the presence of endogenous KISS1R in GT1-7 and GnV3 cells. 
Also, in order to determine whether the KISS1R was functional, inositol IP3 turnover 
was measured. These biochemical assays were complemented by determining 
whether these cell-lines secrete GnRH upon depolarisation with potassium chloride 
stimulation.  
Some important phenotypic characteristics of GnRH neurons found in vivo 
must be present in the in vitro cell-line models in order to study cellular physiology. 
These characteristics should include the expression of endogenous KISS1R. Indeed, 
several research groups demonstrated the existence of KISS1R in GT1-7 and GnV3 
cells (Zhao and Kriegsfeld, 2009, Quaynor et al., 2007, Jacobi et al., 2007). 
However, in this, the results revealed that GT1-7 and GnV3 cell-lines do not express, 
on their cell surface endogenous KISS1R and that they do not secrete GnRH. One 
reason for this might be the lack of KISS1R trafficking proteins. Another possibility 
is that these cells have differentiated away from their previously reported 
characteristics.  
In conclusion, cell-line models for GnRH neurons pose considerable 
challenges, mainly the inability to maintain their phenotypes. Therefore, future 
experiments pertaining to the study of KISS1R interacting proteins should rely on the 
use of the common cell-lines like COS-7 and HEK-293, which can transiently 
express GPCRs well. 
